https://qibawiki.rsna.org/api.php?action=feedcontributions&user=SStanfa&feedformat=atomQIBA Wiki - User contributions [en]2024-03-28T22:40:03ZUser contributionsMediaWiki 1.35.5https://qibawiki.rsna.org/index.php?title=Education&diff=19652Education2024-02-08T22:33:10Z<p>SStanfa: /* QIBA in the Literature Citations */</p>
<hr />
<div>[[Image:QIBA_WIKI_BLURB.jpg|600px]]<br />
<br />
==QIBA in the Literature Citations==<br />
<br />
A list of QIBA generated and/or cited articles can be found [https://pubmed.ncbi.nlm.nih.gov/?term=%28%22quantitative+imaging+biomarker+alliance%22%5BText%5D+OR+%22quantitative+imaging+biomarkers+alliance%22%5BText%5D+OR+%22QIBA%22%5BText%5D%29&filter=years.2007-2024&sort=date '''<u>HERE</u>'''] via a PubMed search.<br />
<br />
==U.S. Food and Drug Administration (FDA) Guidance==<br />
The Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket <br />
Submissions Guidance for Industry and Food and Drug Administration Staff was released on June 16, 2022, and can be accessed at this link or via the PDF below:<br />
<br />
*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-quantitative-imaging-radiological-device-premarket-submissions <br />
<br />
This guidance document provides FDA's recommendations on the information, technical performance assessment, and user information that should be included in a premarket submission for radiological devices that include quantitative imaging functions. The recommendations reflect current review practices and are intended to promote consistency and facilitate efficient review of premarket submissions for radiological devices that include quantitative imaging functions.<br />
<br />
*[[Media:06 16 2022 FDA Guidance.pdf| Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket]] (June 16, 2022)<br />
<br />
==QIBA Historical Initiative==<br />
<br />
:[[Image:Cancer Moonshot.jpg|120px]]<br />
<br />
<br />
'''Cancer Moonshot & QIBA''' [https://medium.com/cancer-moonshot]<br />
*RSNA/QIBA is very pleased to announce that two of the QIBA Profiles relevant to cancer patients have been referenced and supported by the Federal Cancer Moonshot Initiative (https://medium.com/cancer-moonshot) as ways to advance research and outcomes. <br />
*The FDG-PET/CT and CT Volumetry Profiles have been submitted as the most advanced Profiles to-date. Our sincerest appreciation to all of the QIBA participants who helped us arrive at this important milestone.<br />
<br />
==Biomarker Status Update Posters==<br />
<br />
*[[QIBA posters from RSNA 2019 Annual Meeting|RSNA 2019 Posters]]<br />
<br />
'''''[[QIBA Posters from RSNA Annual Meetings Archive]]'''''<br />
<br />
<br />
==QIBA Special Interest Sessions at the RSNA Scientific Assembly and Annual Meeting==<br />
<br />
'''2018'''<br />
<br />
*[https://s3.amazonaws.com/east1.public.rsna.org/qiba/SPSI21-2018.mp4 RSNA 2018 Special Interest Session: Quantitative Imaging Applications in Screening, Treatment Selection, and Treatment Assessment - The Need for Standardization in the Era of Personalized Medicine, Edward F. Jackson, PhD] - November 26, 2018<br />
'''2016'''<br />
<br />
*[[Media:SPSI24.mp4|The Road Ahead: The Role of QIBA in Demonstrating the Value of Quantitative Imaging, Daniel Sullivan, MD]] - November 28, 2016<br />
<br />
*[[Media:SPSI24a.mp4|An Overview of the Quantitative Imaging Biomarkers Alliance (QIBA), Edward Jackson, PhD]] - November 28, 2016<br />
<br />
*[[Media:SPSI24b.mp4|Introduction to the QIBA Process and Methodology, Kevin O'Donnell, MASc]] - November 28, 2016<br />
<br />
*[[Media:SPSI24c.mp4|QIBA Deliverables: Science and Process, Paul Kinahan, PhD]] - November 28, 2016<br />
<br />
<br />
==Presentations==<br />
<br />
'''2018'''<br />
<br />
*[[Media:Conformance Assessment Introduction.pdf| Conformance Assessment Introduction (Nancy Obuchowski, PhD)]] - November 28, 2018<br />
*[[Media:Transitioning QIBs into Clinical Trials.pdf| Transitioning QIBs into Clinical Trials: Practical Implementation Requirements (Nancy Obuchowski, PhD)]] - November 28, 2018<br />
<br />
'''2017'''<br />
<br />
*[[Media:QDET demonstration 20170119.pdf| Round-5 Cross-modality Project: QDET Demonstration]] - January 19, 2017<br />
<br />
'''2016'''<br />
<br />
<font color=green>'''Google Chrome''' or '''Firefox''' browsers are recommended for viewing these PowerPoint presentations.</font><br />
*[[Media:QIBA Process and Metrology-2016.11.18v2-ODonnell.pptx| RSNA2016 QIBA Session - Part II - Process and Metrology]] - Nov 2016<br />
*[[Media:QIBA Intro-2016.07.22.2016.pdf| Introduction to the Quantitative Imaging Biomarkers Alliance {QIBA ®}]] - July 22, 2016<br />
*[[Media:QIBA Expectations for Japan Activities-2016.04.u.pptx|QIBA Expectations for Japan Activities]] - April 17, 2016 JRS Conference, Yokohama, Japan<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2016 2016 QIBA Annual Meeting Presentations] - April 13-14, 2016 Alexandria, VA<br />
<br />
'''2015'''<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2015 2015 QIBA Annual Meeting Presentations] - May 6-7, 2015 Alexandria, VA<br />
<br />
'''2014'''<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2014 2014 QIBA Annual Meeting Presentations] - May 21-22, 2014 Hyatt Regency Crystal City, Arlington, VA<br />
<br />
'''2010'''<br />
*[[Media:Why QIBA CT specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why QIBA PET-CT specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why QIBA MR specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
* [http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm 2010 RSNA QI/IB Special Interest Session Presentations] - November 29, 2010 RSNA, Chicago, IL<br />
<br />
'''2009'''<br />
*[[Media:Oncology section.ppt|2009 Imaging Biomarkers Roundtable - Oncology Section]] - March 16-17, 2009<br />
<br />
''Consider also organizing or tagging presentations by topic?''</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Education&diff=19651Education2024-02-08T22:31:37Z<p>SStanfa: /* QIBA in the Literature Citations */</p>
<hr />
<div>[[Image:QIBA_WIKI_BLURB.jpg|600px]]<br />
<br />
==QIBA in the Literature Citations==<br />
<br />
A list of QIBA generated and/or cited articles can be found HERE via a PubMed search.<br />
<br />
==U.S. Food and Drug Administration (FDA) Guidance==<br />
The Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket <br />
Submissions Guidance for Industry and Food and Drug Administration Staff was released on June 16, 2022, and can be accessed at this link or via the PDF below:<br />
<br />
*https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-performance-assessment-quantitative-imaging-radiological-device-premarket-submissions <br />
<br />
This guidance document provides FDA's recommendations on the information, technical performance assessment, and user information that should be included in a premarket submission for radiological devices that include quantitative imaging functions. The recommendations reflect current review practices and are intended to promote consistency and facilitate efficient review of premarket submissions for radiological devices that include quantitative imaging functions.<br />
<br />
*[[Media:06 16 2022 FDA Guidance.pdf | Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket ]] (June 16, 2022)<br />
<br />
==QIBA Historical Initiative==<br />
<br />
:[[Image:Cancer Moonshot.jpg|120px]]<br />
<br />
<br />
'''Cancer Moonshot & QIBA''' [https://medium.com/cancer-moonshot]<br />
*RSNA/QIBA is very pleased to announce that two of the QIBA Profiles relevant to cancer patients have been referenced and supported by the Federal Cancer Moonshot Initiative (https://medium.com/cancer-moonshot) as ways to advance research and outcomes. <br />
*The FDG-PET/CT and CT Volumetry Profiles have been submitted as the most advanced Profiles to-date. Our sincerest appreciation to all of the QIBA participants who helped us arrive at this important milestone.<br />
<br />
==Biomarker Status Update Posters==<br />
<br />
*[[QIBA posters from RSNA 2019 Annual Meeting|RSNA 2019 Posters]]<br />
<br />
'''''[[QIBA Posters from RSNA Annual Meetings Archive]]'''''<br />
<br />
<br />
==QIBA Special Interest Sessions at the RSNA Scientific Assembly and Annual Meeting==<br />
<br />
'''2018'''<br />
<br />
*[https://s3.amazonaws.com/east1.public.rsna.org/qiba/SPSI21-2018.mp4 RSNA 2018 Special Interest Session: Quantitative Imaging Applications in Screening, Treatment Selection, and Treatment Assessment - The Need for Standardization in the Era of Personalized Medicine, Edward F. Jackson, PhD] - November 26, 2018<br />
'''2016'''<br />
<br />
*[[Media: SPSI24.mp4|The Road Ahead: The Role of QIBA in Demonstrating the Value of Quantitative Imaging, Daniel Sullivan, MD]] - November 28, 2016<br />
<br />
*[[Media: SPSI24a.mp4|An Overview of the Quantitative Imaging Biomarkers Alliance (QIBA), Edward Jackson, PhD]] - November 28, 2016<br />
<br />
*[[Media: SPSI24b.mp4|Introduction to the QIBA Process and Methodology, Kevin O'Donnell, MASc]] - November 28, 2016<br />
<br />
*[[Media: SPSI24c.mp4|QIBA Deliverables: Science and Process, Paul Kinahan, PhD]] - November 28, 2016<br />
<br />
<br />
==Presentations==<br />
<br />
'''2018'''<br />
<br />
*[[Media:Conformance Assessment Introduction.pdf | Conformance Assessment Introduction (Nancy Obuchowski, PhD)]] - November 28, 2018<br />
*[[Media:Transitioning QIBs into Clinical Trials.pdf | Transitioning QIBs into Clinical Trials: Practical Implementation Requirements (Nancy Obuchowski, PhD)]] - November 28, 2018<br />
<br />
'''2017'''<br />
<br />
*[[Media:QDET demonstration 20170119.pdf | Round-5 Cross-modality Project: QDET Demonstration]] - January 19, 2017<br />
<br />
'''2016'''<br />
<br />
<font color=green>'''Google Chrome''' or '''Firefox''' browsers are recommended for viewing these PowerPoint presentations.</font><br />
*[[Media:QIBA_Process_and_Metrology-2016.11.18v2-ODonnell.pptx| RSNA2016 QIBA Session - Part II - Process and Metrology]] - Nov 2016<br />
*[[Media:QIBA Intro-2016.07.22.2016.pdf | Introduction to the Quantitative Imaging Biomarkers Alliance {QIBA ®}]] - July 22, 2016 <br />
*[[Media:QIBA_Expectations_for_Japan_Activities-2016.04.u.pptx|QIBA Expectations for Japan Activities]] - April 17, 2016 JRS Conference, Yokohama, Japan<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2016 2016 QIBA Annual Meeting Presentations] - April 13-14, 2016 Alexandria, VA<br />
<br />
'''2015'''<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2015 2015 QIBA Annual Meeting Presentations] - May 6-7, 2015 Alexandria, VA<br />
<br />
'''2014'''<br />
* [http://www2.rsna.org/re/QIBA_Annual_Meeting_2014 2014 QIBA Annual Meeting Presentations] - May 21-22, 2014 Hyatt Regency Crystal City, Arlington, VA<br />
<br />
'''2010'''<br />
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]]<br />
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]]<br />
* [http://www2.rsna.org/re/QI_IB_Special_Interest_Session_RSNA_2010/Index.htm 2010 RSNA QI/IB Special Interest Session Presentations] - November 29, 2010 RSNA, Chicago, IL<br />
<br />
'''2009'''<br />
*[[Media:Oncology section.ppt|2009 Imaging Biomarkers Roundtable - Oncology Section]] - March 16-17, 2009<br />
<br />
''Consider also organizing or tagging presentations by topic?''</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Selection_Process&diff=19586Selection Process2024-01-17T17:37:54Z<p>SStanfa: /* Criteria */</p>
<hr />
<div>Few imaging biomarkers have reached everyday clinical use. The problem isn't a lack of candidates. There is an enormous number of potential imaging biomarkers.<br />
<br />
QIBA's job is to identify a biomarker that is sufficiently robust, proven and understood to be ready for QIBA to help bridge that last mile.<br />
<br />
QIBA has limited resources to spread across the groundwork and profiling work of the Biomarker Committees so they must be selected carefully. <br />
<br />
==Process==<br />
[[Committees|Coordinating Committees]] prepare proposals that are submitted to the [[Steering Committee]] for approval.<br />
<br />
The Steering Committee evaluates the proposals on a number of criteria and considerations, and '''[[Committee_Procedures#Voting|votes]]''' on whether to approve.<br />
<br />
If approved, a [[Committee Organization|new Biomarker Committee]] is typically formed, although the work could be assigned to an [[Committees|existing Biomarker Committee]]. <br />
<br />
QIBA Leadership may also propose a new biomarker for consideration by the modality-specific Coordinating Committee. This would follow the same review process and final Steering Committee approval.<br />
<br />
<br />
==Criteria==<br />
:* Transformational <br />
::* Addresses a significant medical biomarker need with a likely considerable impact on public health, and addresses a critical gap in the biomarkers qualification/validation process.<br />
:* Translational <br />
::* Will likely result in significant improvement in the development, approval, or delivery of care to patients.<br />
:* Feasible <br />
::* An idea or program whose end goals can likely be achieved in a specific timeframe and that has a reasonable prospect of producing the expected outcomes; ideal programs are those which could result in regulatory qualification of a biomarker in three years. <br />
:* Practical <br />
::* Leverages preexisting resources (e.g., intellectual capital, personnel, facilities, specimens, reagents, data) wherever possible; warrants access to RSNA resources and support.<br />
:* Collaborative <br />
::* Would uniquely benefit from the multi-stakeholder composition and approach of QIBA and could be feasibly executed under its policies e.g. resulting in extension or adoption in product development among hardware, software, or imaging agents. The biomarker has the support of the stakeholder community with the organizational impetus to sustain continued efforts.<br />
<br />
(See [[Media:1-QIBA Biomarkers Selection Criteria 12-31-14.pdf|QIBA Biomarker Selection Criteria 2014]])<br />
<br />
==Considerations==<br />
<br />
TBA</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Profiles&diff=19584Profiles2024-01-17T17:36:52Z<p>SStanfa: /* Stage 1: Public Comment Profiles */</p>
<hr />
<div>__NOTOC__<br />
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. <br />
<br />
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.<br />
<br />
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===<br />
<br />
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]<br />
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]<br />
<br />
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists<br />
<br />
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]<br />
<br />
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]<br />
<br />
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]]<br />
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]<br />
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]<br />
<br />
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf | US Shear Wave Speed for Liver Fibrosis 2024-01-15]]<br />
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]]<br />
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===<br />
<br />
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23<br />
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]<br />
<br />
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]]<br />
<br />
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]<br />
<br />
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]<br />
<br />
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]<br />
<br />
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]<br />
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]<br />
<br />
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]<br />
<br />
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf | US Volume Blood Flow Profile, Consensus version 2024-01-05]]<br />
<br />
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)<br />
<br />
<br />
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<br />
<br />
'''Tools to aid Biomarker Committees in collating these comments:'''<br />
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''<br />
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' <br />
'''<br />
<br />
<br />
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''<br />
<br />
<br />
====Format for Citing Profiles====<br />
Cite QIBA Profile documents as:<br />
<br />
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''<br />
<br />
Example:<br />
<br />
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles<br />
<br />
<br />
====Statements of Endorsement====<br />
*[[Industry]]<br />
*[[Clinical Sites]]<br />
*[[Additional letters of support can be found here]]<br />
<br />
<br />
====See Also====<br />
*[[How to use QIBA Profiles]]<br />
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.<br />
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.<br />
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')<br />
<br />
*[[Work Product for Review]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DWI_MR_Biomarker_Ctte&diff=19531DWI MR Biomarker Ctte2024-01-03T21:19:19Z<p>SStanfa: /* DWI MR Meetings */</p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Michael Boss, PhD; Dariya Malyarenko, PhD; Daniel J. Margolis, MD<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vSIoAbG7elaGhDByZR86qGaMauqwMNEFjvIX3goqalFNj0yV9PYHiVIj8DQbDPBX9MxXOyrXaQmR4ES/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Diffusion Weighted Imaging MR. <br />
<br />
<br />
<br />
==DWI MR Meetings==<br />
<br />
'''Recent Approved call summaries:'''<br />
<br />Note: Summaries are posted after they are approved by the DWI-MR BC during the following monthly Zoom meeting<br />
<br />
*[[Media:2023_12-19_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|December 19, 2023]]<br />
*[[Media:2023_11-14_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|November 14, 2023]]<br />
*[[Media:2023_10-24_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|October 24, 2023]]<br />
<br />
'''''[[DWI MR BC Call Summaries Archive]]'''''<br />
<br />
Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
<br />
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-12-20]] (Stage 2: Consensus)<br />
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] (Stage 1: Public Comment)<br />
<br />
*[[DWI Literature Review]]<br />
<br />
'''''[[DWI Profile Development Archive]]'''''<br />
<br />
==ADC Phantom Materials==<br />
<br />
[[Media:QIBA_Phantom_Preparation-Instructions.pdf|QIBA ADC Phantom Preparation Instructions]] ''03-March-2017''<br />
<br />
[[Media:QIBA IMI August 7 2013-M Boss.pdf|QIBA-IMI ADC Phantom Design Update]] ''07-August-2013''<br />
<br />
[[Media:ADC Phantom Design Feedback Requested.pdf|ADC Phantom Design- Feedback Request]] ''14-March-2013''<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 2====<br />
*[[Media:4-UPenn-Test-Retest.-Yr2.pdf|Test-Retest Evaluation of Repeatability of DCE-MRI and DWI in Human Subjects (University of Pennsylvania)]]<br />
<br />
====Round 3====<br />
*[[Media:4-Software Development for Analysis of QIBA DW-MRI Phantom Data.pdf|Project (B) Software Development for Analysis of QIBA DW-MRI Phantom Data (University of Michigan)]]<br />
<br />
====Round 5====<br />
*[[Media:DWI-DRO Development for ADC Analysis.pdf | Project (G) DWI-DRO Development for ADC Analysis (University of Michigan)]]<br />
*[[Media:Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit.pdf | Project (K) Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit (Duke University)]]<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
==Reference Materials==<br />
Original Proposal to the QIBA Steering Committee</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DWI_MR_BC_Call_Summaries_Archive&diff=19530DWI MR BC Call Summaries Archive2024-01-03T21:18:53Z<p>SStanfa: /* 2023 */</p>
<hr />
<div>==2023==<br />
[[Media:2023_01-24_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|January 24]] | [[Media:2023_02-28_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|February 28]] | [[Media:2023_03-28_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|March 28]] | [[Media:2023_04-25_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|April 25]] | [[Media:2023_05-30_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|May 30]] | [[Media:2023_06-27_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|June 27]] | [[Media:2023_07-25_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|July 25]] | [[Media:2023_08-29_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|August 29]] | [[Media:2023_09-27_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|September 27]]<br />
<br />
==2022==<br />
[[Media:2022_01-19_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|January 19]] | [[Media:2022_02-16_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|February 16]] | [[Media:2022_03-23_QIBA_DWI_BC_Meeting_Summary-FINAL2.pdf|March 23]] | [[Media:2022_04-20_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|April 20]] | [[Media:2022_05-18_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|May 18]] | [[Media:2022_06-15_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|June 15]] | [[Media:2022_07-20_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|July 20]] | [[Media:2022_08-23_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|August 23]] | [[Media:2022_10-25_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|October 25]] | [[Media:2022_11-22_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|November 22]]<br />
<br />
==2021==<br />
[[Media:2021_01-21_QIBA_DWI_BC_Call_Summary-FINAL.pdf|January 21]] | [[Media:2021_02-18_QIBA_DWI_BC_Call_Summary-FINAL.pdf|February 18]] | [[Media:2021_03-25_QIBA_DWI_BC_Call_Summary-FINAL.pdf|March 25]] | [[Media:2021_04-22_QIBA_DWI_BC_Call_Summary-FINAL.pdf|April 22]] | [[Media:2021_06-24_QIBA_DWI_BC_Call_Summary-FINAL.pdf|June 24]] | [[Media:2021_07-15_QIBA_DWI_BC_Call_Summary-FINAL.pdf|July 15]] | [[Media:2021_08-19_QIBA_DWI_BC_Call_Summary-FINAL.pdf|August 19]] | [[Media:2021_09-16_QIBA_DWI_BC_Call_Summary-FINAL.pdf|September 16]] | [[Media:2021_10-28_QIBA_DWI_BC_Call_Summary-FINAL.pdf|October 28]] | [[Media:2021_12-09_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|December 9]]<br />
<br />
==2020==<br />
[[Media:2020_10-15_QIBA_DWI_BC_Call_Summary-FINAL.pdf|October 15]] | [[Media:2020_11-11_QIBA_DWI_BC_Call_Summary-FINAL.pdf|November 11]] | [[Media:2020_12-17_QIBA_DWI_BC_Call_Summary-FINAL.pdf|December 17]]<br />
<br />
==2019==<br />
[[Media:2020_03-19_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 19]] | [[Media:2020_04-16_QIBA_DWI_BC_Call_Summary-FINAL.pdf|April 16]] | [[Media:2020_05-21_QIBA_DWI_BC_Call_Summary-FINAL.pdf|May 21]] | [[Media:2020_06-18_QIBA_DWI_BC_Call_Summary-FINAL.pdf|June 18]] | [[Media:2020_07-16_QIBA_DWI_BC_Call_Summary-FINAL.pdf|July 16]] | [[Media:2020_08-20_QIBA_DWI_BC_Call_Summary-FINAL.pdf|August 20]] | [[Media:2020_09-17_QIBA_DWI_BC_Call_Summary-FINAL.pdf|September 17]]<br />
<br />
<br />
==2019==<br />
[[Media:2019_01-17_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 17]] | [[Media:2019_02-21_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 21]] | [[Media:2019_04-18_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 18]] | [[Media:2019_07-25_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 25]] | [[Media:2019_08-15_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 15]] | [[Media:2019_09-26_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 26]] | [[Media:2019_12-19_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|December 19]]<br />
<br />
<br />
==2018==<br />
[[Media:2018_07-12_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 12]] | [[Media:2018_08-09_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 9]] | [[Media:2018_09-20_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 20]] | [[Media:2018_10-18_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 18]] | [[Media:2018_12-20_QIBA_DWI_Biomarker_Cmte_Call_Summary-FINAL.pdf|December 20]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023_12-19_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf&diff=19529File:2023 12-19 QIBA DWI BC Meeting Summary-FINAL.pdf2024-01-03T21:17:15Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=Process_Coordinating_Committee&diff=19528Process Coordinating Committee2024-01-03T21:14:46Z<p>SStanfa: /* Meeting Agendas/Summaries */</p>
<hr />
<div>{{TOCright}}<br />
:Chairs: Kevin O'Donnell, MASc (Chair); Michael Boss, PhD (Vice Chair)<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTrNnQ5nDG4cx3PR85G9xylDRqBWu9NGPRUyYk2p-f3ryIwE6W1bMmwmxkoFQFTF7w2-c5e3TSgzSkp/pubhtml Roster]<br />
* [https://docs.google.com/spreadsheets/d/13AN9KO9QsLEKJDCsfUDbC3LLCGUKqDfK1_fYna0iwYk/edit?usp=sharing Attendance, Quorum and Voting Eligibility]<br />
<br />
==Scope== <br />
The Process Committee facilitates the QIBA Coordinating Committees and their profiling activities by defining processes and tools to promote consistent quality work product. <br />
:* Develop common Templates & Processes<br />
:* Support & mentor adoption of above<br />
:* Drive consistent content & format of Profiles<br />
:* Support infrastructure for Committees<br />
<br />
==Meeting Agendas/Summaries==<br />
Biweekly Tcons, 1st and 3rd Tuesdays of each month @ 2-3pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
* Quarterly agenda topic: What to highlight during next CC call slots. See [[Process Education]] for potential topics.<br />
<br />
'''Agendas:'''<br />
*[[2022-09-06 Process Committee Agenda]]<br />
*[[2022-08-16 Process Committee Agenda]]<br />
*[[2022-08-02 Process Committee Agenda]]<br />
*[[2022-07-05 Process Committee Agenda]]<br />
*[[2022-05-17 Process Committee Agenda]]<br />
<br />
'''''[[Process Committee Agenda Archive]]'''''<br />
<br />
'''Approved call summaries:'''<br />
*[[Media:2023 12-19 QIBA Process Cmte Meeting Summary-FINAL.pdf|December 19, 2023]]<br />
*[[Media:2023 12-05 QIBA Process Cmte Meeting Summary-FINAL.pdf|December 5, 2023]]<br />
*[[Media:2023 11-21 QIBA Process Cmte Meeting Summary-FINAL.pdf|November 21, 2023]]<br />
<br />
'''''[[Process Committee Call Summaries Archive]]'''''<br />
<br />
==Working Documents==<br />
<br />
* [[Claim Guidance]]<br />
* [[Assessment Procedure Guidance]]<br />
* [[QIBA Profile Stages]]<br />
* [[Process Education]]<br />
* [https://docs.google.com/document/d/100wJv_r0KZVAfIIMP0V8dLDdsjVQb6Uznxymf7yO8LI/edit?usp=sharing Profile Writing Guidance Ideas]<br />
* [https://docs.google.com/spreadsheets/d/1bVP9pSjxtCVinlASCAeGDf5vjc2lCfj16qEg7hkft0Q/edit?usp=sharing Wiki Use Cases]<br />
<br />
<br />
'''New Topics'''<br />
<br />
Review, prioritize, and discuss which might merit a Task Force (to work between Process Cmte Meetings)<br />
<br />
* NEXT - What will "Process" look like after Dec 2023<br />
** NEED/ASK description of how QUIC will be organized and work<br />
*** Continuity of existing process vs "Clean Break" and start over?<br />
*** What Stage is the focus of QUIC? Need deployment. Not clear if QUIC is looking to deploy tested profiles or untested profiles (and let the adopters work things out)<br />
** Which Biomarker Committees will continue to work? Who do they submit their work to?<br />
** Is there any reason to expect different processes?<br />
** Is the current process description/documentation/details adequate to support such ongoing activities<br />
*** How do we support "externally developed" profiles?<br />
** How does wiki and process maintenance work after Dec 2023?<br />
*** Which Cmte would do the maintenance work? (Note that as tech evolves, profiles will become outdated)<br />
** Process Cmte has typically laid the groundwork of "what's next", should continue <br />
** Status Quo - existing processes continue unless an authoritative organization revises or defines new processes<br />
** TODO Consider an "MOU/FAQ/Handbook" for a society that is "adopting" a Biomarker Committee, pointing to the existing processes/templates, etc.<br />
*** ISMRM - PDFF (and others?); AIUM - VBF, PEQUS, maybe CE & SWS; EIBALL - ASL & SLN?; AAPM - various?; some others tentative;<br />
*** What are the expectations of what a hosting society does/provides<br />
*** Maybe also provide a framework for each BC to understand where they're at, and what are the options going forward.<br />
**** What stage is your profile at; will it reach the next by Dec; do you have people to continue work; what org is willing to host the work; etc.<br />
**** Maybe update the dashboard to reflect this? (Copy/revise)<br />
*** Will lose the oversight ballot of Coordinating Cmte?<br />
** <br />
* NOW - What support do the current biomarker committees need during July-Dec 2023<br />
** Do we describe "accelerated approvals"?<br />
*** Note that CC Ballots can be voice vote during a call (but circulate doc 2 weeks before meeting) and that BC Ballots can be as short as 2 weeks (but make sure you're going to have enough reviewers/voters who can review it in that time)<br />
** Is there a mechanisms for ballots to be run/completed after Dec 2023? (RSNA Staff just for ballots? AAPM?)<br />
*** Q. Can we think of a way to publish work that is part way to the next stage to formally log the "final" state of the document.<br />
** Do we need to review the library and given no maintenance process, any that we want to deprecate<br />
** Continue to support usage/understanding of the Requirements Criteria and Streamlined Template.<br />
** Try to help complete SLN V2 release?<br />
* Wiki Cleanup<br />
** Mike: Document some of the additional criteria that seemed helpful during the recent approvals and get it on the wiki<br />
** Resolution Template: A bit of wiki cleanup and also highlight the value to transparency and closing the loop (things don't fall through the cracks)<br />
** Stage 4 guidance - make sure the current criteria are clear, and the thinking behind them.<br />
* Editors Meetings<br />
:* Put in Current work - consider TF - eventually will be a separate meeting track for the actual meetings anyway - would be nice to convene by start of summer<br />
:* Perhaps Quarterly<br />
:* 1) Identify the editors (See Dashboard - ask CC's to confirm Row 12 if their dashboards are up to date) - email to CC cochairs<br />
:* 2) Heads-up email to editors - explain intentions, ask for suggestions of topics/issues/questions and logistics/timing<br />
:* 3) Consider face-to-face time when possible (QIBA Annual Meeting, RSNA Annual Mtg) - happy hour<br />
<br />
* Committee Expertise Roster<br />
:* Dashboard item to confirm representative(s) for major stakeholder groups<br />
::* Radiologists (incl. academic, private practice (might challenging in terms of time) but if we get ACR traction, and QIBs are billable, interest might grow), Physicists, Technologists, Scanner vendors, SW vendors, CRO (implications for recruitment, burden for conducting), Pharma (biological use of the metric, claim details), Statisticians, Regulatory (device regulators, biologic regulators), ...<br />
::* Q. If there are multiple, who do you list?<br />
:* Stakeholder representatives are liaisons responsible for engaging with their stakeholder community<br />
:* If the BC has a roster "gap", need extra engagement effort during public comment, or periodically on a focused call, invite to face-to-face meetings <br />
<br />
* Q. What does the testing & conformance process look like for a Clinical Trial to be QIBA Profile Conformant? (Andy, Gudrun)<br />
<br />
===Current Work===<br />
<br />
====Maintenance Process and Profile Edition & Version Guidance====<br />
* New Steering Committee Priority?<br />
* Discuss some basic concepts then spawn TF if needed<br />
:* Conventions for Published Profile edition/version names<br />
::*[[Profile Editions]]<br />
::* [https://docs.google.com/spreadsheets/d/1_T8MXNkkgFQ7jQmrLMjtuGVqOs-AgA2vU745RMZa1d4/edit#gid=0 Examples]<br />
::* Address same-stage updates, not just stage transitions<br />
::* This is important - when in a stage, how do we update (change requirements) prior to moving to new stage.<br />
::* Highlight the Change Log as a place to point readers to key areas to review (if they were familiar with the old) and perhaps note the implications/significance (release notes)<br />
:* Conventions for internal filenames during Profile development<br />
::* [[Change Tracking and File Naming]]<br />
::* Lower priority but relevant<br />
:* Tracked Change Process<br />
::*[[Maintenance Process]]<br />
::* This is probably needed for the Profile Editions to ensure managed change not arbitrary.<br />
::* Describe what constitutes "editorial change" (that doesn't require re-approval), what requires going through approval again (maybe just at BC level, notify CC chairs and allow them to decide if they want to weigh in?), and what that looks like<br />
::* ISO has a "systematic review" process every 5 years for its standards. Do we want to introduce a similar process, e.g. as part of CC portfolio management. (TODO Write this up as a proposal to the Steering Cmte - '''May 9th''')<br />
::** Profile Renewal Process (WIP Proposal)<br />
::*** Each Modality Coordinating Committee is responsible for managing their portfolio of Profiles<br />
::*** Profiles have the potential to become “stale”<br />
::*** QIBA Staff will notify CC Co-chairs when a Profile is approaching 5 years <u>since most recent publication</u><br />
::**** If a BC is actively progressing a Profile, it would be getting republished "regularly" and would not trigger this review<br />
::**** The CC also has the responsibility to do such a review earlier if they have the sense that technology or clinical practice has evolved<br />
::*** The CC should notify the BC (if that committee/mailing list is still active)<br />
::*** The CC may request a formal assessment/recommendation from the BC<br />
::*** The CC will vote to Revise (modify, re-approve, re-publish), Renew (re-publish unchanged), or Retire (withdraw from current publication) the Profile<br />
::**** Retired Profiles will still be available on the website, but won’t be on the page of current Profiles<br />
::*** Suggested criteria/considerations (TODO Add text that these are not If-Then criteria, but rather things to spur discussions. It's OK to renew an unadopted Profile, might need more time)<br />
::**** Is there work underway in the BC? If so, it likely makes sense to allow that to proceed (effectively a “Revise” decision)<br />
::**** Is there known adoption of the Profile? If so, Renew or Revise are likely appropriate<br />
::**** Does the Claim performance meet current clinical needs? If not, consider Revise or Retire<br />
::**** Has technology advanced to the point where conformance could be made easier, or performance could be better? If so, consider Revise<br />
::**** Have new clinical practices or consensus emerged that the Profile could align to? If so, consider Revise<br />
::***** Consensus about "best practices" and guidelines may have emerged/shifted and the Profile should take into consideration/harmonize/promote<br />
::***** Also the clinical expectations and usage may have evolved and we should harmonize<br />
::***** Partnership with other organizations and specifications means we may have "convergence" activities to do (e.g. EANM) <br />
::**** Has the regulatory/certification/site conformance criteria environment changed in ways we should harmonize with<br />
::**** Have any new publications or trials come out that inform changes in our Profile?<br />
* Do as one work item or divide into multiple - some complexity<br />
:* Key people - MRE (Kay), FDG (Gudrun will ask Jeff to recommend), DWI (Mike)<br />
<br />
====Streamlined Profile Template====<br />
* Mike & Kevin taking first pass at streamlining Profile document (some additional points in the draft template)<br />
:* Revisit the topic of dropping requirements post-TechConf to see how feedback informs<br />
:* Flavors of possible drops: (Some things are always being done, others are not affecting the claim even if not done)<br />
:* Reluctance to discarding information that took effort/time to develop (keep? preserve in appendix?)<br />
:* Streamlining is partly moving things around for better ordering, some is taking things out (or moving to appendix)<br />
:* Plan a small call on DWI - Mike/Kevin<br />
::* Are there structures we could think of to deal with the multi-organ usage of DWI? Optional modules? Multi-profiles with common parts?<br />
:* Once we vet it internally, we can make it available for voluntary use/conversion by committees.<br />
:* Don't want to distract committees, or force "unnecessary" work. <br />
:* Plan to publicize it in the CC meetings and promote the benefits/concepts. <br />
::* Don't want to blindside any BCs. Maybe start telegraphing the situation now... Reassure we're not going to force rewrites.<br />
::* Harmonize assessment procedures across profiles<br />
<br />
====Estimates of Precision (Wrap)====<br />
* TODO Need some guidance text (like '''[[Vetting Requirements|Criteria page]]''') for BCs to understand; keep as a high priority item. Need to tidy up following text<br />
* Nancy will work on some guidance text in Word for later in March; after review can fold into Wiki.<br />
* Homework for Nancy & Kevin & (Nancy designee)(Nick?)<br />
:* Estimates of Precision when BC Stages Profiles and when Sites Conform to Profiles<br />
::* This came out of issues raised by Nancy about when/where/who should do test/retest type estimates of precision<br />
::* The following rough notes are from the 4/5 meeting<br />
:::* Address such Estimation as part of conformance assessment of each site and/or actor<br />
:::* Discuss BC choice to include assessment of actors/site precision as profile conformance requirement<br />
:::* Detail situations that would necessitate such profile requirements <br />
:::* Made all BC put in a Section 4 procedure to test linearity and bias with phantoms to ensure estimate is under the claim.<br />
:::* Q. Do we require the BC to do it once? Or do we require each site to do it as part of conformance?<br />
:::* At Stage 3, we might not need it as BC, but if we suspect we’re going to need it, we should test the practicality. <br />
:::* How much of a burden is test/retest? It varies depending on the amount of data required. When phantom data captures the variability you are looking for, it can be fairly easy (assuming access to the phantom is easy and the time is short).<br />
:::* BC also chooses the pass/fail threshold that provides reasonable confidence in meeting the claim.<br />
:::* If we see profiles mostly stopping at Stage 3, does it make sense to include a test/retest <br />
:::* Given that Stage 4 is a lighter weight Stage 5, What if we had an even “lighter-weight” that is not enough to reach Stage 3 but is somehow better.<br />
:::* Gap: we’re not doing groundwork with the procedures we have made in the profile (Basically that’s Stage 4) – it’s better if there have been Stage 1 groundwork that are roughly following the requirements, but most profiles do not have this.<br />
::* Key Point is Communication of what the conformance means at each level<br />
:::* The profile might state at in/near the claim what conformance means<br />
:::* There is value to all levels of conformance<br />
:::* Stage 2 - clearly(?) the claim is off the table. Stage 4 - clearly the claim is on the table.<br />
:::* Stage 3 is the current "danger" area. <br />
:::* So conformance to Stage 3 does not require 95% testing, but if a site is willing to do that (and thus help the BC on it's way to getting the profile to Stage 4 where everyone who then conforms can invoke the claim) how do we document/acknowledge/credit/thank them for that.<br />
::::* Guidance for how to design the Stage 3 to Stage 4 study. Note that the BC can decide to either tighten requirements or loosen claim if they two don't match. - NOTE this changes the design of the study. BC might need to weigh in which way they want to go before designing the study.<br />
::::* Some profiles have very stringent testing (e.g. claim says wcv is 10%, the profile/actor must show with 95% CI that wcv <=10%) in that we are requesting they confirm the claim directly as part of conformance. Need to better distinguish what BC does for Stage 4 vs what a Profile requires for conformance.<br />
<br />
====Stage 3 Resolution Template (Wrap)====<br />
* Have the templates '''TODO''' need to finish cleaning up the Process Page, check above bullets, then close out.<br />
* Homework - Kevin - links/pointers<br />
* Map out how to collate practical feedback from sites into a sheet for resolution similar to public comments.<br />
* Use the checklists - it's what they'd see in the field and it's "simple" - they can scan and we'll transcribe<br />
* Additionally, the overall questions solicit broader comments which is really useful as well.<br />
* Don't want identification being a barrier to feedback. But it's nice to be able to followup.<br />
* Be VERY clear that we don't intend to broadcast the site details<br />
* Do some clean up and run it around the coordinating/biomarker committees for feedback.<br />
* Cover letter to solicit broad feedback, and the checklists both feed material into the resolution sheet.<br />
* <See notes on Process Page for Tech Conf><br />
* '''Discussion Point''': To what degree are we collecting feedback (survey) vs doing a dry run of site conformance process vs both<br />
:* Consider starting some Blog threads e.g. feedback on the Tech Conf<br />
<br />
:* Conformance Process<br />
::* What should go into a Conformance Record? - (e.g. findings from Technical Confirmation tests)<br />
::* Need a common view of what conformance entails, how it is achieved, what it looks like to a product, how it is documented, etc.<br />
::* Then we need to ensure that the QIBA Templates/Process supports those things clearly.<br />
::* Kevin will put some initial thoughts on a Wiki page and we can review/add<br />
::* How often should conformance assessment be done, who will assess, who will keep records?<br />
::* Should QIBA get into hosting the Conformance Statements on our site (and then we could link to them from the Profiles page which would be very handy)<br />
::* Consider the RSNA Image Share Conformance Assessment Program and whether we should do something similar for QIBA <br />
:::* Process committee can think through the details of a process and confer with RSNA whether they would be interested<br />
<br />
===Priority (Next)===<br />
<br />
====Profile Selection Process (SCP)====<br />
* Move into Current Work - Consider setting up a TF - gauge participants - below Version/Naming<br />
* Review/update review criteria/evaluations for new BC proposals<br />
:* Harvest from past experiences<br />
::* [https://docs.google.com/document/d/1PmWlLZE8lRmH4gZXi_TQA3wtDRvrEyX_iDLfEX3L5Zg/edit?usp=sharing Profile Success Factors and Challenges Survey Planning]<br />
:* Given limited resources, how to approve not just good proposals but the best proposals<br />
::* It's not just about saying "Yes". It's about When should we say "No". When should we say "Not Yet"<br />
:* Evidence that the biomarker already has vendor and user adoption and just needs the "last mile" improvements that QIBA brings.<br />
* Consider Prior Project completion when Steering Cmte reviews new Proposals from the same PI.<br />
:* timing overlap of prior cycle completion period with new proposal period needs to be one considered.<br />
:* possible solution would require final reports for prior COMPLETED funding cycles before considering a new project proposal<br />
* Discuss which profiles have been most successful, which have hit bumps, which have foundered<br />
:* What characteristics of each contributed to the success/problems? Can we look for those during selection?<br />
:* As we refine criteria for new proposals, also see how they do/don't apply well to existing profile work<br />
* Discuss Nancy's criteria for ultimate Claim Confirmation?<br />
:* BCs should understand what they are getting into and start planning for it<br />
:* If the profile will depend on a large test/retest being completed and it seems highly unlikely that would ever be doable, should that weigh on the SC approving the BC?<br />
<br />
===ToDo===<br />
<br />
====Profile Format Harmonization====<br />
* Various profiles differ in their layout and content which makes it harder for users<br />
:* Use of New Templates has not been mandated, but rather left to committee discretion so as not to be disruptive<br />
:* Various committees have deviated from the template and/or introduced variations without discussing with the Process Cmte<br />
* Consider starting with a table showing which template each profile is using<br />
:* Process makes table; Tags for Informal template; Formal#1, Formal#2 (Streamlined) and other divergence notes<br />
:* CCs get it populated; SC decides on priority/mandate? of harmonizing<br />
:* Use to inform "harmonization pressure" efforts?<br />
<br />
====Communicating Uncertainty to Radiologists====<br />
::* "No measurement is complete without a statement of it's uncertainty" - NIST<br />
::* Measurement uncertainty is at the heart of what QIBA does<br />
::* If people don't recognize/appreciate measurement uncertainty they can't grasp the value of QIBA fully (or at all?)<br />
::* How do we get radiologists to appreciate the uncertainty of each measurement and incorporate it into their thinking and decision making?<br />
::* What should best practice be for communicating the uncertainty of each measurement to radiologists?<br />
:::* Always give a confidence interval rather than a value?<br />
::* Very Important Problem, not clear we could make a dent on solution in 5 months (but maybe problem definition?)<br />
::** And is this the Process Cmte job? Note really. Find a way to hand off to QUIC. Need to put more punch behind the message. <br />
::** Get it on the wiki for posterity and consultation<br />
<br />
====On-boarding Process====<br />
* Goal: Help new committees, new members, new authors, new reviewers, new adopters<br />
* Communication Committee might shoulder some of this too and only come to Process when gaps are found.<br />
* Reviewed "How to develop a Profile" Guidance<br />
:* Email How-To guide to current authors and ask them to read/feedback<br />
:* Then email to the current community since it is helpful for all contributors<br />
* Maybe update Profiles and Protocols page to focus less on UPICT and more on QIBA Profiles today.<br />
:* Linear layout<br />
:* Explain the mechanics of who does what with a profile (vendors, rads, techs, regulators, etc.)<br />
* Maybe add some "How to Read a Profile" guidance (also useful for reviewers), e.g. focus on Spec tables. Look at your relevant Activities/Procedures. Read the Discussion sections for more background.<br />
:* Explain about the Claims, the Actors, the Requirements and the Assessment Procedures structure of a Profile<br />
:* Advice may vary depending on viewpoint of the reader.<br />
:* Consider/discuss relative merits of moving the checklists from Annex E into Section 5 of the template<br />
* Joe's intro email, current template and stage docs, QIBA Fact Sheet<br />
:* Find a way to link directly into the "current" version of documents without having to update the links. Now we link to the Profile template page then you have to click a second time put pull up the template.<br />
* Could use a "fresh eyes"/newcomer commentary - find a newcomer guinea pig<br />
:* Kevin will work with Joe to get it into a Google Doc for revision and linking from the Wiki.<br />
:* https://docs.google.com/document/d/1jB1CPy1Mll_v-yzvSZk7acYv_SfC3VDAgS_WJ3y2pm8/edit?usp=sharing<br />
:* Include link to How-To guide<br />
:* Some people might like videos/webinars<br />
* Pictures and diagrams would help a lot for people reading what is "dry" text.<br />
* Types of newcomers/stakeholders - link from an "intro to QIBA - mother page" - '''[[Stakeholder Viewpoints]]'''<br />
:* Practicing [[QIBA for Radiologists]] (Dan), [[QIBA for Physicists]] (Tom Chenevert, Sam Armato, Paul K.), [[QIBA for Technologists]] (Mike), [[QIBA for Imaging Vendors]] (Kevin), analysis SW vendors/developers (Cathy?), researchers, clinical trialists, pharma (Gudrun?), [[QIBA for Core Labs]] (Pat?), [[QIBA for Regulators]] (both device and drug?) (Nick), patients/advocates/lay public, government policy, payers, [[QIBA for Statisticians]] (Nancy)<br />
:* DONE targeted intro to each?groups? of those viewpoints<br />
::* What is QIBA basically about, what is the key value of QIBA to them, how do they "use"/"interact with" QIBA (some of them are "actors", some are not)<br />
::* easy language, a few paragraphs, and links to specific wiki pages/documents/slides that would be a good next step for them<br />
:* Maybe add a "First Steps" section for each page (see [[QIBA for Statisticians]] for example) telling them the first things they could/should do<br />
:* Might be good to also have "stories from your colleagues" who are already in QIBA and their experiences.<br />
<br />
* Contact page on wiki? Point to qiba@rsna.org for questions/info on any committee, QIDW, etc.<br />
<br />
====Publication Process====<br />
* Ask Steering Cmte to determine whether having others publish is a necessity or not (Mike to draft some pro/con points - Kevin can help)<br />
::* Do the vendors and sites and trials that would be involved in using Profiles have an issue with these "standards" being published by QIBA (RSNA)?<br />
::* Would it be better if QIBA Profiles were balloted/published by another organization? IEC? IHE? AAPM? MITA?<br />
::* Would there be an impact in switching to a different document structure, formatting conventions, review/approval processes?<br />
<br />
====Clinical Confirmation Process====<br />
::* Methodology/Study Design guidance/requirements for achieving "Clinically Confirmed"<br />
<br />
====QIBA Tooling====<br />
::* How to use Google Docs? <br />
:::* Issues with references, access restricted by federal agencies and some companies<br />
::* Round trip fidelity between Word-Google-Word<br />
<br />
====QIBA Wiki====<br />
* [[QIBA Wiki Improvements]]<br />
* Wiki serves QIBA Committee work. Consider a new user oriented site (clinicians, administrators)?<br />
* Wiki vs RSNA.org<br />
:* Address relationship between wiki content (current, easy to update) and website content (authoritative, stable)<br />
::* Likely RSNA staff will periodically mirror wiki content up onto the website; address this in publication process.<br />
:* Consider how to handle handoffs between RSNA website<br />
::* RSNA website is controlled by the RSNA Marketing Department, must meet certain style requirements, and require resources beyond QIBA staff<br />
::* QIBA would still like to find a way for the more formal publications (e.g. later stage profiles) to be accessible from the RSNA website.<br />
<br />
====Literature Search Guidance====<br />
::* Process/best practices for review of literature around a new biomarker/profile (search is relatively straight forward)<br />
::* Assemble draft guidance to kick this off (Hendrik Laue, Ona Wu, Caroline? Chung)<br />
:::* See existing material - http://qibawiki.rsna.org/index.php/Tools_and_recommendation_for_structured_literature_review<br />
::* Where do you store references, what kind of search works best, what exactly are you looking for?<br />
::* Also meta-analysis guidance to determine sources and levels of variance<br />
::* PDF/DWI - using Google Sheet to track/tabulate/organize - inherently input from many sources so nice to have centralized, commonly edited, accessible<br />
<br />
====Product Reference Guidelines====<br />
* Draft Guidelines for Reference Implementations and commercial products in Profiles<br />
:* e.g., the underlying algorithm should be open/public/available/documented, QIBA will list all comers, non-commercial?, etc)<br />
* Level playing field, no favorites<br />
<br />
====Public Comment Attribution====<br />
::* don't push for anonymity. Encourage people to identify themselves (deserve credit and we want to be able to followup)<br />
::* form can accept anonymous, but encourage constructive criticism that will be taken in the spirit given.<br />
<br />
===Hold===<br />
Todo items that are on hold pending some trigger:<br />
<br />
====Claim Guidance====<br />
::* Hold pending people with questions/clarification needs on current text<br />
<br />
====[[Guidance Document Process]]====<br />
* Hold pending interest in "lightweight" QIBA output without claims/conformance<br />
* Basically "best practice" recommendations<br />
* Less rigor; Much easier to write, <br />
<br />
====Profile Retirement Process====<br />
::* Hold pending a profile we want to retire<br />
::* When do we "withdraw" or at least stop maintaining/promoting a Profile<br />
::* Review/borrow from corresponding IHE Process - http://wiki.ihe.net/index.php/Evaluation_of_Published_Profiles<br />
::* Review DICOM retirement concept (stays available in archives, not maintained/promoted)<br />
<br />
====Profile Disclaimer====<br />
::* Hold pending revist of Discriminatory Claims<br />
::* For now QIBA addresses technical performance. Getting into the clinical performance associated with Discriminatory Claims would open a lot of issues.<br />
<br />
====Statistical Assumption Testing Guidance====<br />
::* Conformance with the statistical assumptions is required at the various QIBA profile stages. <br />
::* Need guidance on the assumptions in the profile, validating the assumptions and testing actors for meeting those assumptions.<br />
::* Symmetrical vs Assymetrical change intervals?<br />
::* Questions about the numbers in "Academic Radiology: ?? Paper"<br />
<br />
===Past Work===<br />
This isn't all of it but here's some notes...<br />
<br />
====Conflict of Interest Policy====<br />
* Should have a policy statement on the wiki on QIBA expectations (e.g. what kind of things might come up and how might handle, e.g. recusal from votes or ballots)<br />
:* Dan has extracted some example wording used elsewhere (e.g. protocol approval committees, other orgs, AAPM)<br />
:* Is there a personal (financial?) benefit to the individual<br />
:* This may link into the question of getting cochairs to sign RSNA conflict of interest policy<br />
::* AGREE - guidance for guidances.<br />
* DONE - prepped language with examples and forwarded to SC/EC for approval and posting to the wiki<br />
<br />
====Public Comment Resolution====<br />
* DONE Set up Wiki page for holding all the comment resolution records from past public comment. - [[Profiles]]<br />
* Work with RSNA on a boilerplate email to send to commenters (who gave their email on the comment form) pointing to the resolutions document for their submitted comments. (Staff will draft some proposed text for review)<br />
:* (DONE) Could build it into the automatic confirmation message that the confirmation form sends out. <br />
* DONE Revised process to highlight circulating resolutions with ballots and posting by RSNA Staff when complete<br />
* DONE Updated resolution page<br />
* ONGOING get additional profiles to post their resolutions<br />
<br />
====Coordinating Committee Membership Criteria====<br />
* Review the current criteria [[Committee_Organization#Committee_Membership]]<br />
* Feedback to SC/EC<br />
:* Remove Modality Scientific Liaison (can bring in SMEs as voting/non-voting)<br />
:* Remove explicit cap on voting membership<br />
:* Flag "additional voting" as "At Large Members - suggest 2-4 people"<br />
:* Keep all Co-chairs of BCs<br />
:* Suggest adding 3-year term (renewable) for CC xChairs - RSNA Staff will think through logistics - currently doing a CC membership review - will be some turnover. Staggered rotations is desirable.<br />
:* Process Cmte participation (periodic education agenda item like for BC) is useful, but can fit easily under the non-voting SME umbrella.<br />
<br />
====Profile Ballot Reminders====<br />
* Consider something like the following:<br />
: ''Please indicate below whether this Profile''<br />
::* ''meets the criteria for this stage'' [link to criteria]<br />
::* ''conforms to profile guidelines'' [link to guidelines]<br />
::* ''is of sufficient quality to publish''<br />
:: ''Note: if you are unable to read through the profile, you may Abstain.''<br />
<br />
====Requirement Criteria====<br />
* Making profiles shorter...<br />
:* Drop requirements that aren't critical<br />
:* DONE - devised, documented and communicated an approach to [[Vetting Requirements]]<br />
::* Impact Criteria Assessment: Asking existing profiles to go back and fill in a column may invoke some resistance to the effort required.<br />
::* One approach: Have the BC go through all the requirements and do an impact pruning just before Pub Cmte release<br />
:::* Don't require long winded justifications, a short clear statement should be sufficient<br />
* QIB Guidance documents (not Profiles) can have a role since they don't have a claim so dropping "requirements" is less of an issue<br />
<br />
====Driving Profile Adoption====<br />
* Adoption of Profiles<br />
:* Maybe a new TF to support Adoption (can include some Process people)<br />
::* Ed, Brad, Joe, Kevin, Dan, RSNA Webperson<br />
::* Start by looking at what is on the RSNA QIBA pages,<br />
* [https://docs.google.com/document/d/1YM0mreBRLNNQZicDatx1IE3Zi1NZeaojQJczrEIbvsk/edit?usp=sharing Biomarker Adoption Steps] - Framework for when/how site stakeholders are engaged<br />
:* Basis for reviewing organization/content/structure of current QIBA documents/deliverables<br />
* Ultimately addressed by formation of [[QIBA Sustainability Implementation Committee (QSIC)]]<br />
:* For further details, see [[QIBA Sustainability Implementation Committee (QSIC)|QSIC page]]<br />
:* Process Cmte can support QSIC when process questions/refinements come up.<br />
<br />
====Committee Leadership Process====<br />
* Address BC and CC leadership<br />
* Continue with variations of '''co-chair/chair/vice-chair'''? - Maybe call everything below Steering Cmte as co-chairs and let them work out working patterns.<br />
* Describe process for '''nominating & selecting''' that is transparent, allows time for nominations & self-nominations, encourages diversity<br />
:* Mostly current system has been working without major issues, but would like to have efficient flow rather than everyone re-thinking/re-inventing a process<br />
* Process for recognizing cases where cochair availability/activity has decreased and need to call-the-question and trigger "replacement".<br />
:* Having '''"terms"''' would help trigger. E.g. 3-year terms, and limit of two terms to promote turnover, new faces, new ideas in some committees, on the other hand keeping experienced people and having continuity is good and there may be a limited supply of motivated leadership.<br />
:* CC term limits might be OK, but BC should maybe not have limits because they are intended to a have a limited life to start, and the chair is a key leader and change could falter<br />
:* If we stick with 3 year terms, might want to have a procedure where a cochair missing 8 meetings in a row triggers the secretariat doing a checkin to confirm that they still have the bandwidth/availability, and give them the opportunity to step aside if their other responsibilities have intruded. <br />
* '''Stakeholder diversity''' (silent, recommend, or require)<br />
:* Having "only academic representation" is an adoption risk to QIBA, so there is a value to making some effort to have diversity<br />
:* Variability in the size of some committees so tough to enforce<br />
:* Lets Strongly Recommend (and maybe make it a review point in the Coord Cmte and the Steering Cmte to ask about attempts to improve?)<br />
:* Also consider this when forming a Biomarker Committee - require? At least formally build into the evaluation process.<br />
:* Consider handling committee stakeholder diversity in the committee formation and dashboard process, not the leadership process<br />
:* Define Stakeholder diversity; do we make user/vendor classes? or is one academic radiologist and one clinical trial radiologist the intended degree of diversity?<br />
<br />
* For comparison - DICOM:<br />
:* For Working Groups it's required but unconstrained "Working Groups shall elect a chair or co-chairs."<br />
:* For the DSC (Steering Cmte) it's more constrained<br />
::* There shall be two co-chairs – one representing a producer and one representing a biomedical professional organization.<br />
::* Each co-chair shall serve a two-year term and may serve no more than two consecutive terms. The terms of the co-chairs shall expire in alternate years.<br />
::* At the meeting preceding the meeting before the last Committee meeting each year, the co-chairs shall appoint a three-member nominating subcommittee consisting of at least one representative of a producer , one representative of a biomedical professional organization and one former committee officer (if one is available). The former officer (if one is available) shall chair the nominating subcommittee. Members of the nominating subcommittee shall develop and submit to the secretariat a slate of candidates. The names of the candidates should be submitted to the secretariat no later than 30 days prior to the meeting preceding the last meeting of the year so that their names may be included in the published agenda. Additional nominations may be made from the floor at this meeting.<br />
::* Prior to the last meeting of the year the secretariat shall conduct a letter ballot. The name of the person elected shall be announced at the last meeting of the year. That person shall assume office immediately following the last meeting of the year.<br />
::* The Committee has the right to recall a co-chair.<br />
<br />
* For comparison - IHE:<br />
:* There are general cochair guidelines in section 12.2.7 of the Governance: https://www.ihe.net/wp-content/uploads/2018/07/IHE-International-Principles-of-Governance.pdf<br />
:* The Board adds the constraint "The Board shall elect as co-chairs, two Board Members drawn from Member Organizations in the User category. They will serve as co-chairs for renewable two-year terms."<br />
:* The Domain Planning Cmtes adds the recommendation "It is recommended that one Domain Planning Committee co-chair be selected from the User member category and one from the Developer member category."<br />
<br />
* For comparison - RSNA:<br />
:* A nomination announcement contains a link to an online nomination form and deadline<br />
::* A comment box provides for nominators or self-nominators to state why they wanted to serve/would be a good addition to the leadership<br />
:* Once the nomination period ended, another announcement contains a link to an eballot listing nominees and their qualifications<br />
::* Joe helpfully pointed out that we need to clearly define voting eligibility (i.e. do voting privileges apply to chair selection or can everyone vote)<br />
<br />
==See Also==<br />
<br />
<br />
This page is based on the [[Committee Template]]. Add any good ideas you have to the template.</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023_12-19_QIBA_Process_Cmte_Meeting_Summary-FINAL.pdf&diff=19527File:2023 12-19 QIBA Process Cmte Meeting Summary-FINAL.pdf2024-01-03T21:14:38Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=Process_Committee_Call_Summaries_Archive&diff=19526Process Committee Call Summaries Archive2024-01-03T21:14:03Z<p>SStanfa: /* 2023 */</p>
<hr />
<div>==2023==<br />
[[Media:2023 01-03 QIBA Process Cmte Meeting Summary-FINAL.pdf|January 3]] | [[Media:2023 02-21 QIBA Process Cmte Meeting Summary-FINAL.pdf|February 21]] | [[Media:2023 03-07 QIBA Process Cmte Meeting Summary-FINAL.pdf|March 7]] | [[Media:2023 03-21 QIBA Process Cmte Meeting Summary-FINAL.pdf|March 21]] | [[Media:2023 04-18 QIBA Process Cmte Meeting Summary-FINAL.pdf|April 18]] | [[Media:2023 05-02 QIBA Process Cmte Meeting Summary-FINAL.pdf|May 2]] | [[Media:2023 05-16 QIBA Process Cmte Meeting Summary-FINAL.pdf|May 16]] | [[Media:2023 06-06 QIBA Process Cmte Meeting Summary-FINAL.pdf|June 6]] | [[Media:2023 08-01 QIBA Process Cmte Meeting Summary-FINAL.pdf|August 1]] | [[Media:2023 08-15 QIBA Process Cmte Meeting Summary-FINAL.pdf|August 15]] | [[Media:2023 09-05 QIBA Process Cmte Meeting Summary-FINAL.pdf|September 5]] | [[Media:2023 09-19 QIBA Process Cmte Meeting Summary-FINAL.pdf|September 19]] | [[Media:2023 10-03 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 3]] | [[Media:2023 10-17 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 17]] | [[Media:2023 10-31 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 31]]<br />
<br />
==2022==<br />
[[Media:2022_01-04_QIBA_Process_Cmte_Meeting_Summary-FINAL.pdf|January 4]] | [[Media:2022_01-18_QIBA_Process_Cmte_Meeting_Summary-FINAL.pdf|January 18]] | [[Media:2022 02-01 QIBA Process Cmte Meeting Summary-FINAL.pdf|February 1]] | [[Media:2022 03-01 QIBA Process Cmte Meeting Summary-FINAL.pdf|March 1]] | [[Media:2022 03-15 QIBA Process Cmte Meeting Summary-FINAL.pdf|March 15]] | [[Media:2022 04-19 QIBA Process Cmte Meeting Summary-FINAL.pdf|April 19]] | [[Media:2022 05-03 QIBA Process Cmte Meeting Summary-FINAL.pdf|May 3]] | [[Media:2022 05-17 QIBA Process Cmte Meeting Summary-FINAL.pdf|May 17]] | [[Media:2022 07-05 QIBA Process Cmte Meeting Summary-FINAL.pdf|July 5]] | [[Media:2022 08-02 QIBA Process Cmte Meeting Summary-FINAL.pdf|August 2]] | [[Media:2022 08-16 QIBA Process Cmte Meeting Summary-FINAL.pdf|August 16]] | [[Media:2022 09-06 QIBA Process Cmte Meeting Summary-FINAL.pdf|September 6]] | [[Media:2022 09-20 QIBA Process Cmte Meeting Summary-FINAL.pdf|September 20]] | [[Media:2022 10-04 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 4]] | [[Media:2022 10-18 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 18]] | [[Media:2022 11-01 QIBA Process Cmte Meeting Summary-FINAL.pdf|November 1]] | [[Media:2022 11-15 QIBA Process Cmte Meeting Summary-FINAL.pdf|November 15]] | [[Media:2022 12-06 QIBA Process Cmte Meeting Summary-FINAL.pdf|December 6]]<br />
<br />
==2021==<br />
[[Media:2021_01-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 5]] | [[Media:2021_01-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 19]] | [[Media:2021_02-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 2]] | [[Media:2021_02-16_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 16]] | [[Media:2021_03-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 2]] | [[Media:2021_04-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 5]] | [[Media:2021_04-20_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 20]] | [[Media:2021_05-04_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 4]] | [[Media:2021_05-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 18]] | [[Media:2021_06-01_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 1]] | [[Media:2021_06-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 15]] | [[Media:2021_07-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 6]] | [[Media:2021_08-03_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 3]] | [[Media:2021_08-17_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 17]] | [[Media:2021_09-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 7]] | [[Media:2021_09-21_QIBA_Process_Cmte_Call_Summary-FINAL-2.pdf|September 21]] | [[Media:2021_10-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 5]] | [[Media:2021_10-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 19]] | [[Media:2021_11-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 2]] | [[Media:2021_12-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 7]]<br />
<br />
==2020==<br />
[[Media:2020_01-21_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 21]] | [[Media:2020_02-04_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 4]] | [[Media:2020_02-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 18]] | [[Media:2020_03-03_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 3]] | [[Media:2020_03-17_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 17]] | [[Media:2020_04-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 7]] | [[Media:2020_04-21_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 21]] | [[Media:2020_05-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 5]] [[Media:2020_05-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 19]] | [[Media:2020_06-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 2]] | [[Media:2020_06-16_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 16]] | [[Media:2020_07-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 7]] | [[Media:2020_07-21_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 21]] | [[Media:2020_08-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 18]] | [[Media:2020_09-01_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 1]] | [[Media:2020_09-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 15]] | [[Media:2020_10-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 6]] | [[Media:2020_11-03_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 3]] | [[Media:2020_11-24_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 24]] | [[Media:2020_12-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 15]]<br />
<br />
==2019==<br />
[[Media:2019_01-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 15]] | [[Media:2019_02-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 5]] | [[Media:2019_02-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 19]] | [[Media:2019_03-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 5]] | [[Media:2019_03-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 19]] | [[Media:2019_04-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 2]] | [[Media:2019_05-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 7]] | [[Media:2019_05-30_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 30]] | [[Media:2019_06-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 18]] | [[Media:2019_07-23_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 23]] | [[Media:2019_08-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 6]] | [[Media:2019_08-20_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 20]] | [[Media:2019_09-17_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 17]] | [[Media:2019_10-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 15]] | [[Media:2019_11-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 5]] | [[Media:2019_11-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 19]] | [[Media:2019_12-17_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 17]]<br />
<br />
==2018==<br />
<br />
[[Media:2018_01-23_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 23]] | [[Media:2018_02-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 6]] | [[Media:2018_02-20_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 20]] | [[Media:2018_03-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 6]] | [[Media:2018_03-20_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 20]] | [[Media:2018_04-03_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 3]] | [[Media:2018_05-01_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 1]] | [[Media:2018_06-12_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 12]] | [[Media:2018_07-10_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 10]] | [[Media:2018_08-21_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 21]] | [[Media:2018_09-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 18]] | [[Media:2018_10-16_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 16]] | [[Media:2018_12-04_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 4]] | [[Media:2018_12-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 18]]<br />
<br />
==2017==<br />
<br />
[[Media:2017_01-11_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 11]] | [[Media:2017_01-25_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 25]] | [[Media:2017_01-25_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|January 25]] | [[Media:2017_02-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 6]] | [[Media:2017_02-22_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|February 22]] | [[Media:2017_03-08_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|March 8]] | [[Media:2017_04-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|April 19]] | [[Media:2017_05-03_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 3]] | [[Media:2017_05-31_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|May 31]] | [[Media:2017_06-07_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 7]] | [[Media:2017_06-28_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|June 28]] | [[Media:2017_07-26_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|July 26]] | [[Media:2017_08-09_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|August 9]] | [[Media:2017_09-06_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 6]] | [[Media:2017_09-20_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|September 20]] | [[Media:2017_10-18_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 18]] | [[Media:2017_11-01_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 1]] | [[Media:2017_11-15_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 15]] | [[Media:2017_12-13_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 13]] | <br />
<br />
==2016==<br />
[[Media:2016_12-14_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|December 14]] | [[Media:2016_11-16_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 16]] | [[Media:2016_11-02_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|November 2]] | [[Media:2016_10-19_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 19]] | [[Media:2016_10-05_QIBA_Process_Cmte_Call_Summary-FINAL.pdf|October 5]] | [[Media:08 24 2016 QIBA Process Cmte Call Summary-FINAL.pdf|August 24]] | [[Media:07 27 2016 QIBA Process Cmte Call Summary-FINAL.pdf|July 27]] | [[Media:07 13 2016 QIBA Process Cmte Call Summary-FINAL.pdf|July 13]] | [[Media:06 29 2016 QIBA Process Cmte Call Summary-FINAL.pdf|June 29]] | [[Media:06 15 2016 QIBA Process Cmte Call Summary-FINAL.pdf|June 15]] | [[Media:05 18 2016 QIBA Process Cmte Call Summary-FINAL.pdf|May 18]] | [[Media:05 04 2016 QIBA Process Cmte Call Summary-FINAL.pdf|May 4]] | [[Media:04 06 2016 QIBA Process Cmte Call Summary-FINAL.pdf|April 6]] | [[Media:03 23 2016 QIBA Process Cmte Call Summary-FINAL.pdf|March 23]] | [[Media:03 09 2016 QIBA Process Cmte Call Summary-FINAL.pdf|March 9]] | [[Media:02 24 2016 QIBA Process CC Call Summary-FINAL.pdf|February 24]] | [[Media:02 12 2016 QIBA Process CC Call Summary-FINAL.pdf|February 12]] | [[Media:01 20 2016 QIBA Process CC Call Summary-FINAL.pdf|January 20]]<br />
<br />
==2015==<br />
[[Media:12 16 2015 QIBA Process CC Call Summary-FINAL.pdf|December 16]] | [[Media:11 18 2015 QIBA Process CC Call Summary-FINAL.pdf|November 18]] | [[Media:11 04 2015 QIBA Process CC Call Summary-FINAL.pdf|November 4]] | [[Media:10 21 2015 QIBA Process CC Call Summary-FINAL.pdf|October 21]] | [[Media:09 16 2015 QIBA Process CC Call Summary-FINAL.pdf|September 16]] | [[Media:08 12 2015 QIBA Process CC Call Summary-FINAL.pdf|August 12]] | [[Media:07 29 2015 QIBA Process CC Call Summary-FINAL.pdf|July 29]] | [[Media:07 15 2015 QIBA Process CC Call Summary-FINAL.pdf|July 15]] | [[Media:07 01 2015 QIBA Process CC Call Summary-FINAL.pdf|July 1]] | [[Media:06 03 2015 QIBA Process CC Call Summary-FINAL.pdf|June 3]] | [[Media:05 20 2015 QIBA Process CC Call Summary-FINAL.pdf|May 20]] | [[Media:04 22 2015 QIBA Process CC Call Summary-FINAL.pdf|April 22]] | [[Media:04 08 2015 QIBA Process CC Call Summary-FINAL.pdf|April 8]] | [[Media:03 25 2015 QIBA Process CC Call Summary-FINAL.pdf|March 25]] | [[Media:03 11 2015 QIBA Process CC Call Summary-FINAL.pdf|March 11]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=EIBIR/QIBA_ASL_Biomarker_Ctte&diff=19475EIBIR/QIBA ASL Biomarker Ctte2023-12-21T16:45:53Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Xavier Golay, PhD; Karl-Olof Lovblad, MD; Patricia Clement, PhD<br />
:Staff Support provided by: Eszter Balázs, MRes (EIBIR)<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTfdVJPKExZCVqTaX6_i6CEcqCViSS45tpfBItBr5W2Z6Hv5-sbqitUmWKGMnkuJ0uvVQUQ5B55fQwl/pubhtml '''Roster''']<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Arterial Spin Labeling imaging. <br />
<br />
This effort is supported by EIBIR, using the QIBA Process for Profile development.<br />
<br />
==ASL BC Meetings==<br />
'''Recent approved meeting summaries:'''<br />
<br />Note: Meeting summaries are posted after they are approved by the ASL BC during the following t-con<br />
<br />
*[[Media:2023_10-11_EIBIR-QIBA_ASL_Meeting_Summary.pdf|October 11, 2023]]<br />
*[[Media:2023_02-24_EIBALL-QIBA_ASL_BC_Meeting_Summary-FINAL.pdf|February 24, 2023]]<br />
*[[Media:2022_06-30_EIBIR-QIBA_ASL_BC_Meeting_Summary-FINAL.pdf|June 30, 2022]]<br />
<br />
'''''[[ASL Meeting Summaries Archive]]'''''<br />
<br />
<br/><br />
<br />
==Profile Development==<br />
*[[Media:Profile to be added]]<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
==Reference Materials==<br />
Original Proposal to the QIBA Steering Committee<br />
[[File:To be added.pdf]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Perfusion,_Diffusion_and_Flow-MRI_Biomarker_Ctte&diff=19474Perfusion, Diffusion and Flow-MRI Biomarker Ctte2023-12-21T16:44:54Z<p>SStanfa: </p>
<hr />
<div>:Co-chairs: Michael Boss, PhD; John Kirsch, PhD; Daniel Barboriak, MD<br />
<br />
* [http://tinyurl.com/QIBA-PDF-MRI-Roster Roster]<br />
<br />
<br />
'''NOTICE''': This committee has been [[Committee Sunset Process|dissolved]] as of June 6, 2018.<br />
* PDF served as the launching point for work on [[DWI MR Biomarker Ctte | DWI]], [[DCE MRI Biomarker Ctte |DCE]], and [[DSC MRI Biomarker Ctte | DSC]], which now have their own Biomarker Committees, as well as DTI.<br />
* This page is persisted to provide access to earlier call summaries and profiling materials<br />
<br />
<br />
==Recent PDF-MRI Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br />
*[[Media:2018_05-09_QIBA_PDF-MRI_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 9, 2018]]<br />
*[[Media:2018_04-25_QIBA_PDF-MRI_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 25, 2018]]<br />
*[[Media:2018_02-14_QIBA_PDF-MRI_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 14, 2018]]<br />
<br />
'''''[[PDF BC Call Summaries Archive]]'''''<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:QIBA Profile compliance clinical environment-30AUGUST2013.pdf|QIBA Profile Compliance - Clinical Environment]] ''30-August-2013''<br />
*[[Media:PDF MRI TC Update 20130130A.pdf|PDF-MRI Technical Committee Report to the Steering Committee - 01.31.2013]]<br />
<br />
*[[Media:MDACC QIBA Scans 20090215 Summary Plot.pdf|MDACC QIBA Scans 20090215 Summary Plot]]<br />
*[[Media:MDACC QIBA Scans 20090215 Summary Table.pdf|MDACC QIBA Scans 20090215 Summary Table]]<br />
<br />
*[[Media:Siemens QIBA protocol 7-1-09 D PURDY.pdf|Siemens-QIBA Protocol -- July 1, 2009 -- Dr David Purdy]]<br />
*[[Media:UC_MDACC_Comparison_20090902Tcon.xls|MDACC/U Chicago Phantom Data Analysis Comparison -- Sept 2, 2009 -- Dr Edward Jackson]]<br />
<br />
<br />
==QIBA / QuIC-ConCePT (IMI) Collaboration==<br />
<br />
*[[QIBA / QuIC-ConCePT Call Summaries]]<br />
*[[Ambition Levels for Collaboration]]<br />
*[[Clinical Trials Collaboration]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DTI_MRI_Biomarker_Ctte&diff=19473DTI MRI Biomarker Ctte2023-12-21T16:44:35Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Walter Schneider, PhD; Christopher Whitlow, MD, PhD<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vS-ZSC6I0AVhBrNH47YHV6HdZh2Xpgl90wa5N-9Gf-xVFdt0SkJhkQ3TEyM4jE_nzNNCMsRS6z2YA4Q/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Diffusion Tensor Imaging MRI. <br />
<br />
<br />
<br />
==DTI+ MR Meetings==<br />
'''Recent Approved call summaries:'''<br />
<br />Note: notes are posted after they are approved by the DTI+ BC during the following t-con<br />
<br />
*[[Media:2020_11-02_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|November 2, 2020]]<br />
*[[Media:2020_10-05_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|October 5, 2020]]<br />
*[[Media:2020_05-14_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|May 14, 2020]]<br />
<br /><br />
Earlier materials can be found on the [[http://qibawiki.rsna.org/index.php/Perfusion,_Diffusion_and_Flow-MRI_Biomarker_Ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
==Reference Materials==<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 5 (placeholder)====<br />
<br />
====Round 6 (placeholder)====</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DSC_MRI_Biomarker_Ctte&diff=19472DSC MRI Biomarker Ctte2023-12-21T16:44:25Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Leland S. Hu, MD; Mark S. Shiroishi, MD; Ona Wu, PhD<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vSj4UaTtwxjce5uTwiOxw6bjbWwH1q82nhNMsyOsOJJy_mGEsaxky---jmU5B42nShc--icFt4T1Kok/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Dynamic Susceptibility Contrast MRI.<br />
<br />
<br />
This QIBA Profile, Dynamic-Susceptibility-Contrast Magnetic Resonance Imaging (DSC-MRI), released 2020-10-22, addresses the measurement of an imaging biomarker for relative Cerebral Blood Volume (rCBV) for the evaluation of brain tumor progression or response to therapy. We note here, that this profile does not claim to be measuring quantitative rCBV due to lack of existing supporting literature; it does provide claims for a biomarker that is proportional to rCBV, which is the tissue-normalized area under the contrast-agent concentration curve (AUC-TN). The AUC-TN therefore has merit as a potential biomarker for diseases or treatments that impact rCBV. <br />
<br />
This profile places requirements on Sites, Acquisition Devices, Contrast Injectors, Contrast Media, Radiologists, Physicists, Technologists, Reconstruction Software, Image Analysis Tools and Image Analysts involved in Site Conformance, Staff Qualification, Product Validation, Pre-delivery, Periodic QA, Protocol Design, Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, Image Distribution, Image Analysis and Image Interpretation. The requirements are focused on achieving known (ideally negligible) bias and avoiding unnecessary variability of the of the AUC-TN measurements.<br />
<br />
The clinical performance is characterized by a 95% confidence interval for a true change in AUC-TN in enhancing tumor tissue and in normal tissue with respect to baseline values. These estimates are based on current literature values but may be updated based on future studies. <br />
<br />
This profile is intended to help clinicians basing decisions on this biomarker, imaging staff generating this biomarker, vendor staff developing related products, purchasers of such products and investigators designing trials with imaging endpoints.<br />
<br />
Note that this profile only states requirements to achieve the claim, '''not''' “requirements on standard of care.” Conformance to this Profile is secondary to properly caring for the patient.<br />
<br />
==DSC MRI Meetings==<br />
'''Recent Approved call summaries:'''<br />
<br />Note: Call summaries are posted after they are approved by the DSC-MRI BC during the following t-con<br />
<br />
*[[Media:2023-12-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|December 13, 2023]]<br />
*[[Media:2023-11-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|November 8, 2023]]<br />
*[[Media:2023-10-11_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|October 11, 2023]]<br />
<br />
'''''[[DSC-MRI Call Summaries Archive]]'''''<br />
<br />
* Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
<br/><br />
<br />
==Profile Development==<br />
<br />
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile-2023_08-09.pdf | DSC-MRI Stage 2 Consensus Profile August 09, 2023 Maintenance Version (published on September 5, 2023)]]<br />
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf | DSC-MRI Stage 2 Consensus Profile (published on October 22, 2020)]]<br />
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf | DSC-MRI Stage 1 Public Comment Profile]] (comments closed on May 15, 2020)]]<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
<br/><br />
<br />
==Reference Materials==<br />
<br />
*[[Media:QIBA DSC Phantom Manual.pdf|QIBA/NIST DSC Phantom User & Software Manual]]<br />
*[http://qibadscdro.rsna.org/home DSC MRI Digital Reference Object]<br />
<br />
<br/><br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 5====<br />
*[[Media:DSC-MRI Phantom.pdf|Project (H) Dynamic Susceptibility Contrast MRI Phantom (Massachusetts General Hospital)]]<br />
<br />
:Original Proposal to the QIBA Steering Committee<br />
<br />
====Round 6====<br />
*[[Media:A Web-based Tool for Creating DSC DROs.pdf | Project (Y) A Web-based Tool for Creating DSC Digital Reference Objects (DROs) (Mayo Clinic)]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DCE_MRI_Biomarker_Ctte&diff=19471DCE MRI Biomarker Ctte2023-12-21T16:44:12Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Hendrik Laue, PhD; James O'Connor, MD, PhD<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRzQYPdYm51Ak3VYii84CtIDFiYRIylH2IkHQZxdAAjJTAVX4iRqlGl2tety1pnDFKN9kLxoKI-RcoM/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Dynamic Contrast Enhanced MRI.<br />
<br />
*[[MR Acquisition Protocols]]<br />
*[[Synthetic DCE-MRI Data]]<br />
<br />
<br />
==DCE MRI Meetings==<br />
Biweekly Zoom meetings, 2nd and 4th Mondays of each month @ 11am-12pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
<br />
'''Recently Approved Call Summaries'''<br />
<br />
*[[Media:2023_12-11_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|December 11, 2023]]<br />
*[[Media:2023_11-13_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|November 13, 2023]]<br />
*[[Media:2023_10-23_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|October 23, 2023]]<br />
<br />
'''''[[DCE-MRI BC Call Summaries Archive]]'''''<br />
<br /><br />
<br /><br />
* [[QIBA DCE-MRI Technical Committee Call Summaries|DCE-MRI TC Call Summaries Archive 2008-2012]]<br />
* Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|'''MR DCE-MRI Quantification (DCEMRI-Q) (V.2) - Stage 2: Consensus 2023-12-06''']]<br />
*[[Media: QIBA DCE v2.0-Stage1 Public Comment Profile.pdf| '''MR DCE-MRI Quantification (DCEMRI-Q) (V.2) - Stage 1: Public Comment 2020-12-09''']]<br />
*[[Media:Compliance v 1 7.doc|DCE-MRI Profile, Section IV Compliance-AG v1.7]] ''05-21-2014''<br />
*[[Media:Compliance (2).doc|DCE-MRI Profile, Section IV Compliance-AG]] ''01-22-2014''<br />
*[[Media:DCEMRIProfile v1 6-20111213.pdf|'''DCE-MRI Quantification Profile v1.6 2011-12-13''']]<br />
*[[Media:Profile Literature Review 20110427 Rev1.xls|DCE-MRI Profile Supporting Literature Review]] ''Revised 05.02.2011''<br />
<br />
*[[Tools and recommendation for structured literature review]]<br />
*[[Archived DCE-MRI Profiles]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Barboriak T1 DRO report 20130903a.pdf|T1 DRO Report -- 20130903 -- Dr Barboriak]]<br />
*[[Media:DWI proposal of DCE-MRI TC 16Nov2011 (2).doc|DWI Proposal for the DCE-MRI Tech Ctte]] ''12.14.2011''<br />
*[[Media:Synthetic data presentation 20110929 redact.pdf|QIBA DCE-MRI Synthetic Data Presentation -- 20110929--Dr. Barboriak]]<br />
*[[Media:RSNA QIBA May2010 MR Phantom.pdf|MR Phantom Development / Data Efforts - May 2010 QIBA Meeting Breakout Session]]<br />
*[[Media:Prototype Phantom 20100203.pdf|Prototype Phantom - 20100203]]<br />
*[[Media:Q-MRI-Poster1-Jackson-20091118.ppt|QIBA Quantitative MRI Poster for RSNA 2009 Annual Meeting]]<br />
*[[Media:Phantom Study Protocol rev20091028.pdf|DCE-MRI Phantom Study Protocol -- rev20091028]]<br />
*[[Proposed Changes to Acquisition Protocol -- 20090315 - E Jackson]]<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 1====<br />
*[[VirtualScopics, Inc.]]<br />
**[[Media:DrJackson QIBA Phantom 09203 AMR3.pdf|Example RSNA DCE-MRI Phantom Data Analysis Report]]<br />
<br />
*[[Duke University Medical Center]]<br />
*[[The University of Texas M.D. Anderson Cancer Center]]<br />
<br />
====Round 2====<br />
<br />
*[[Media:4-UPenn-Test-Retest.-Yr2.pdf|Test-Retest Evaluation of Repeatability of DCE-MRI and DWI in Human Subjects]]<br />
<br />
====Round 3====<br />
<br />
*[[QIBA Artificial Data Evaluation Software]]<br />
<br />
*[[Media:Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis.pdf|Project (J) Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis (Fraunhofer MEVIS, Germany)]]<br />
<br />
*[[Media:DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T.pdf | Project (H) DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T (University Hospital Cologne, Germany)]]<br />
<br />
====Round 4====<br />
<br />
*[[Media:Digital Reference Object for DCE-MRI Analysis Software Verification.pdf|Project (AA) Digital Reference Object for DCE-MRI Analysis Software Verification (Cleveland Clinic Foundation)]]<br />
<br />
*[[Media:DRO for DCE-MRI Analysis Software Verification.pdf|Project (T) Digital Reference Object for DCE-MRI Analysis Software Verification 2 (Duke University)]]<br />
<br />
*[[Media:RSNA DCE-MRI Phantom Automated Analysis Software Package Development.pdf|Project (U) RSNA DCE-MRI Phantom Automated Analysis Software Package Development (University of Wisconsin)]]<br />
<br />
====Round 5====<br />
*[[Media:Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit.pdf | Project (K) Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit (Duke University)]]<br />
<br />
====Round 6====<br />
*[[Media:Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI.pdf | Project (Z) Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI (University of Southern California)]]<br />
<br />
==Historical Background - Formation of the Group==</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DWI_MR_Biomarker_Ctte&diff=19470DWI MR Biomarker Ctte2023-12-21T16:43:52Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Michael Boss, PhD; Dariya Malyarenko, PhD; Daniel J. Margolis, MD<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vSIoAbG7elaGhDByZR86qGaMauqwMNEFjvIX3goqalFNj0yV9PYHiVIj8DQbDPBX9MxXOyrXaQmR4ES/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Diffusion Weighted Imaging MR. <br />
<br />
<br />
<br />
==DWI MR Meetings==<br />
<br />
'''Recent Approved call summaries:'''<br />
<br />Note: Summaries are posted after they are approved by the DWI-MR BC during the following monthly Zoom meeting<br />
<br />
*[[Media:2023_11-14_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|November 14, 2023]]<br />
*[[Media:2023_10-24_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|October 24, 2023]]<br />
*[[Media:2023_09-27_QIBA_DWI_BC_Meeting_Summary-FINAL.pdf|September 27, 2023]]<br />
<br />
'''''[[DWI MR BC Call Summaries Archive]]'''''<br />
<br />
Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
<br />
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-12-20]] (Stage 2: Consensus)<br />
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] (Stage 1: Public Comment)<br />
<br />
*[[DWI Literature Review]]<br />
<br />
'''''[[DWI Profile Development Archive]]'''''<br />
<br />
==ADC Phantom Materials==<br />
<br />
[[Media:QIBA_Phantom_Preparation-Instructions.pdf|QIBA ADC Phantom Preparation Instructions]] ''03-March-2017''<br />
<br />
[[Media:QIBA IMI August 7 2013-M Boss.pdf|QIBA-IMI ADC Phantom Design Update]] ''07-August-2013''<br />
<br />
[[Media:ADC Phantom Design Feedback Requested.pdf|ADC Phantom Design- Feedback Request]] ''14-March-2013''<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 2====<br />
*[[Media:4-UPenn-Test-Retest.-Yr2.pdf|Test-Retest Evaluation of Repeatability of DCE-MRI and DWI in Human Subjects (University of Pennsylvania)]]<br />
<br />
====Round 3====<br />
*[[Media:4-Software Development for Analysis of QIBA DW-MRI Phantom Data.pdf|Project (B) Software Development for Analysis of QIBA DW-MRI Phantom Data (University of Michigan)]]<br />
<br />
====Round 5====<br />
*[[Media:DWI-DRO Development for ADC Analysis.pdf | Project (G) DWI-DRO Development for ADC Analysis (University of Michigan)]]<br />
*[[Media:Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit.pdf | Project (K) Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit (Duke University)]]<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
==Reference Materials==<br />
Original Proposal to the QIBA Steering Committee</div>SStanfahttps://qibawiki.rsna.org/index.php?title=MSK_Biomarker_Ctte&diff=19469MSK Biomarker Ctte2023-12-21T16:43:35Z<p>SStanfa: </p>
<hr />
<div><br />
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD <br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster]<br />
<br />
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.<br />
<br />
==Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br />
*[[Media:2023_12-12_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|December 12, 2023]]<br />
*[[Media:2023_10-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|October 24, 2023]]<br />
*[[Media:2023_09-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|September 26, 2023]]<br />
<br />
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''<br />
<br />
==Profile Documents==<br />
*[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile]]<br />
*[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile]]<br />
<br />
==Statistical Reference Documents==<br />
<br />
==Workflow Documents==<br />
<br />
==Reference Materials==</div>SStanfahttps://qibawiki.rsna.org/index.php?title=MRE_Biomarker_Ctte&diff=19468MRE Biomarker Ctte2023-12-21T16:43:17Z<p>SStanfa: </p>
<hr />
<div>:Co-chairs: Richard L. Ehman, MD; Patricia Cole, PhD, MD<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRXlDgOiADuCP3e9iHApSt4Z3zpel94OJN12IEQY8C4OT4u4LiiNnp9EWBP5FnCAgDL-YMe-m1NjasH/pubhtml?gid=1930876020&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
The MRE Biomarker Committee seeks to develop a quantitative Profile for MRE.<br />
<br />
MRE Profile to be data-driven: <br />
*focusing on the characterization of bias and precision in MRE measurement targets for achieving these measurements<br />
*focusing on issues important to specific reproducibility<br />
<br />
<br />
==Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br >Note: The last meeting of this group was held on December 20, 2021; notes are posted after they are approved by the MRE BC during the following t-con<br />
<br />
*[[Media:2021_12-20_QIBA_MRE_BC_Call_Summary-FINAL.pdf|December 20, 2021]]<br />
*[[Media:2021_03-15_QIBA_MRE_BC_Call_Summary-FINAL.pdf|March 15, 2021]]<br />
*[[Media:2020_01-23_QIBA_MRE_BC_Call_Summary-FINAL.pdf|January 23, 2020]]<br />
<br />
'''''[[MRE BC Call Summaries Archive]]'''''<br />
<br />
==MRE Profile Development==<br />
*[[Media:MRE-QIBAProfile-2023-11-09-CLINICALLY-FEASIBLE-maintenance.pdf|''MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft (November 9, 2023)'']]<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|'''MR Elastography of the Liver, Clinically Feasible Profile (February 14, 2022)''']]<br />
*[[Media:MRE-QIBA_Profile-2021-06-22-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 22, 2021)'']]<br />
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 6, 2019)'']] <br />
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | '''MR Elastography of the Liver, Consensus Profile (May 2, 2018)''']] <br />
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf|'''MR Elastography of the Liver, Public Comment Profile (July 28, 2017)''']]<br />
*[[Media:Draft-MRE-QIBAProfile-2017-07-06.pdf|''MR Elastography of the Liver, Initial Draft (July 6, 2017)'']]<br />
<br />
==Working Documents==<br />
<br />
==Statistical Reference Documents==<br />
<br />
<br />
==Workflow Documents==<br />
<br />
<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Repeatability_Literature_Review.pdf|Repeatability Literature Review Citation List]]<br />
*[[Media:MREPresentationApril142015.pdf|MRE Presentation Slides from April 14, 2015 Meeting]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=FMRI_Biomarker_Ctte&diff=19467FMRI Biomarker Ctte2023-12-21T16:43:05Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}} <br />
:Co-chairs: Feroze Mohamed, PhD; Jay Pillai, MD, David Soltysik, PhD<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRmbBBPzs35pygRlHH-UtLJWZ9VbYBj3oFsAmQSFkp-OWx3-6YV8Yk5BaGTnUCKnSH0J_cjk1bIsd9f/pubhtml '''Roster''']<br />
<br />
<br />
<br />
==Meetings==<br />
Biweekly Tcons, 1st and 3rd Wednesdays of each month @ 11am-12pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
<br />
'''Recently approved call summaries:'''<br />
<br />
*[[Media:2023 12-20 QIBA fMRI BC Meeting Summary-FINAL.pdf|December 20, 2023]]<br />
*[[Media:2023 12-06 QIBA fMRI BC Meeting Summary-FINAL.pdf|December 6, 2023]]<br />
*[[Media:2023 11-15 QIBA fMRI BC Meeting Summary-FINAL.pdf|November 15, 2023]]<br />
<br />
'''''[[fMRI Call Summaries Archive]]'''''<br />
<br />
==Working Documents==<br />
<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] ''June 28, 2017 Profile for Public Comment''<br />
*[[fMRI Working Documents Archive]] ''(includes materials more than 2 years old)''<br />
==Statistical Reference Documents==<br />
*[[Media:FMRITechnicalPerformanceIndices042613.pdf|QIBA fMRI Technical Performance Indices]] ''Dr. Erich Huang 4.26.2013 (PDF)''<br />
*[[Media:FMRITechnicalPerformanceIndices042613.doc|QIBA fMRI Technical Performance Indices]] ''Dr. Erich Huang 4.26.2013 (Word doc)''<br />
<br />
<br />
<br />
==Workflow Documents==<br />
<br />
*[[Media:ASFNR QIBA fMRI poster2013 V3.pdf|QIBA fMRI Workflow Survey Results - ASFNR 2013 poster]]<br />
*[[Media:QIBA-fMRI ASFNR poll 2012.pdf|QIBA fMRI Technical Committee ASFNR poll 2012]]<br />
*[[Media:QIBAWorkflowChecklistJV.xls|QIBA fMRI Workflow Checklist]] ''Dr Voyvodic 11.11.2010''<br />
*[[Media:DeYoe workflow-20101004.doc|Workflow - Dr. DeYoe - October 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010.NNL.CE.QIBA-1.doc|Workflow - Dr. Elsinger - October 2010]]<br />
*[[Media:Reuss Prism fMRI workflow 20100930.doc|Workflow - Dr. Reuss - September 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010-05-18 MNI.pdf|Workflow - Dr. Tucker - July 2010]]<br />
*[[Media:Duke Workflow for May 2010 Mtg.doc|Workflow - Drs Voyvodic and Petrella - May 2010]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Language fMRI Studies for Presurgical Planning.xlsx|Language fMRI Studies for Presurgical Planning]]<br />
<br />
*[[Media:QIBA-fMRI abstract ASFNR 2012.doc|ASFNR Abstract 2012 for group review]]<br />
<br />
* Friston KJ. Nonlinear Responses in fMRI: The Balloon Model, Volterra Kernels, and Other Hemodynamics. ''Neuroimage'' 2000; 12: 466-77. http://www.ncbi.nlm.nih.gov/pubmed/10988040 <br />
<br />
*[[Media:FMRI-Linear Systems Model-11Dec2012.pdf|fMRI Linear Systems Model Diagram]] ''11Dec2012''<br />
<br />
*'''''J Cereb Blood Flow Metab'''''. 2012 Nov;32(11):2044-54. doi: 10.1038/jcbfm.2012.105. Epub 2012 Jul 25.<br />
Visualization of altered neurovascular coupling in chronic stroke patients using multimodal functional MRI.<br />
Blicher JU, Stagg CJ, O'Shea J, Ostergaard L, Macintosh BJ, Johansen-Berg H, Jezzard P, Donahue MJ.<br />
<br />
''Source''<br />
1] Research Unit, Hammel Neurocentre, Aarhus University Hospital, Hammel, Denmark [2] CFIN, Aarhus University Hospital, Hammel, Denmark.<br />
PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/22828998<br />
<br />
*[[Media:DrTuckerSlides 2010 11 WG16.ppt -Compatibility M.pdf|Dr. Tucker's DICOM Work Group 16 Slide Set - Nov 2010]]<br />
<br />
*[[Media:FMRI Reproducibility071410.pdf|fMRI Reproducibility Study]] ''Dr Voyvodic - 07-14-2010''<br />
<br />
*[[Media:FMRI Subctte ReportOut-QIBA2010.ppt|fMRI SubCtte Breakout Session Report at QIBA 2010 - 05.26.2010]]<br />
<br />
*[[Media:American Academy of Neurology Classification of Evidence-20100504.doc|American Academy of Neurology Classification of Evidence]]<br />
<br />
*The Profile: [http://qibawiki.rsna.org/index.php?title=Profile:_CT_Lung_Nodule_Volume_Measurement_for_Primary/Regional_Nodes_and_Metastatic_Sites CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites] uses the UPICT template as a structure.<br />
<br />
*[[Media:ACR fMRI Clinical Guidelines.pdf|ACR fMRI Clinical Guidelines]]<br />
<br />
*[[Media:Bizzi et al Radiology 2008-20100210.pdf|Bizzi A, et al. '''Presurgical Functional MR Imaging of Language and Motor Functions: Validation with Intraoperative Electrocortical Mapping.''' Radiology 2008; 248:579-589]]<br />
<br />
*[[Media:DrMohamed-Price etal 2010-20100420.pdf|The anatomy of language: a review of 100 fMRI studies published in 2009, Cathy J. Price (Ann. N.Y. Acad. Sci. ISSN 0077-8923)]] ''Posted 04.20.2010''<br />
<br />
==fMRI Poster for RSNA Annual Meeting==<br />
<br />
*[[Media:QIBA 2012 fMRI QIBA RSNA.pdf|RSNA 2012 QIBA fMRI Tech Ctte Poster]]<br />
*[[Media:RSNA QIBA fMRI SCposter2011.Final.ppt|RSNA 2011 QIBA fMRI Ctte Poster]]<br />
*[[Media:RSNA QIBA fMRI SCposter2010.V2.ppt|RSNA 2010 QIBA fMRI SubCtte Poster - V2]]<br />
<br />
<br />
==PubMed Search Strategy==<br />
<br />
'''Search topic: fMRI in Presurgical Brain Mapping'''<br />
<br />
"Brain Mapping"[Mesh] AND "Magnetic Resonance Imaging"[Mesh] AND (functional[All Fields] OR "fmri"[All Fields]) AND (presurgical[All Fields] OR "Preoperative Care"[Mesh] OR "Surgery, Computer-Assisted"[Mesh]) AND ("humans"[MeSH Terms] AND English[lang])<br />
<br />
[http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brain%20Mapping%22%5BMesh%5D%20AND%20%22Magnetic%20Resonance%20Imaging%22%5BMesh%5D%20AND%20%28functional%5BAll%20Fields%5D%20OR%20%22fmri%22%5BAll%20Fields%5D%29%20AND%20%28presurgical%5BAll%20Fields%5D%20OR%20%22Preoperative%20Care%22%5BMesh%5D%20OR%20%22Surgery%2C%20Computer-Assisted%22%5BMesh%5D%29%20AND%20%28%22humans%22%5BMeSH%20Terms%5D%20AND%20English%5Blang%5D%29&cmd=DetailsSearch fMRI in Presurgical Brain Mapping - Click for PubMed search results]<br />
<br />
<br />
==fMRI-Bias Task Force==<br />
[[Archived: fMRI Bias WG Call Summaries]]<br />
<br />
<br />
==fMRI-DICOM Work Group==<br />
<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.13.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.13.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.11.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.11.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.4.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.04.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 09.01.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment-08.24.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 08.24.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment 07.27.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 07.27.2011''<br />
<br />
*[[Media:10.12.11 QIBA fMRI-DICOM WG Summary-FINAL.pdf|10.12.11 QIBA fMRI-DICOM Work Group Call Summary]]<br />
*[[Media:05.21.10 QIBA fMRI-DICOM WG Summary-FINAL.pdf|05.21.10 QIBA fMRI-DICOM Work Group Call Summary]]<br />
<br />
<br />
==fMRI Reproducibility Work Group==<br />
<br />
[[Archived: fMRI Reproducibility Call Summaries]]<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 1====<br />
*[[Media:1-Duke Brain Center - Yr1.pdf|Quantitative Measures of fMRI Reproducibility for Pre-Surgical Planning - Development of Reproducibility Metrics (Duke University)]]<br />
*[[Media:2-Medical College of Wisconsin-Yr1.pdf|Quantitative Measures of fMRI Reproducibility for Pre-Surgical Planning – Long Term and Functional Reproducibility (Medical College of Wisconsin)]]<br />
<br />
====Round 2====<br />
*[[Media:3-Johns Hopkins-Yr2.pdf|Project (19a): Validation of Breath Hold Task for Assessment of Cerebrovascular Responsiveness and Calibration of Language Activation Maps to Optimize Reproducibility (Johns Hopkins)]]<br />
<br />
====Round 3====<br />
*[[Media:FMRI DRO.pdf|Project (G) fMRI Digital Reference Objects for Profile Development and Verification (Medical College of Wisconsin)]]<br />
<br />
====Round 4====<br />
*[[Media:Generation and Testing of Advanced Digital Reference Objects for fMRI.pdf|Project (V) Generation and Testing of Advanced Digital Reference Objects for fMRI (Medical College of Wisconsin)]]<br />
<br />
====Round 5====<br />
*[[Media:Quantitating Clinical fMRI Mapping of Language-Center, Spatial Extent, and Relative Strength of Active Areas.pdf| Project (D) Quantitating Clinical fMRI Mapping of Language-Center, Spatial Extent, and Relative Strength of Active Areas (Duke University)]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=MR_Coordinating_Committee&diff=19466MR Coordinating Committee2023-12-21T16:42:53Z<p>SStanfa: </p>
<hr />
<div>__NOTOC__<br />
<br />
Co-Chairs: Michael Boss, PhD; Thomas L. Chenevert, PhD; Nandita deSouza, MD, Jacob (Bram) Stolk, PhD, MBA<br />
*[https://docs.google.com/spreadsheets/d/e/2PACX-1vReaE9KRKRnlwhq95r9wrvLzVcZMg5iehJatSFB4ZtrDgP99-Fg-kT1Mqiqhxj6IkUDgFqF-jItmXEO/pubhtml?gid=1050413002&single=true '''Roster''']<br />
<br />
==Scope== <br />
The MR Coordinating Committee is responsible for:<br />
:* Monitoring and coordinating the activities of MR Biomarker Committees<br />
::* [https://docs.google.com/spreadsheets/d/1A7_uieyw0uu2DKbP6Vkzd37JuBEb2zmm-yqfXJtV-p4/edit?usp=sharing QIBA Profile Dashboard] (MR Page)<br />
:* Considering and proposing new candidate Biomarker Committees to the [[Steering Committee]]<br />
:* Preparing/Reviewing and Prioritizing groundwork funding proposals for submission to the Steering Committee<br />
:* Approving for publication Biomarker Profiles developed by the MR Biomarker Committees<br />
<br />
==Meetings==<br />
<br />
* Tcons are held Quarterly. Contact RSNA Staff for details.</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Process_Coordinating_Committee&diff=19465Process Coordinating Committee2023-12-21T16:42:24Z<p>SStanfa: </p>
<hr />
<div>{{TOCright}}<br />
:Chairs: Kevin O'Donnell, MASc (Chair); Michael Boss, PhD (Vice Chair)<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTrNnQ5nDG4cx3PR85G9xylDRqBWu9NGPRUyYk2p-f3ryIwE6W1bMmwmxkoFQFTF7w2-c5e3TSgzSkp/pubhtml Roster]<br />
* [https://docs.google.com/spreadsheets/d/13AN9KO9QsLEKJDCsfUDbC3LLCGUKqDfK1_fYna0iwYk/edit?usp=sharing Attendance, Quorum and Voting Eligibility]<br />
<br />
==Scope== <br />
The Process Committee facilitates the QIBA Coordinating Committees and their profiling activities by defining processes and tools to promote consistent quality work product. <br />
:* Develop common Templates & Processes<br />
:* Support & mentor adoption of above<br />
:* Drive consistent content & format of Profiles<br />
:* Support infrastructure for Committees<br />
<br />
==Meeting Agendas/Summaries==<br />
Biweekly Tcons, 1st and 3rd Tuesdays of each month @ 2-3pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
* Quarterly agenda topic: What to highlight during next CC call slots. See [[Process Education]] for potential topics.<br />
<br />
'''Agendas:'''<br />
*[[2022-09-06 Process Committee Agenda]]<br />
*[[2022-08-16 Process Committee Agenda]]<br />
*[[2022-08-02 Process Committee Agenda]]<br />
*[[2022-07-05 Process Committee Agenda]]<br />
*[[2022-05-17 Process Committee Agenda]]<br />
<br />
'''''[[Process Committee Agenda Archive]]'''''<br />
<br />
'''Approved call summaries:'''<br />
*[[Media:2023 12-05 QIBA Process Cmte Meeting Summary-FINAL.pdf|December 5, 2023]]<br />
*[[Media:2023 11-21 QIBA Process Cmte Meeting Summary-FINAL.pdf|November 21, 2023]]<br />
*[[Media:2023 10-31 QIBA Process Cmte Meeting Summary-FINAL.pdf|October 31, 2023]]<br />
<br />
'''''[[Process Committee Call Summaries Archive]]'''''<br />
<br />
==Working Documents==<br />
<br />
* [[Claim Guidance]]<br />
* [[Assessment Procedure Guidance]]<br />
* [[QIBA Profile Stages]]<br />
* [[Process Education]]<br />
* [https://docs.google.com/document/d/100wJv_r0KZVAfIIMP0V8dLDdsjVQb6Uznxymf7yO8LI/edit?usp=sharing Profile Writing Guidance Ideas]<br />
* [https://docs.google.com/spreadsheets/d/1bVP9pSjxtCVinlASCAeGDf5vjc2lCfj16qEg7hkft0Q/edit?usp=sharing Wiki Use Cases]<br />
<br />
<br />
'''New Topics'''<br />
<br />
Review, prioritize, and discuss which might merit a Task Force (to work between Process Cmte Meetings)<br />
<br />
* NEXT - What will "Process" look like after Dec 2023<br />
** NEED/ASK description of how QUIC will be organized and work<br />
*** Continuity of existing process vs "Clean Break" and start over?<br />
*** What Stage is the focus of QUIC? Need deployment. Not clear if QUIC is looking to deploy tested profiles or untested profiles (and let the adopters work things out)<br />
** Which Biomarker Committees will continue to work? Who do they submit their work to?<br />
** Is there any reason to expect different processes?<br />
** Is the current process description/documentation/details adequate to support such ongoing activities<br />
*** How do we support "externally developed" profiles?<br />
** How does wiki and process maintenance work after Dec 2023?<br />
*** Which Cmte would do the maintenance work? (Note that as tech evolves, profiles will become outdated)<br />
** Process Cmte has typically laid the groundwork of "what's next", should continue <br />
** Status Quo - existing processes continue unless an authoritative organization revises or defines new processes<br />
** TODO Consider an "MOU/FAQ/Handbook" for a society that is "adopting" a Biomarker Committee, pointing to the existing processes/templates, etc.<br />
*** ISMRM - PDFF (and others?); AIUM - VBF, PEQUS, maybe CE & SWS; EIBALL - ASL & SLN?; AAPM - various?; some others tentative;<br />
*** What are the expectations of what a hosting society does/provides<br />
*** Maybe also provide a framework for each BC to understand where they're at, and what are the options going forward.<br />
**** What stage is your profile at; will it reach the next by Dec; do you have people to continue work; what org is willing to host the work; etc.<br />
**** Maybe update the dashboard to reflect this? (Copy/revise)<br />
*** Will lose the oversight ballot of Coordinating Cmte?<br />
** <br />
* NOW - What support do the current biomarker committees need during July-Dec 2023<br />
** Do we describe "accelerated approvals"?<br />
*** Note that CC Ballots can be voice vote during a call (but circulate doc 2 weeks before meeting) and that BC Ballots can be as short as 2 weeks (but make sure you're going to have enough reviewers/voters who can review it in that time)<br />
** Is there a mechanisms for ballots to be run/completed after Dec 2023? (RSNA Staff just for ballots? AAPM?)<br />
*** Q. Can we think of a way to publish work that is part way to the next stage to formally log the "final" state of the document.<br />
** Do we need to review the library and given no maintenance process, any that we want to deprecate<br />
** Continue to support usage/understanding of the Requirements Criteria and Streamlined Template.<br />
** Try to help complete SLN V2 release?<br />
* Wiki Cleanup<br />
** Mike: Document some of the additional criteria that seemed helpful during the recent approvals and get it on the wiki<br />
** Resolution Template: A bit of wiki cleanup and also highlight the value to transparency and closing the loop (things don't fall through the cracks)<br />
** Stage 4 guidance - make sure the current criteria are clear, and the thinking behind them.<br />
* Editors Meetings<br />
:* Put in Current work - consider TF - eventually will be a separate meeting track for the actual meetings anyway - would be nice to convene by start of summer<br />
:* Perhaps Quarterly<br />
:* 1) Identify the editors (See Dashboard - ask CC's to confirm Row 12 if their dashboards are up to date) - email to CC cochairs<br />
:* 2) Heads-up email to editors - explain intentions, ask for suggestions of topics/issues/questions and logistics/timing<br />
:* 3) Consider face-to-face time when possible (QIBA Annual Meeting, RSNA Annual Mtg) - happy hour<br />
<br />
* Committee Expertise Roster<br />
:* Dashboard item to confirm representative(s) for major stakeholder groups<br />
::* Radiologists (incl. academic, private practice (might challenging in terms of time) but if we get ACR traction, and QIBs are billable, interest might grow), Physicists, Technologists, Scanner vendors, SW vendors, CRO (implications for recruitment, burden for conducting), Pharma (biological use of the metric, claim details), Statisticians, Regulatory (device regulators, biologic regulators), ...<br />
::* Q. If there are multiple, who do you list?<br />
:* Stakeholder representatives are liaisons responsible for engaging with their stakeholder community<br />
:* If the BC has a roster "gap", need extra engagement effort during public comment, or periodically on a focused call, invite to face-to-face meetings <br />
<br />
* Q. What does the testing & conformance process look like for a Clinical Trial to be QIBA Profile Conformant? (Andy, Gudrun)<br />
<br />
===Current Work===<br />
<br />
====Maintenance Process and Profile Edition & Version Guidance====<br />
* New Steering Committee Priority?<br />
* Discuss some basic concepts then spawn TF if needed<br />
:* Conventions for Published Profile edition/version names<br />
::*[[Profile Editions]]<br />
::* [https://docs.google.com/spreadsheets/d/1_T8MXNkkgFQ7jQmrLMjtuGVqOs-AgA2vU745RMZa1d4/edit#gid=0 Examples]<br />
::* Address same-stage updates, not just stage transitions<br />
::* This is important - when in a stage, how do we update (change requirements) prior to moving to new stage.<br />
::* Highlight the Change Log as a place to point readers to key areas to review (if they were familiar with the old) and perhaps note the implications/significance (release notes)<br />
:* Conventions for internal filenames during Profile development<br />
::* [[Change Tracking and File Naming]]<br />
::* Lower priority but relevant<br />
:* Tracked Change Process<br />
::*[[Maintenance Process]]<br />
::* This is probably needed for the Profile Editions to ensure managed change not arbitrary.<br />
::* Describe what constitutes "editorial change" (that doesn't require re-approval), what requires going through approval again (maybe just at BC level, notify CC chairs and allow them to decide if they want to weigh in?), and what that looks like<br />
::* ISO has a "systematic review" process every 5 years for its standards. Do we want to introduce a similar process, e.g. as part of CC portfolio management. (TODO Write this up as a proposal to the Steering Cmte - '''May 9th''')<br />
::** Profile Renewal Process (WIP Proposal)<br />
::*** Each Modality Coordinating Committee is responsible for managing their portfolio of Profiles<br />
::*** Profiles have the potential to become “stale”<br />
::*** QIBA Staff will notify CC Co-chairs when a Profile is approaching 5 years <u>since most recent publication</u><br />
::**** If a BC is actively progressing a Profile, it would be getting republished "regularly" and would not trigger this review<br />
::**** The CC also has the responsibility to do such a review earlier if they have the sense that technology or clinical practice has evolved<br />
::*** The CC should notify the BC (if that committee/mailing list is still active)<br />
::*** The CC may request a formal assessment/recommendation from the BC<br />
::*** The CC will vote to Revise (modify, re-approve, re-publish), Renew (re-publish unchanged), or Retire (withdraw from current publication) the Profile<br />
::**** Retired Profiles will still be available on the website, but won’t be on the page of current Profiles<br />
::*** Suggested criteria/considerations (TODO Add text that these are not If-Then criteria, but rather things to spur discussions. It's OK to renew an unadopted Profile, might need more time)<br />
::**** Is there work underway in the BC? If so, it likely makes sense to allow that to proceed (effectively a “Revise” decision)<br />
::**** Is there known adoption of the Profile? If so, Renew or Revise are likely appropriate<br />
::**** Does the Claim performance meet current clinical needs? If not, consider Revise or Retire<br />
::**** Has technology advanced to the point where conformance could be made easier, or performance could be better? If so, consider Revise<br />
::**** Have new clinical practices or consensus emerged that the Profile could align to? If so, consider Revise<br />
::***** Consensus about "best practices" and guidelines may have emerged/shifted and the Profile should take into consideration/harmonize/promote<br />
::***** Also the clinical expectations and usage may have evolved and we should harmonize<br />
::***** Partnership with other organizations and specifications means we may have "convergence" activities to do (e.g. EANM) <br />
::**** Has the regulatory/certification/site conformance criteria environment changed in ways we should harmonize with<br />
::**** Have any new publications or trials come out that inform changes in our Profile?<br />
* Do as one work item or divide into multiple - some complexity<br />
:* Key people - MRE (Kay), FDG (Gudrun will ask Jeff to recommend), DWI (Mike)<br />
<br />
====Streamlined Profile Template====<br />
* Mike & Kevin taking first pass at streamlining Profile document (some additional points in the draft template)<br />
:* Revisit the topic of dropping requirements post-TechConf to see how feedback informs<br />
:* Flavors of possible drops: (Some things are always being done, others are not affecting the claim even if not done)<br />
:* Reluctance to discarding information that took effort/time to develop (keep? preserve in appendix?)<br />
:* Streamlining is partly moving things around for better ordering, some is taking things out (or moving to appendix)<br />
:* Plan a small call on DWI - Mike/Kevin<br />
::* Are there structures we could think of to deal with the multi-organ usage of DWI? Optional modules? Multi-profiles with common parts?<br />
:* Once we vet it internally, we can make it available for voluntary use/conversion by committees.<br />
:* Don't want to distract committees, or force "unnecessary" work. <br />
:* Plan to publicize it in the CC meetings and promote the benefits/concepts. <br />
::* Don't want to blindside any BCs. Maybe start telegraphing the situation now... Reassure we're not going to force rewrites.<br />
::* Harmonize assessment procedures across profiles<br />
<br />
====Estimates of Precision (Wrap)====<br />
* TODO Need some guidance text (like '''[[Vetting Requirements|Criteria page]]''') for BCs to understand; keep as a high priority item. Need to tidy up following text<br />
* Nancy will work on some guidance text in Word for later in March; after review can fold into Wiki.<br />
* Homework for Nancy & Kevin & (Nancy designee)(Nick?)<br />
:* Estimates of Precision when BC Stages Profiles and when Sites Conform to Profiles<br />
::* This came out of issues raised by Nancy about when/where/who should do test/retest type estimates of precision<br />
::* The following rough notes are from the 4/5 meeting<br />
:::* Address such Estimation as part of conformance assessment of each site and/or actor<br />
:::* Discuss BC choice to include assessment of actors/site precision as profile conformance requirement<br />
:::* Detail situations that would necessitate such profile requirements <br />
:::* Made all BC put in a Section 4 procedure to test linearity and bias with phantoms to ensure estimate is under the claim.<br />
:::* Q. Do we require the BC to do it once? Or do we require each site to do it as part of conformance?<br />
:::* At Stage 3, we might not need it as BC, but if we suspect we’re going to need it, we should test the practicality. <br />
:::* How much of a burden is test/retest? It varies depending on the amount of data required. When phantom data captures the variability you are looking for, it can be fairly easy (assuming access to the phantom is easy and the time is short).<br />
:::* BC also chooses the pass/fail threshold that provides reasonable confidence in meeting the claim.<br />
:::* If we see profiles mostly stopping at Stage 3, does it make sense to include a test/retest <br />
:::* Given that Stage 4 is a lighter weight Stage 5, What if we had an even “lighter-weight” that is not enough to reach Stage 3 but is somehow better.<br />
:::* Gap: we’re not doing groundwork with the procedures we have made in the profile (Basically that’s Stage 4) – it’s better if there have been Stage 1 groundwork that are roughly following the requirements, but most profiles do not have this.<br />
::* Key Point is Communication of what the conformance means at each level<br />
:::* The profile might state at in/near the claim what conformance means<br />
:::* There is value to all levels of conformance<br />
:::* Stage 2 - clearly(?) the claim is off the table. Stage 4 - clearly the claim is on the table.<br />
:::* Stage 3 is the current "danger" area. <br />
:::* So conformance to Stage 3 does not require 95% testing, but if a site is willing to do that (and thus help the BC on it's way to getting the profile to Stage 4 where everyone who then conforms can invoke the claim) how do we document/acknowledge/credit/thank them for that.<br />
::::* Guidance for how to design the Stage 3 to Stage 4 study. Note that the BC can decide to either tighten requirements or loosen claim if they two don't match. - NOTE this changes the design of the study. BC might need to weigh in which way they want to go before designing the study.<br />
::::* Some profiles have very stringent testing (e.g. claim says wcv is 10%, the profile/actor must show with 95% CI that wcv <=10%) in that we are requesting they confirm the claim directly as part of conformance. Need to better distinguish what BC does for Stage 4 vs what a Profile requires for conformance.<br />
<br />
====Stage 3 Resolution Template (Wrap)====<br />
* Have the templates '''TODO''' need to finish cleaning up the Process Page, check above bullets, then close out.<br />
* Homework - Kevin - links/pointers<br />
* Map out how to collate practical feedback from sites into a sheet for resolution similar to public comments.<br />
* Use the checklists - it's what they'd see in the field and it's "simple" - they can scan and we'll transcribe<br />
* Additionally, the overall questions solicit broader comments which is really useful as well.<br />
* Don't want identification being a barrier to feedback. But it's nice to be able to followup.<br />
* Be VERY clear that we don't intend to broadcast the site details<br />
* Do some clean up and run it around the coordinating/biomarker committees for feedback.<br />
* Cover letter to solicit broad feedback, and the checklists both feed material into the resolution sheet.<br />
* <See notes on Process Page for Tech Conf><br />
* '''Discussion Point''': To what degree are we collecting feedback (survey) vs doing a dry run of site conformance process vs both<br />
:* Consider starting some Blog threads e.g. feedback on the Tech Conf<br />
<br />
:* Conformance Process<br />
::* What should go into a Conformance Record? - (e.g. findings from Technical Confirmation tests)<br />
::* Need a common view of what conformance entails, how it is achieved, what it looks like to a product, how it is documented, etc.<br />
::* Then we need to ensure that the QIBA Templates/Process supports those things clearly.<br />
::* Kevin will put some initial thoughts on a Wiki page and we can review/add<br />
::* How often should conformance assessment be done, who will assess, who will keep records?<br />
::* Should QIBA get into hosting the Conformance Statements on our site (and then we could link to them from the Profiles page which would be very handy)<br />
::* Consider the RSNA Image Share Conformance Assessment Program and whether we should do something similar for QIBA <br />
:::* Process committee can think through the details of a process and confer with RSNA whether they would be interested<br />
<br />
===Priority (Next)===<br />
<br />
====Profile Selection Process (SCP)====<br />
* Move into Current Work - Consider setting up a TF - gauge participants - below Version/Naming<br />
* Review/update review criteria/evaluations for new BC proposals<br />
:* Harvest from past experiences<br />
::* [https://docs.google.com/document/d/1PmWlLZE8lRmH4gZXi_TQA3wtDRvrEyX_iDLfEX3L5Zg/edit?usp=sharing Profile Success Factors and Challenges Survey Planning]<br />
:* Given limited resources, how to approve not just good proposals but the best proposals<br />
::* It's not just about saying "Yes". It's about When should we say "No". When should we say "Not Yet"<br />
:* Evidence that the biomarker already has vendor and user adoption and just needs the "last mile" improvements that QIBA brings.<br />
* Consider Prior Project completion when Steering Cmte reviews new Proposals from the same PI.<br />
:* timing overlap of prior cycle completion period with new proposal period needs to be one considered.<br />
:* possible solution would require final reports for prior COMPLETED funding cycles before considering a new project proposal<br />
* Discuss which profiles have been most successful, which have hit bumps, which have foundered<br />
:* What characteristics of each contributed to the success/problems? Can we look for those during selection?<br />
:* As we refine criteria for new proposals, also see how they do/don't apply well to existing profile work<br />
* Discuss Nancy's criteria for ultimate Claim Confirmation?<br />
:* BCs should understand what they are getting into and start planning for it<br />
:* If the profile will depend on a large test/retest being completed and it seems highly unlikely that would ever be doable, should that weigh on the SC approving the BC?<br />
<br />
===ToDo===<br />
<br />
====Profile Format Harmonization====<br />
* Various profiles differ in their layout and content which makes it harder for users<br />
:* Use of New Templates has not been mandated, but rather left to committee discretion so as not to be disruptive<br />
:* Various committees have deviated from the template and/or introduced variations without discussing with the Process Cmte<br />
* Consider starting with a table showing which template each profile is using<br />
:* Process makes table; Tags for Informal template; Formal#1, Formal#2 (Streamlined) and other divergence notes<br />
:* CCs get it populated; SC decides on priority/mandate? of harmonizing<br />
:* Use to inform "harmonization pressure" efforts?<br />
<br />
====Communicating Uncertainty to Radiologists====<br />
::* "No measurement is complete without a statement of it's uncertainty" - NIST<br />
::* Measurement uncertainty is at the heart of what QIBA does<br />
::* If people don't recognize/appreciate measurement uncertainty they can't grasp the value of QIBA fully (or at all?)<br />
::* How do we get radiologists to appreciate the uncertainty of each measurement and incorporate it into their thinking and decision making?<br />
::* What should best practice be for communicating the uncertainty of each measurement to radiologists?<br />
:::* Always give a confidence interval rather than a value?<br />
::* Very Important Problem, not clear we could make a dent on solution in 5 months (but maybe problem definition?)<br />
::** And is this the Process Cmte job? Note really. Find a way to hand off to QUIC. Need to put more punch behind the message. <br />
::** Get it on the wiki for posterity and consultation<br />
<br />
====On-boarding Process====<br />
* Goal: Help new committees, new members, new authors, new reviewers, new adopters<br />
* Communication Committee might shoulder some of this too and only come to Process when gaps are found.<br />
* Reviewed "How to develop a Profile" Guidance<br />
:* Email How-To guide to current authors and ask them to read/feedback<br />
:* Then email to the current community since it is helpful for all contributors<br />
* Maybe update Profiles and Protocols page to focus less on UPICT and more on QIBA Profiles today.<br />
:* Linear layout<br />
:* Explain the mechanics of who does what with a profile (vendors, rads, techs, regulators, etc.)<br />
* Maybe add some "How to Read a Profile" guidance (also useful for reviewers), e.g. focus on Spec tables. Look at your relevant Activities/Procedures. Read the Discussion sections for more background.<br />
:* Explain about the Claims, the Actors, the Requirements and the Assessment Procedures structure of a Profile<br />
:* Advice may vary depending on viewpoint of the reader.<br />
:* Consider/discuss relative merits of moving the checklists from Annex E into Section 5 of the template<br />
* Joe's intro email, current template and stage docs, QIBA Fact Sheet<br />
:* Find a way to link directly into the "current" version of documents without having to update the links. Now we link to the Profile template page then you have to click a second time put pull up the template.<br />
* Could use a "fresh eyes"/newcomer commentary - find a newcomer guinea pig<br />
:* Kevin will work with Joe to get it into a Google Doc for revision and linking from the Wiki.<br />
:* https://docs.google.com/document/d/1jB1CPy1Mll_v-yzvSZk7acYv_SfC3VDAgS_WJ3y2pm8/edit?usp=sharing<br />
:* Include link to How-To guide<br />
:* Some people might like videos/webinars<br />
* Pictures and diagrams would help a lot for people reading what is "dry" text.<br />
* Types of newcomers/stakeholders - link from an "intro to QIBA - mother page" - '''[[Stakeholder Viewpoints]]'''<br />
:* Practicing [[QIBA for Radiologists]] (Dan), [[QIBA for Physicists]] (Tom Chenevert, Sam Armato, Paul K.), [[QIBA for Technologists]] (Mike), [[QIBA for Imaging Vendors]] (Kevin), analysis SW vendors/developers (Cathy?), researchers, clinical trialists, pharma (Gudrun?), [[QIBA for Core Labs]] (Pat?), [[QIBA for Regulators]] (both device and drug?) (Nick), patients/advocates/lay public, government policy, payers, [[QIBA for Statisticians]] (Nancy)<br />
:* DONE targeted intro to each?groups? of those viewpoints<br />
::* What is QIBA basically about, what is the key value of QIBA to them, how do they "use"/"interact with" QIBA (some of them are "actors", some are not)<br />
::* easy language, a few paragraphs, and links to specific wiki pages/documents/slides that would be a good next step for them<br />
:* Maybe add a "First Steps" section for each page (see [[QIBA for Statisticians]] for example) telling them the first things they could/should do<br />
:* Might be good to also have "stories from your colleagues" who are already in QIBA and their experiences.<br />
<br />
* Contact page on wiki? Point to qiba@rsna.org for questions/info on any committee, QIDW, etc.<br />
<br />
====Publication Process====<br />
* Ask Steering Cmte to determine whether having others publish is a necessity or not (Mike to draft some pro/con points - Kevin can help)<br />
::* Do the vendors and sites and trials that would be involved in using Profiles have an issue with these "standards" being published by QIBA (RSNA)?<br />
::* Would it be better if QIBA Profiles were balloted/published by another organization? IEC? IHE? AAPM? MITA?<br />
::* Would there be an impact in switching to a different document structure, formatting conventions, review/approval processes?<br />
<br />
====Clinical Confirmation Process====<br />
::* Methodology/Study Design guidance/requirements for achieving "Clinically Confirmed"<br />
<br />
====QIBA Tooling====<br />
::* How to use Google Docs? <br />
:::* Issues with references, access restricted by federal agencies and some companies<br />
::* Round trip fidelity between Word-Google-Word<br />
<br />
====QIBA Wiki====<br />
* [[QIBA Wiki Improvements]]<br />
* Wiki serves QIBA Committee work. Consider a new user oriented site (clinicians, administrators)?<br />
* Wiki vs RSNA.org<br />
:* Address relationship between wiki content (current, easy to update) and website content (authoritative, stable)<br />
::* Likely RSNA staff will periodically mirror wiki content up onto the website; address this in publication process.<br />
:* Consider how to handle handoffs between RSNA website<br />
::* RSNA website is controlled by the RSNA Marketing Department, must meet certain style requirements, and require resources beyond QIBA staff<br />
::* QIBA would still like to find a way for the more formal publications (e.g. later stage profiles) to be accessible from the RSNA website.<br />
<br />
====Literature Search Guidance====<br />
::* Process/best practices for review of literature around a new biomarker/profile (search is relatively straight forward)<br />
::* Assemble draft guidance to kick this off (Hendrik Laue, Ona Wu, Caroline? Chung)<br />
:::* See existing material - http://qibawiki.rsna.org/index.php/Tools_and_recommendation_for_structured_literature_review<br />
::* Where do you store references, what kind of search works best, what exactly are you looking for?<br />
::* Also meta-analysis guidance to determine sources and levels of variance<br />
::* PDF/DWI - using Google Sheet to track/tabulate/organize - inherently input from many sources so nice to have centralized, commonly edited, accessible<br />
<br />
====Product Reference Guidelines====<br />
* Draft Guidelines for Reference Implementations and commercial products in Profiles<br />
:* e.g., the underlying algorithm should be open/public/available/documented, QIBA will list all comers, non-commercial?, etc)<br />
* Level playing field, no favorites<br />
<br />
====Public Comment Attribution====<br />
::* don't push for anonymity. Encourage people to identify themselves (deserve credit and we want to be able to followup)<br />
::* form can accept anonymous, but encourage constructive criticism that will be taken in the spirit given.<br />
<br />
===Hold===<br />
Todo items that are on hold pending some trigger:<br />
<br />
====Claim Guidance====<br />
::* Hold pending people with questions/clarification needs on current text<br />
<br />
====[[Guidance Document Process]]====<br />
* Hold pending interest in "lightweight" QIBA output without claims/conformance<br />
* Basically "best practice" recommendations<br />
* Less rigor; Much easier to write, <br />
<br />
====Profile Retirement Process====<br />
::* Hold pending a profile we want to retire<br />
::* When do we "withdraw" or at least stop maintaining/promoting a Profile<br />
::* Review/borrow from corresponding IHE Process - http://wiki.ihe.net/index.php/Evaluation_of_Published_Profiles<br />
::* Review DICOM retirement concept (stays available in archives, not maintained/promoted)<br />
<br />
====Profile Disclaimer====<br />
::* Hold pending revist of Discriminatory Claims<br />
::* For now QIBA addresses technical performance. Getting into the clinical performance associated with Discriminatory Claims would open a lot of issues.<br />
<br />
====Statistical Assumption Testing Guidance====<br />
::* Conformance with the statistical assumptions is required at the various QIBA profile stages. <br />
::* Need guidance on the assumptions in the profile, validating the assumptions and testing actors for meeting those assumptions.<br />
::* Symmetrical vs Assymetrical change intervals?<br />
::* Questions about the numbers in "Academic Radiology: ?? Paper"<br />
<br />
===Past Work===<br />
This isn't all of it but here's some notes...<br />
<br />
====Conflict of Interest Policy====<br />
* Should have a policy statement on the wiki on QIBA expectations (e.g. what kind of things might come up and how might handle, e.g. recusal from votes or ballots)<br />
:* Dan has extracted some example wording used elsewhere (e.g. protocol approval committees, other orgs, AAPM)<br />
:* Is there a personal (financial?) benefit to the individual<br />
:* This may link into the question of getting cochairs to sign RSNA conflict of interest policy<br />
::* AGREE - guidance for guidances.<br />
* DONE - prepped language with examples and forwarded to SC/EC for approval and posting to the wiki<br />
<br />
====Public Comment Resolution====<br />
* DONE Set up Wiki page for holding all the comment resolution records from past public comment. - [[Profiles]]<br />
* Work with RSNA on a boilerplate email to send to commenters (who gave their email on the comment form) pointing to the resolutions document for their submitted comments. (Staff will draft some proposed text for review)<br />
:* (DONE) Could build it into the automatic confirmation message that the confirmation form sends out. <br />
* DONE Revised process to highlight circulating resolutions with ballots and posting by RSNA Staff when complete<br />
* DONE Updated resolution page<br />
* ONGOING get additional profiles to post their resolutions<br />
<br />
====Coordinating Committee Membership Criteria====<br />
* Review the current criteria [[Committee_Organization#Committee_Membership]]<br />
* Feedback to SC/EC<br />
:* Remove Modality Scientific Liaison (can bring in SMEs as voting/non-voting)<br />
:* Remove explicit cap on voting membership<br />
:* Flag "additional voting" as "At Large Members - suggest 2-4 people"<br />
:* Keep all Co-chairs of BCs<br />
:* Suggest adding 3-year term (renewable) for CC xChairs - RSNA Staff will think through logistics - currently doing a CC membership review - will be some turnover. Staggered rotations is desirable.<br />
:* Process Cmte participation (periodic education agenda item like for BC) is useful, but can fit easily under the non-voting SME umbrella.<br />
<br />
====Profile Ballot Reminders====<br />
* Consider something like the following:<br />
: ''Please indicate below whether this Profile''<br />
::* ''meets the criteria for this stage'' [link to criteria]<br />
::* ''conforms to profile guidelines'' [link to guidelines]<br />
::* ''is of sufficient quality to publish''<br />
:: ''Note: if you are unable to read through the profile, you may Abstain.''<br />
<br />
====Requirement Criteria====<br />
* Making profiles shorter...<br />
:* Drop requirements that aren't critical<br />
:* DONE - devised, documented and communicated an approach to [[Vetting Requirements]]<br />
::* Impact Criteria Assessment: Asking existing profiles to go back and fill in a column may invoke some resistance to the effort required.<br />
::* One approach: Have the BC go through all the requirements and do an impact pruning just before Pub Cmte release<br />
:::* Don't require long winded justifications, a short clear statement should be sufficient<br />
* QIB Guidance documents (not Profiles) can have a role since they don't have a claim so dropping "requirements" is less of an issue<br />
<br />
====Driving Profile Adoption====<br />
* Adoption of Profiles<br />
:* Maybe a new TF to support Adoption (can include some Process people)<br />
::* Ed, Brad, Joe, Kevin, Dan, RSNA Webperson<br />
::* Start by looking at what is on the RSNA QIBA pages,<br />
* [https://docs.google.com/document/d/1YM0mreBRLNNQZicDatx1IE3Zi1NZeaojQJczrEIbvsk/edit?usp=sharing Biomarker Adoption Steps] - Framework for when/how site stakeholders are engaged<br />
:* Basis for reviewing organization/content/structure of current QIBA documents/deliverables<br />
* Ultimately addressed by formation of [[QIBA Sustainability Implementation Committee (QSIC)]]<br />
:* For further details, see [[QIBA Sustainability Implementation Committee (QSIC)|QSIC page]]<br />
:* Process Cmte can support QSIC when process questions/refinements come up.<br />
<br />
====Committee Leadership Process====<br />
* Address BC and CC leadership<br />
* Continue with variations of '''co-chair/chair/vice-chair'''? - Maybe call everything below Steering Cmte as co-chairs and let them work out working patterns.<br />
* Describe process for '''nominating & selecting''' that is transparent, allows time for nominations & self-nominations, encourages diversity<br />
:* Mostly current system has been working without major issues, but would like to have efficient flow rather than everyone re-thinking/re-inventing a process<br />
* Process for recognizing cases where cochair availability/activity has decreased and need to call-the-question and trigger "replacement".<br />
:* Having '''"terms"''' would help trigger. E.g. 3-year terms, and limit of two terms to promote turnover, new faces, new ideas in some committees, on the other hand keeping experienced people and having continuity is good and there may be a limited supply of motivated leadership.<br />
:* CC term limits might be OK, but BC should maybe not have limits because they are intended to a have a limited life to start, and the chair is a key leader and change could falter<br />
:* If we stick with 3 year terms, might want to have a procedure where a cochair missing 8 meetings in a row triggers the secretariat doing a checkin to confirm that they still have the bandwidth/availability, and give them the opportunity to step aside if their other responsibilities have intruded. <br />
* '''Stakeholder diversity''' (silent, recommend, or require)<br />
:* Having "only academic representation" is an adoption risk to QIBA, so there is a value to making some effort to have diversity<br />
:* Variability in the size of some committees so tough to enforce<br />
:* Lets Strongly Recommend (and maybe make it a review point in the Coord Cmte and the Steering Cmte to ask about attempts to improve?)<br />
:* Also consider this when forming a Biomarker Committee - require? At least formally build into the evaluation process.<br />
:* Consider handling committee stakeholder diversity in the committee formation and dashboard process, not the leadership process<br />
:* Define Stakeholder diversity; do we make user/vendor classes? or is one academic radiologist and one clinical trial radiologist the intended degree of diversity?<br />
<br />
* For comparison - DICOM:<br />
:* For Working Groups it's required but unconstrained "Working Groups shall elect a chair or co-chairs."<br />
:* For the DSC (Steering Cmte) it's more constrained<br />
::* There shall be two co-chairs – one representing a producer and one representing a biomedical professional organization.<br />
::* Each co-chair shall serve a two-year term and may serve no more than two consecutive terms. The terms of the co-chairs shall expire in alternate years.<br />
::* At the meeting preceding the meeting before the last Committee meeting each year, the co-chairs shall appoint a three-member nominating subcommittee consisting of at least one representative of a producer , one representative of a biomedical professional organization and one former committee officer (if one is available). The former officer (if one is available) shall chair the nominating subcommittee. Members of the nominating subcommittee shall develop and submit to the secretariat a slate of candidates. The names of the candidates should be submitted to the secretariat no later than 30 days prior to the meeting preceding the last meeting of the year so that their names may be included in the published agenda. Additional nominations may be made from the floor at this meeting.<br />
::* Prior to the last meeting of the year the secretariat shall conduct a letter ballot. The name of the person elected shall be announced at the last meeting of the year. That person shall assume office immediately following the last meeting of the year.<br />
::* The Committee has the right to recall a co-chair.<br />
<br />
* For comparison - IHE:<br />
:* There are general cochair guidelines in section 12.2.7 of the Governance: https://www.ihe.net/wp-content/uploads/2018/07/IHE-International-Principles-of-Governance.pdf<br />
:* The Board adds the constraint "The Board shall elect as co-chairs, two Board Members drawn from Member Organizations in the User category. They will serve as co-chairs for renewable two-year terms."<br />
:* The Domain Planning Cmtes adds the recommendation "It is recommended that one Domain Planning Committee co-chair be selected from the User member category and one from the Developer member category."<br />
<br />
* For comparison - RSNA:<br />
:* A nomination announcement contains a link to an online nomination form and deadline<br />
::* A comment box provides for nominators or self-nominators to state why they wanted to serve/would be a good addition to the leadership<br />
:* Once the nomination period ended, another announcement contains a link to an eballot listing nominees and their qualifications<br />
::* Joe helpfully pointed out that we need to clearly define voting eligibility (i.e. do voting privileges apply to chair selection or can everyone vote)<br />
<br />
==See Also==<br />
<br />
<br />
This page is based on the [[Committee Template]]. Add any good ideas you have to the template.</div>SStanfahttps://qibawiki.rsna.org/index.php?title=MSK_Biomarker_Ctte&diff=19464MSK Biomarker Ctte2023-12-21T16:30:35Z<p>SStanfa: /* Meetings */</p>
<hr />
<div><br />
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD <br />
<br />RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster]<br />
<br />
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.<br />
<br />
==Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br />
*[[Media:2023_12-12_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|December 12, 2023]]<br />
*[[Media:2023_10-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|October 24, 2023]]<br />
*[[Media:2023_09-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|September 26, 2023]]<br />
<br />
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''<br />
<br />
==Profile Documents==<br />
*[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile]]<br />
*[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile]]<br />
<br />
==Statistical Reference Documents==<br />
<br />
==Workflow Documents==<br />
<br />
==Reference Materials==</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023_12-12_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf&diff=19463File:2023 12-12 QIBA MSK BC Meeting Summary-FINAL.pdf2023-12-21T16:30:27Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=MSK_Biomarker_Committee_Call_Summaries_Archive&diff=19462MSK Biomarker Committee Call Summaries Archive2023-12-21T16:29:48Z<p>SStanfa: /* 2023 */</p>
<hr />
<div>==2023==<br />
[[Media:2023_01-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|January 24]] | [[Media:2023_04-25_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|April 25]] | [[Media:2023_05-23_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|May 23]] | [[Media:2023_07-25_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|July 25]] | [[Media:2023_08-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|August 22]]<br />
<br />
==2022==<br />
[[Media:2022-01-25_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|January 25]] | [[Media:2022-02-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|February 22]] | [[Media:2022-03-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|March 22]] | [[Media:2022-04-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|April 26]] | [[Media:2022-05-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|May 24]] | [[Media:2022-06-28_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|June 28]] | [[Media:2022-07-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|July 26]] | [[Media:2022-09-27_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|September 27]] | [[Media:2022-11-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|November 22]]<br />
<br />
==2021==<br />
[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26]] | [[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23]] | [[Media:2021_03-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|March 23]] | [[Media:2021_04-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|April 27]] | [[Media:2021_07-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|July 27]] | [[Media:2021_08-24_QIBA_MSK_BC_Call_Summary-FINAL.pdf|August 24]] | [[Media:2021_09-28_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 28]] | [[Media:2021_11-23_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|November 23]]<br />
<br />
==2020==<br />
[[Media:2020_03-24_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 24]] | [[Media:2020_04-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 28]] | [[Media:2020_05-26_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 26]] | [[Media:2020_06-23_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 23]] | [[Media:2020_07-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 28]] | [[Media:2020_09-22_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 22]] | [[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27]]<br />
<br />
==2019==<br />
[[Media:2019_01-15_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 15]] | [[Media:2019_02-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 19]] | [[Media:2019_03-26_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 26]] | <br />
[[Media:2019_04-23_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 23]] | [[Media:2019_05-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 28]] | [[Media:2019_06-25_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 25]] | [[Media:2019_09-24_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 24]] | [[Media:2019_10-22_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 22]]<br />
<br />
==2018==<br />
[[Media:2018_01-16_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 16]] | [[Media:2018_02-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 21]] | [[Media:2018_03-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 20]] | [[Media:2018_04-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 17]] | [[Media:2018_06-12_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 12]] | [[Media:2018_08-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 21]] | [[Media:2018_09-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 18]] | [[Media:2018_10-16_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 16]] | [[Media:2018_11-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 20]]<br />
<br />
==2017==<br />
[[Media:2017_06-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 20]] | [[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 18]] | [[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 29]] | [[Media:2017_10-17_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 17]] | [[Media:2017_11-21_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=FMRI_Biomarker_Ctte&diff=19461FMRI Biomarker Ctte2023-12-21T16:23:04Z<p>SStanfa: /* Meetings */</p>
<hr />
<div>{{TOCright}} <br />
:Co-chairs: Feroze Mohamed, PhD; Jay Pillai, MD, David Soltysik, PhD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRmbBBPzs35pygRlHH-UtLJWZ9VbYBj3oFsAmQSFkp-OWx3-6YV8Yk5BaGTnUCKnSH0J_cjk1bIsd9f/pubhtml '''Roster''']<br />
<br />
<br />
<br />
==Meetings==<br />
Biweekly Tcons, 1st and 3rd Wednesdays of each month @ 11am-12pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
<br />
'''Recently approved call summaries:'''<br />
<br />
*[[Media:2023 12-20 QIBA fMRI BC Meeting Summary-FINAL.pdf|December 20, 2023]]<br />
*[[Media:2023 12-06 QIBA fMRI BC Meeting Summary-FINAL.pdf|December 6, 2023]]<br />
*[[Media:2023 11-15 QIBA fMRI BC Meeting Summary-FINAL.pdf|November 15, 2023]]<br />
<br />
'''''[[fMRI Call Summaries Archive]]'''''<br />
<br />
==Working Documents==<br />
<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] ''June 28, 2017 Profile for Public Comment''<br />
*[[fMRI Working Documents Archive]] ''(includes materials more than 2 years old)''<br />
==Statistical Reference Documents==<br />
*[[Media:FMRITechnicalPerformanceIndices042613.pdf|QIBA fMRI Technical Performance Indices]] ''Dr. Erich Huang 4.26.2013 (PDF)''<br />
*[[Media:FMRITechnicalPerformanceIndices042613.doc|QIBA fMRI Technical Performance Indices]] ''Dr. Erich Huang 4.26.2013 (Word doc)''<br />
<br />
<br />
<br />
==Workflow Documents==<br />
<br />
*[[Media:ASFNR QIBA fMRI poster2013 V3.pdf|QIBA fMRI Workflow Survey Results - ASFNR 2013 poster]]<br />
*[[Media:QIBA-fMRI ASFNR poll 2012.pdf|QIBA fMRI Technical Committee ASFNR poll 2012]]<br />
*[[Media:QIBAWorkflowChecklistJV.xls|QIBA fMRI Workflow Checklist]] ''Dr Voyvodic 11.11.2010''<br />
*[[Media:DeYoe workflow-20101004.doc|Workflow - Dr. DeYoe - October 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010.NNL.CE.QIBA-1.doc|Workflow - Dr. Elsinger - October 2010]]<br />
*[[Media:Reuss Prism fMRI workflow 20100930.doc|Workflow - Dr. Reuss - September 2010]]<br />
*[[Media:Clinical fMRI Workflow and Data 2010-05-18 MNI.pdf|Workflow - Dr. Tucker - July 2010]]<br />
*[[Media:Duke Workflow for May 2010 Mtg.doc|Workflow - Drs Voyvodic and Petrella - May 2010]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Language fMRI Studies for Presurgical Planning.xlsx|Language fMRI Studies for Presurgical Planning]]<br />
<br />
*[[Media:QIBA-fMRI abstract ASFNR 2012.doc|ASFNR Abstract 2012 for group review]]<br />
<br />
* Friston KJ. Nonlinear Responses in fMRI: The Balloon Model, Volterra Kernels, and Other Hemodynamics. ''Neuroimage'' 2000; 12: 466-77. http://www.ncbi.nlm.nih.gov/pubmed/10988040 <br />
<br />
*[[Media:FMRI-Linear Systems Model-11Dec2012.pdf|fMRI Linear Systems Model Diagram]] ''11Dec2012''<br />
<br />
*'''''J Cereb Blood Flow Metab'''''. 2012 Nov;32(11):2044-54. doi: 10.1038/jcbfm.2012.105. Epub 2012 Jul 25.<br />
Visualization of altered neurovascular coupling in chronic stroke patients using multimodal functional MRI.<br />
Blicher JU, Stagg CJ, O'Shea J, Ostergaard L, Macintosh BJ, Johansen-Berg H, Jezzard P, Donahue MJ.<br />
<br />
''Source''<br />
1] Research Unit, Hammel Neurocentre, Aarhus University Hospital, Hammel, Denmark [2] CFIN, Aarhus University Hospital, Hammel, Denmark.<br />
PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/22828998<br />
<br />
*[[Media:DrTuckerSlides 2010 11 WG16.ppt -Compatibility M.pdf|Dr. Tucker's DICOM Work Group 16 Slide Set - Nov 2010]]<br />
<br />
*[[Media:FMRI Reproducibility071410.pdf|fMRI Reproducibility Study]] ''Dr Voyvodic - 07-14-2010''<br />
<br />
*[[Media:FMRI Subctte ReportOut-QIBA2010.ppt|fMRI SubCtte Breakout Session Report at QIBA 2010 - 05.26.2010]]<br />
<br />
*[[Media:American Academy of Neurology Classification of Evidence-20100504.doc|American Academy of Neurology Classification of Evidence]]<br />
<br />
*The Profile: [http://qibawiki.rsna.org/index.php?title=Profile:_CT_Lung_Nodule_Volume_Measurement_for_Primary/Regional_Nodes_and_Metastatic_Sites CT Lung Nodule Volume Measurement for Primary/Regional Nodes and Metastatic Sites] uses the UPICT template as a structure.<br />
<br />
*[[Media:ACR fMRI Clinical Guidelines.pdf|ACR fMRI Clinical Guidelines]]<br />
<br />
*[[Media:Bizzi et al Radiology 2008-20100210.pdf|Bizzi A, et al. '''Presurgical Functional MR Imaging of Language and Motor Functions: Validation with Intraoperative Electrocortical Mapping.''' Radiology 2008; 248:579-589]]<br />
<br />
*[[Media:DrMohamed-Price etal 2010-20100420.pdf|The anatomy of language: a review of 100 fMRI studies published in 2009, Cathy J. Price (Ann. N.Y. Acad. Sci. ISSN 0077-8923)]] ''Posted 04.20.2010''<br />
<br />
==fMRI Poster for RSNA Annual Meeting==<br />
<br />
*[[Media:QIBA 2012 fMRI QIBA RSNA.pdf|RSNA 2012 QIBA fMRI Tech Ctte Poster]]<br />
*[[Media:RSNA QIBA fMRI SCposter2011.Final.ppt|RSNA 2011 QIBA fMRI Ctte Poster]]<br />
*[[Media:RSNA QIBA fMRI SCposter2010.V2.ppt|RSNA 2010 QIBA fMRI SubCtte Poster - V2]]<br />
<br />
<br />
==PubMed Search Strategy==<br />
<br />
'''Search topic: fMRI in Presurgical Brain Mapping'''<br />
<br />
"Brain Mapping"[Mesh] AND "Magnetic Resonance Imaging"[Mesh] AND (functional[All Fields] OR "fmri"[All Fields]) AND (presurgical[All Fields] OR "Preoperative Care"[Mesh] OR "Surgery, Computer-Assisted"[Mesh]) AND ("humans"[MeSH Terms] AND English[lang])<br />
<br />
[http://www.ncbi.nlm.nih.gov/pubmed?term=%22Brain%20Mapping%22%5BMesh%5D%20AND%20%22Magnetic%20Resonance%20Imaging%22%5BMesh%5D%20AND%20%28functional%5BAll%20Fields%5D%20OR%20%22fmri%22%5BAll%20Fields%5D%29%20AND%20%28presurgical%5BAll%20Fields%5D%20OR%20%22Preoperative%20Care%22%5BMesh%5D%20OR%20%22Surgery%2C%20Computer-Assisted%22%5BMesh%5D%29%20AND%20%28%22humans%22%5BMeSH%20Terms%5D%20AND%20English%5Blang%5D%29&cmd=DetailsSearch fMRI in Presurgical Brain Mapping - Click for PubMed search results]<br />
<br />
<br />
==fMRI-Bias Task Force==<br />
[[Archived: fMRI Bias WG Call Summaries]]<br />
<br />
<br />
==fMRI-DICOM Work Group==<br />
<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.13.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.13.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.11.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.11.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment -10.4.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 10.04.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 09.01.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment-08.24.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 08.24.2011''<br />
*[[Media:Reuss-Proposal-DICOM-functional-assessment 07.27.2011.pdf|Proposal-DICOM Functional Assessment]] ''Dr Reuss 07.27.2011''<br />
<br />
*[[Media:10.12.11 QIBA fMRI-DICOM WG Summary-FINAL.pdf|10.12.11 QIBA fMRI-DICOM Work Group Call Summary]]<br />
*[[Media:05.21.10 QIBA fMRI-DICOM WG Summary-FINAL.pdf|05.21.10 QIBA fMRI-DICOM Work Group Call Summary]]<br />
<br />
<br />
==fMRI Reproducibility Work Group==<br />
<br />
[[Archived: fMRI Reproducibility Call Summaries]]<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 1====<br />
*[[Media:1-Duke Brain Center - Yr1.pdf|Quantitative Measures of fMRI Reproducibility for Pre-Surgical Planning - Development of Reproducibility Metrics (Duke University)]]<br />
*[[Media:2-Medical College of Wisconsin-Yr1.pdf|Quantitative Measures of fMRI Reproducibility for Pre-Surgical Planning – Long Term and Functional Reproducibility (Medical College of Wisconsin)]]<br />
<br />
====Round 2====<br />
*[[Media:3-Johns Hopkins-Yr2.pdf|Project (19a): Validation of Breath Hold Task for Assessment of Cerebrovascular Responsiveness and Calibration of Language Activation Maps to Optimize Reproducibility (Johns Hopkins)]]<br />
<br />
====Round 3====<br />
*[[Media:FMRI DRO.pdf|Project (G) fMRI Digital Reference Objects for Profile Development and Verification (Medical College of Wisconsin)]]<br />
<br />
====Round 4====<br />
*[[Media:Generation and Testing of Advanced Digital Reference Objects for fMRI.pdf|Project (V) Generation and Testing of Advanced Digital Reference Objects for fMRI (Medical College of Wisconsin)]]<br />
<br />
====Round 5====<br />
*[[Media:Quantitating Clinical fMRI Mapping of Language-Center, Spatial Extent, and Relative Strength of Active Areas.pdf| Project (D) Quantitating Clinical fMRI Mapping of Language-Center, Spatial Extent, and Relative Strength of Active Areas (Duke University)]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=FMRI_Call_Summaries_Archive&diff=19460FMRI Call Summaries Archive2023-12-21T16:22:36Z<p>SStanfa: /* 2023 */</p>
<hr />
<div>==2023==<br />
[[Media:2023 01-04 QIBA fMRI BC Meeting Summary-FINAL.pdf|January 4]] | [[Media:2023 01-18 QIBA fMRI BC Meeting Summary-FINAL.pdf|January 18]] | [[Media:2023 02-01 QIBA fMRI BC Meeting Summary-FINAL.pdf|February 1]] | [[Media:2023 02-15 QIBA fMRI BC Meeting Summary-FINAL.pdf|February 15]] | [[Media:2023 03-01 QIBA fMRI BC Meeting Summary-FINAL.pdf|March 1]] | [[Media:2023 03-01 QIBA fMRI BC Meeting Summary-FINAL.pdf|March 1]] | [[Media:2023 03-15 QIBA fMRI BC Meeting Summary-FINAL.pdf|March 15]] | [[Media:2023 04-05 QIBA fMRI BC Meeting Summary-FINAL.pdf|April 5]] | [[Media:2023 05-03 QIBA fMRI BC Meeting Summary-FINAL.pdf|May 3]] | [[Media:2023 06-07 QIBA fMRI BC Meeting Summary-FINAL.pdf|June 7]] | [[Media:2023 06-21 QIBA fMRI BC Meeting Summary-FINAL.pdf|June 21]] | [[Media:2023 07-05 QIBA fMRI BC Meeting Summary-FINAL.pdf|July 5]] | [[Media:2023 07-19 QIBA fMRI BC Meeting Summary-FINAL.pdf|July 19]] | [[Media:2023 08-02 QIBA fMRI BC Meeting Summary-FINAL.pdf|August 2]] | [[Media:2023 08-16 QIBA fMRI BC Meeting Summary-FINAL.pdf|August 16]] | [[Media:2023 09-06 QIBA fMRI BC Meeting Summary-FINAL.pdf|September 6]] | [[Media:2023 09-20 QIBA fMRI BC Meeting Summary-FINAL.pdf|September 20]] | [[Media:2023 10-04 QIBA fMRI BC Meeting Summary-FINAL.pdf|October 4]] | [[Media:2023 10-18 QIBA fMRI BC Meeting Summary-FINAL.pdf|October 18]] | [[Media:2023 11-01 QIBA fMRI BC Meeting Summary-FINAL.pdf|November 1]]<br />
<br />
==2022==<br />
[[Media:2022_01-05_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|January 5]] | [[Media:2022_01-19_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|January 19]] | [[Media:2022_02-02_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|February 2]] | [[Media:2022_02-16_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|February 16]] | [[Media:2022_03-02_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|March 2]] | [[Media:2022_03-16_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|March 16]] | [[Media:2022_04-20_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|April 20]] | [[Media:2022_05-04_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|May 4]] | [[Media:2022_05-18_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|May 18]] | [[Media:2022_06-01_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|June 1]] | [[Media:2022_06-15_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf|June 15]] | [[Media:2022 07-06 QIBA fMRI BC Meeting Summary-FINAL.pdf|July 6]] | [[Media:2022 07-20 QIBA fMRI BC Meeting Summary-FINAL.pdf|July 20]] | [[Media:2022 08-03 QIBA fMRI BC Meeting Summary-FINAL.pdf|August 3]] | [[Media:2022 08-17 QIBA fMRI BC Meeting Summary-FINAL.pdf|August 17]] | [[Media:2022 09-07 QIBA fMRI BC Meeting Summary-FINAL.pdf|September 7]] | [[Media:2022 09-21 QIBA fMRI BC Meeting Summary-FINAL.pdf|September 21]] | [[Media:2022 10-05 QIBA fMRI BC Meeting Summary-FINAL.pdf|October 5]] | [[Media:2022 10-19 QIBA fMRI BC Meeting Summary-FINAL.pdf|October 19]] | [[Media:2022 11-02 QIBA fMRI BC Meeting Summary-FINAL.pdf|November 2]] | [[Media:2022 11-16 QIBA fMRI BC Meeting Summary-FINAL.pdf|November 16]] | [[Media:2022 12-07 QIBA fMRI BC Meeting Summary-FINAL.pdf|December 7]]<br />
<br />
==2021==<br />
[[Media:2021_01-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 6]] | [[Media:2021_02-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 3]] | [[Media:2021_02-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 17]] | [[Media:2021_03-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 3]] | [[Media:2021_03-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 17]] | [[Media:2021_04-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 7]] | [[Media:2021_04-21_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 21]] | [[Media:2021_05-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 5]] | [[Media:2021_06-02_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 2]] | [[Media:2021_06-16_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 16]] | [[Media:2021_07-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 7]] | [[Media:2021_07-21_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 21]] | [[Media:2021_08-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 4]] | [[Media:2021_08-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 18]] | [[Media:2021_09-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 1]] | [[Media:2021_09-15_QIBA_fMRI_BC_Call_Summary-FINAL-2.pdf|September 15]] | [[Media:2021_10-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 6]] | [[Media:2021_10-20_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 20]] | [[Media:2021_11-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 3]] | [[Media:2021_11-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 17]] | [[Media:2021_12-15_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 15]]<br />
<br />
==2020==<br />
[[Media:2020_01-15_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 15]] | [[Media:2020_02-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 5]] | [[Media:2020_02-19_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 19]] | [[Media:2020_03-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 4]] | [[Media:2020_03-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 18]] | [[Media:2020_04-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 1]] | [[Media:2020_04-15_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 15]] | [[Media:2020_05-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 6]] | [[Media:2020_05-20_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 20]] | [[Media:2020_06-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 3]] | [[Media:2020_06-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 17]] | [[Media:2020_07-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 1]] | [[Media:2020_07-15_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 15]] | [[Media:2020_08-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 5]] | [[Media:2020_08-19_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 19]] | [[Media:2020_09-02_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 2]] | [[Media:2020_09-16_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 16]] | [[Media:2020_10-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 7]] | [[Media:2020_10-21_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 21]] | [[Media:2020_11-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 4]] | [[Media:2020_11-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 18]] | [[Media:2020_12-16_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 16]]<br />
<br />
==2019==<br />
[[Media:2019_01-16_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 16]] | [[Media:2019_02-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 6]] | [[Media:2019_02-20_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 20]] | [[Media:2019_03-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 6]] | [[Media:2019_03-20_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 20]] | [[Media:2019_04-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 3]] | [[Media:2019_04-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 17]] | [[Media:2019_05-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 1]] | [[Media:2019_06-05_QIBA_fMRI_BC_Call_Summary-FINAL-2.pdf|June 5]] | [[Media:2019_06-19_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 19]] | [[Media:2019_07-17_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 17]] | [[Media:2019_08-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 7]] | [[Media:2019_08-21_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 21]] | [[Media:2019_09-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 4]] | [[Media:2019_09-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 18]] | [[Media:2019_10-02_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 2]] | [[Media:2019_10-16_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 16]] | [[Media:2019_11-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 6]] | [[Media:2019_11-20_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 20]] | [[Media:2019_12-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 18]]<br />
<br />
==2018==<br />
[[Media:2018_01-10_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 10]] | [[Media:2018_01-24_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 24]] | [[Media:2018_02-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 7]] | [[Media:2018_03-07_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 7]] | [[Media:2018_03-21_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 21]] | [[Media:2018_04-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 4]] | [[Media:2018_04-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 18]] | [[Media:2018_05-02_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 2]] | [[Media:2018_05-31_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 31]] | [[Media:2018_06-27_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 27]] | [[Media:2018_07-11_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 11]] | [[Media:2018_07-25_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 25]] | [[Media:2018_08-08_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 8]] | [[Media:2018_08-22_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 22]] | [[Media:2018_09-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 5]] | [[Media:2018_09-19_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 19]] | [[Media:2018_10-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 3]] | [[Media:2018_10-31_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 31]] | [[Media:2018_11-14_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 14]] | [[Media:2018_12-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 5]]<br />
<br />
==2017==<br />
[[Media:2017_01-11_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 11]] | [[Media:2017_01-25_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|January 25]] | [[Media:2017_02-08_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|February 8]] | [[Media:2017_03-08_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 8]] | [[Media:2017_03-22_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|March 22]] | [[Media:2017_04-05_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 5]] | [[Media:2017_04-19_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|April 19]] | [[Media:2017_05-03_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|May 3]] | [[Media:2017_06-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 1]] | [[Media:2017_06-14_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 14]] | [[Media:2017_06-28_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|June 28]] | [[Media:2017_07-12_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 12]] | [[Media:2017_07-26_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|July 26]] | [[Media:2017_08-09_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 9]] | [[Media:2017_08-23_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|August 23]] | [[Media:2017_09-06_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|September 6]] | [[Media:2017_10-04_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 4]] | [[Media:2017_10-18_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|October 18]] | [[Media:2017_11-01_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 1]] | [[Media:2017_11-15_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 15]] | [[Media:2017_12-13_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 13]]<br />
<br />
==2016==<br />
[[Media:01 13 2016 QIBA fMRI BC Call Notes-FINAL.pdf|January 13]] | [[Media:02 10 2016 QIBA fMRI BC Call Notes-FINAL.pdf|February 10]] | [[Media:02 24 2016 QIBA fMRI BC Call Notes-FINAL-updated.pdf|February 24]] | [[Media:03 09 2016 QIBA fMRI BC Call Notes-FINAL.pdf|March 9]] | [[Media:03 23 2016 QIBA fMRI BC Call Notes-FINAL.pdf|March 23]] | [[Media:04 06 2016 QIBA fMRI BC Call Notes-FINAL.pdf|April 6]] | [[Media:04 20 2016 QIBA fMRI BC Call Notes-FINAL.pdf|April 20]] | [[Media:05 04 2016 QIBA fMRI BC Call Notes-FINAL.pdf|May 4]] | [[Media:05 18 2016 QIBA fMRI BC Call Notes-FINAL.pdf|May 18]] | [[Media:06 01 2016 QIBA fMRI BC Call Notes-FINAL.pdf|June 1]] | [[Media:06 15 2016 QIBA fMRI BC Call Notes-FINAL.pdf|June 15]] | [[Media:06 29 2016 QIBA fMRI BC Call Notes-FINAL.pdf|June 29]] | [[Media:07 13 2016 QIBA fMRI BC Call Notes-FINAL.pdf|July 13]] | [[Media:07 27 2016 QIBA fMRI BC Call Notes-FINAL.pdf|July 27]] | [[Media:08 24 2016 QIBA fMRI BC Call Notes-FINAL.pdf|August 24]] | [[Media:09 07 2016 QIBA fMRI BC Call Notes-FINAL.pdf|September 7]] | [[Media:09 27 2016 QIBA fMRI BC Call Notes-FINAL.pdf|September 27]] | [[Media:10 05 2016 QIBA fMRI BC Call Notes-FINAL.pdf|October 5]] | [[Media:2016_11-02_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|November 2]] | [[Media:2016_12-14_QIBA_fMRI_BC_Call_Summary-FINAL.pdf|December 14]]<br />
<br />
==2015==<br />
[[Media:01 14 2015 QIBA fMRI Biomarker Ctte Call Summary-FINAL.pdf|January 14]] | [[Media:01 28 2015 QIBA fMRI Biomarker Ctte Call Summary-FINAL.pdf|January 28]] | [[Media:02 11 2015 QIBA fMRI Biomarker Ctte Call Summary-FINAL.pdf|February 11]] | [[Media:02 25 2015 QIBA fMRI Biomarker Ctte Call Summary-FINAL.pdf|February 25]] | [[Media:03 11 2015 QIBA fMRI BC Call Notes-DRAFT.pdf|March 11]] | [[Media:03 25 2015 QIBA fMRI BC Call Notes-FINAL.pdf|March 25]] | [[Media:04 08 2015 QIBA fMRI BC Call Notes-FINAL.pdf|April 8]] | [[Media:04 22 2015 QIBA fMRI BC Call Notes-FINAL.pdf|April 22]] | [[Media:05 20 2015 QIBA fMRI BC Call Notes-FINAL.pdf|May 20]] | [[Media:06 03 2015 QIBA fMRI BC Call Notes-FINAL.pdf|June 3]] | [[Media:06 17 2015 QIBA fMRI BC Call Notes-FINAL.pdf|June 17]] | [[Media:07 01 2015 QIBA fMRI BC Call Notes-FINAL.pdf|July 1]] | [[Media:07 15 2015 QIBA fMRI BC Call Notes-FINAL.pdf|July 15]] | [[Media:07 29 2015 QIBA fMRI BC Call Notes-FINAL.pdf|July 29]] | [[Media:08 12 2015 QIBA fMRI BC Call Notes-FINAL.pdf|August 12]] | [[Media:08 26 2015 QIBA fMRI BC Call Notes-FINAL.pdf|August 26]] | [[Media:09 09 2015 QIBA fMRI BC Call Notes-FINAL.pdf|September 9]] | [[Media:09 23 2015 QIBA fMRI BC Call Notes-FINAL.pdf|September 23]] | [[Media:10 07 2015 QIBA fMRI BC Call Notes-FINAL.pdf|October 7]] | [[Media:10 21 2015 QIBA fMRI BC Call Notes-FINAL.pdf|October 21]] | [[Media:11 04 2015 QIBA fMRI BC Call Notes-FINAL.pdf|November 4]] | [[Media:11 18 2015 QIBA fMRI BC Call Notes-FINAL.pdf|November 18]] | [[Media:12 16 2015 QIBA fMRI BC Call Notes-FINAL.pdf|December 16]]<br />
<br />
==2014==<br />
*[[Media:12 17 2014 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|12.17.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11 19 2014 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|11.19.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11 05 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|11.05.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 22 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.22.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 08 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.08.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 24 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|09.24.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 10 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|09.10.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 27 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|08.27.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 13 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|08.13.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07 30 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|07.30.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07 16 2014 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|07.16.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07 02 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|07.02.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06 06 2014 QIBA fMRI Technical Ctte Summary-FINAL.pdf|06.06.2014 QIBA fMRI Technical Committee Call Summary - 1/2 Day Call Summary]]<br />
*[[Media:06 04 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|06.04.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:05 07 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|05.07.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 23 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.23.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 09 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.09.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03 26 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|03.26.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03 12 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|03.12.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 26 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|02.26.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 12 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|02.12.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01 29 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|01.29.2014 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01 15 2014 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|01.15.2014 QIBA fMRI Technical Committee Call Summary]]<br />
<br />
==2013==<br />
*[[Media:12 18 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|12.18.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11 20 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|11.20.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11 06 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|11.06.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 23 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.23.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 09 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.09.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 25 2013 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|09.25.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 11 2013 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|09.11.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 28 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|08.28.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 14 2013 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|08.14.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07 31 2013 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|07.31.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07 03 2013 QIBA fMRI Technical Ctte Call Summary-FINAL-JP.pdf|07.03.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06 19 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|06.19.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06 05 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|06.05.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:05 08 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|05.08.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 24 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.24.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 10 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.10.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03 27 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|03.27.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 27 2013 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|02.27.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 13 2013 QIBA fMRI Technical Ctte Call Summary-FINAL2.pdf|02.13.2013 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01 16 2013 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|01.16.2013 QIBA fMRI Technical Committee Call Summary]]<br />
<br />
==2012==<br />
*[[Media:12 19 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|12.19.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:12 05 2012 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|12.05.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11 07 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|11.07.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 24 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.24.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 24 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|10.24.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10 10 2012 QIBA fMRI Technical Ctte Call Summary-DRAFT.pdf|10.10.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 26 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|09.26.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 12 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|09.12.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 29 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|08.29.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 15 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|08.15.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06 20 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|06.20.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06 06 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|06.06.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:05 09 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|05.09.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 25 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.25.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04 11 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|04.11.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03 14 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|03.14.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 29 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|02.29.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02 15 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|02.15.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01 18 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|01.18.2012 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01 04 2012 QIBA fMRI Technical Ctte Call Summary-FINAL.pdf|01.04.2012 QIBA fMRI Technical Committee Call Summary]]<br />
<br />
==2011==<br />
*[[Media:12.21.2011 QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|12.21.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11.30.2011 QIBA fMRI Tech Ctte Breakout Session at RSNA 2011.pdf|11.30.2011 QIBA fMRI Technical Committee Breakout Session at RSNA 2011]]<br />
*[[Media:11.16.2011 QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|11.16.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:11.02.2011 QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|11.02.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10.19.2011 QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|10.19.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:10.05.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|10.05.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09.21.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|09.21.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:09 07 2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|09.07.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:08 24 2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|08.24.2011 QIBA fMRI Technical Committee/Reproducibility Call Summary]]<br />
*[[Media:08.10.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|08.10.2011 QIBA fMRI Technical Committee/Reproducibility Call Summary]]<br />
*[[Media:07 27 2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|07.27.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:07.19.2011QIBA fMRI Tech Repro Ctte Call Summary-FINAL2.pdf|07.19.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06.15.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|06.15.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:06.01.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|06.01.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:05.04.2011QIBA fMRI Tech Ctte Call Summary-FINAL.pdf|05.04.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:04.06.2011QIBA_fMRI_Tech_Ctte_Call_Summary-FINAL.pdf|04.06.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03.23.2011 QIBA fMRI TechCtteUpdate Call Summary-FINAL.pdf|03.23.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:03.09.2011 QIBA fMRI Technical Committee Call Summary-FINAL.pdf|03.09.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02.23.2011 QIBA fMRI TC Call Summary-FINAL.pdf|02.23.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:02.09.2011 QIBA fMRI TC Update Call Summary-FINAL.pdf|02.09.2011 QIBA fMRI Technical Committee Call Summary]]<br />
*[[Media:01.12.11 QIBA fMRI TC Call Summary-FINAL.pdf|01.12.2011 QIBA fMRI Technical Committee Call Summary]]<br />
<br />
==2010==<br />
*[[Media:12.15.10 QIBA fMRI TC Call Summary-FINAL.pdf|12.15.2010 QIBA fMRI Call Summary]]<br />
*[[Media:12.7.2010 QIBA fMRI TC Call Summary-FINAL.pdf|12.07.2010 QIBA fMRI Call Summary]]<br />
*[[Media:11.17.2010 QIBA fMRI Call Summary-FINAL.pdf|11.17.2010 QIBA fMRI Call Summary]]<br />
*[[Media:11.03.10 QIBA fMRI SubCmte Update Call Summary-FINAL.pdf|11.03.2010 QIBA fMRI Call Summary]]<br />
*[[Media:10.20.2010 QIBA fMRI call summary-FINAL.pdf|10.20.2010 QIBA fMRI Call Summary]]<br />
*[[Media:09.08.2010 QIBA fMRI SubCmte Update Call Summary-FINAL.pdf|09.08.2010 QIBA fMRI Call Summary]]<br />
*[[Media:08.25.2010 QIBA fMRI Committee Call Summary-FINAL.pdf|08.25.2010 QIBA fMRI Call Summary]]<br />
*[[Media:07.14.2010 QIBA fMRI Committee Call Summary-FINAL.pdf|07.14.2010 QIBA fMRI Call Summary]]<br />
*[[Media:06.30.2010 QIBA fMRI Committee Call Summary-FINAL.pdf|06.30.2010 QIBA fMRI Call Summary]]<br />
*[[Media:05.25.26.2010 QIBA fFMRI SubCtte F2F Summary-FINAL.pdf|05.25-26.2010 QIBA fMRI SubCtte Breakout Session Summary for QIBA Annual Meeting]]<br />
*[[Media:05.05.2010 QIBA fMRI SubCtte Call Summary-FINAL.pdf|05.05.2010 QIBA fMRI Call Summary]]<br />
*[[Media:04.20.2010 QIBA fMRI SubCtte Call Summary-FINAL.pdf|04.20.2010 QIBA fMRI Call Summary]]<br />
*[[Media:04.07.2010 QIBA fMRI SubCtte Call Summary-FINAL.pdf|04.07.2010 QIBA fMRI Call Summary]]<br />
*[[Media:03.24.2010 QIBA fMRI SubCtte Call Summary-FINAL.pdf|03.24.2010 QIBA fMRI Call Summary]]<br />
*[[Media:03.10.2010 QIBA fMRI Ctte Call Summary-FINAL.pdf|03.10.2010 QIBA fMRI Call Summary]]<br />
*[[Media:02.10.2010 QIBA fMRI Ctte Call Summary-FINAL.pdf|02.10.2010 QIBA fMRI Call Summary]]<br />
*[[Media:01.27.2010 QIBA fMRI Ctte Call Summary-FINAL.pdf|01.27.2010 QIBA fMRI Call Summary]]<br />
*[[Media:01.13.2010 QIBA fMRI Ctte Call Summary-FINAL.pdf|01.13.2010 QIBA fMRI Call Summary]]<br />
<br />
==2009==<br />
[[Media:12.16.2009 QIBA fMRI SubCtte Call Summary-FINAL.pdf|December 16]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023_12-20_QIBA_fMRI_BC_Meeting_Summary-FINAL.pdf&diff=19459File:2023 12-20 QIBA fMRI BC Meeting Summary-FINAL.pdf2023-12-21T16:21:58Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=ISMRM/QIBA_PDFF_Biomarker_Ctte&diff=19458ISMRM/QIBA PDFF Biomarker Ctte2023-12-21T16:00:35Z<p>SStanfa: </p>
<hr />
<div><br />
:Co-chairs: Diego Hernando, PhD; Houchun (Harry) Hu, PhD<br />
:ISMRM Staff Support: Gerardo Mopera<br />
<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vQZBtnrVMpQOU8BEKlY_4hs21JQoEhq_926-HCFtPm77AHzJ3-dp_S6cedeDfbIIILljxJVongZMJsb/pubhtml?gid=1460430101&single=true Roster]<br />
<br />
The PDFF Biomarker Committee seeks to develop a quantitative Profile for PDFF. This effort is supported by ISMRM, using the QIBA Process for Profile development.<br />
<br />
<br />
==Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br />Notes are posted after they are approved by the PDFF BC during the following t-con. The last meeting was on February 3, 2022.<br />
<br />
*[[Media:2023_01-26_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|January 26, 2023]]<br />
*[[Media:2022_02-03_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|February 3, 2022]]<br />
*[[Media:2021_04-01_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf|April 1, 2021]]<br />
<br />
'''''[[PDFF Biomarker Committee Call Summaries Archive]]'''''<br />
<br />
==Working Documents==<br />
<br />
==Statistical Reference Documents==<br />
<br />
==Workflow Documents==<br />
<br />
==Reference Materials==</div>SStanfahttps://qibawiki.rsna.org/index.php?title=PDFF_Biomarker_Committee_Call_Summaries_Archive&diff=19457PDFF Biomarker Committee Call Summaries Archive2023-12-21T15:59:50Z<p>SStanfa: /* 2021 */</p>
<hr />
<div>==2021==<br />
[[Media:2021_01-07_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|January 7]] | [[Media:2021_02-04_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|February 4]]<br />
<br />
==2020==<br />
[[Media:2020_07-02_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|July 2]] | [[Media:2020_11-05_QIBA_PDFF_BC_Call_Summary-FINAL.pdf|November 5]]<br />
<br />
==2019==<br />
[[Media:2019_02-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 7]] | [[Media:2019_04-04_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 4]] | [[Media:2019_05-02_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 2]] | [[Media:2019_06-06_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 6]] | [[Media:2019_08-01_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 1]] | [[Media:2019_09-05_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 5]] | [[Media:2019_11-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 7]]<br />
<br />
==2018==<br />
[[Media:2018_01-04_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 4]] | [[Media:2018_02-01_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 1]] | [[Media:2018_03-01_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 1]] | [[Media:2018_04-05_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 5]] | [[Media:2018_05-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 3]] | [[Media:2018_08-02_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 2]] | [[Media:2018_09-13_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 13]] | [[Media:2018_10-04_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 4]] | [[Media:2018_11-01_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 1]]<br />
<br />
==2017==<br />
[[Media:2017_01-05_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 5]] | [[Media:2017_02-09_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 9]] | [[Media:2017_04-06_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 6]] | [[Media:2017_06-01_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|June 1]] | [[Media:2017_08-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 3]] | [[Media:2017_07-06_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 6]] | [[Media:2017_09-07_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 7]] | [[Media:2017_11-02_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 2]]<br />
<br />
==2016==<br />
[[Media:04 07 2016 QIBA PDFF-MRI Biomarker Cmte Call Summary-FINAL.pdf|April 7]] | [[Media:06 02 2016 QIBA PDFF-MRI Biomarker Cmte Call Summary-FINAL.pdf|June 2]] | [[Media:08 04 2016 QIBA PDFF-MRI Biomarker Cmte Call Summary-FINAL.pdf|August 4]] | [[Media:09 08 2016 QIBA PDFF-MRI Biomarker Cmte Call Summary-FINAL.pdf|September 8]] | [[Media:2016_10-06_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 6]] | [[Media:2016_11-03_QIBA_PDFF_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 3]] |</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023_01-26_QIBA_PDFF_BC_Meeting_Summary-FINAL.pdf&diff=19456File:2023 01-26 QIBA PDFF BC Meeting Summary-FINAL.pdf2023-12-21T15:59:24Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2020_11-02_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf&diff=19455File:2020 11-02 QIBA DTI-MR BC Call Summary-FINAL.pdf2023-12-21T15:56:16Z<p>SStanfa: SStanfa uploaded a new version of File:2020 11-02 QIBA DTI-MR BC Call Summary-FINAL.pdf</p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=MRE_Biomarker_Ctte&diff=19454MRE Biomarker Ctte2023-12-21T15:54:47Z<p>SStanfa: /* Meetings */</p>
<hr />
<div>:Co-chairs: Richard L. Ehman, MD; Patricia Cole, PhD, MD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRXlDgOiADuCP3e9iHApSt4Z3zpel94OJN12IEQY8C4OT4u4LiiNnp9EWBP5FnCAgDL-YMe-m1NjasH/pubhtml?gid=1930876020&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
The MRE Biomarker Committee seeks to develop a quantitative Profile for MRE.<br />
<br />
MRE Profile to be data-driven: <br />
*focusing on the characterization of bias and precision in MRE measurement targets for achieving these measurements<br />
*focusing on issues important to specific reproducibility<br />
<br />
<br />
==Meetings==<br />
<br />
'''Approved call summaries:'''<br />
<br >Note: The last meeting of this group was held on December 20, 2021; notes are posted after they are approved by the MRE BC during the following t-con<br />
<br />
*[[Media:2021_12-20_QIBA_MRE_BC_Call_Summary-FINAL.pdf|December 20, 2021]]<br />
*[[Media:2021_03-15_QIBA_MRE_BC_Call_Summary-FINAL.pdf|March 15, 2021]]<br />
*[[Media:2020_01-23_QIBA_MRE_BC_Call_Summary-FINAL.pdf|January 23, 2020]]<br />
<br />
'''''[[MRE BC Call Summaries Archive]]'''''<br />
<br />
==MRE Profile Development==<br />
*[[Media:MRE-QIBAProfile-2023-11-09-CLINICALLY-FEASIBLE-maintenance.pdf|''MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft (November 9, 2023)'']]<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|'''MR Elastography of the Liver, Clinically Feasible Profile (February 14, 2022)''']]<br />
*[[Media:MRE-QIBA_Profile-2021-06-22-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 22, 2021)'']]<br />
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 6, 2019)'']] <br />
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | '''MR Elastography of the Liver, Consensus Profile (May 2, 2018)''']] <br />
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf|'''MR Elastography of the Liver, Public Comment Profile (July 28, 2017)''']]<br />
*[[Media:Draft-MRE-QIBAProfile-2017-07-06.pdf|''MR Elastography of the Liver, Initial Draft (July 6, 2017)'']]<br />
<br />
==Working Documents==<br />
<br />
==Statistical Reference Documents==<br />
<br />
<br />
==Workflow Documents==<br />
<br />
<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Repeatability_Literature_Review.pdf|Repeatability Literature Review Citation List]]<br />
*[[Media:MREPresentationApril142015.pdf|MRE Presentation Slides from April 14, 2015 Meeting]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2021_12-20_QIBA_MRE_BC_Call_Summary-FINAL.pdf&diff=19453File:2021 12-20 QIBA MRE BC Call Summary-FINAL.pdf2023-12-21T15:54:40Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=MRE_BC_Call_Summaries_Archive&diff=19452MRE BC Call Summaries Archive2023-12-21T15:53:28Z<p>SStanfa: </p>
<hr />
<div>=2019 Call Summaries=<br />
[[Media:2019_04-01_QIBA_MRE_BC_Call_Summary-FINAL.pdf|April 1]]<br />
<br />
=2018 Call Summaries=<br />
[[Media:2018_04-09_QIBA_MRE_BC_Call_Summary-FINAL.pdf|April 9]] | [[Media:2018_11-20_QIBA_MRE_BC_Call_Summary-FINAL.pdf|November 20]]<br />
<br />
=2017 Call Summaries=<br />
[[Media:2017_01-30_QIBA_MRE_BC_Call_Summary-FINAL.pdf|January 30]]<br />
<br />
<br />
=2016 Call Summaries=<br />
[[Media:2016_11-07_QIBA_MRE_BC_Call_Summary-FINAL.pdf|November 7]]<br />
<br />
<br />
=2015 Call Summaries=<br />
[[Media:01 13 2015 QIBA MRE Call Summary-DRAFT.pdf|January 13]] | [[Media:03 10 2015 QIBA MRE Call Summary-DRAFT.pdf|March 10]] | [[Media:04 14 2015 QIBA MRE BC Call Summary-FINAL.pdf|April 14]] | [[Media:07 07 2015 QIBA MRE BC Call Summary-FINAL.pdf|July 7]] | [[Media:08 12 2015 QIBA MRE BC Call Summary-FINAL.pdf|August 12]] | [[Media:09 08 2015 QIBA MRE BC Call Summary-FINAL.pdf|September 8]] | [[Media:10 13 2015 QIBA MRE BC Call Summary-FINAL.pdf|October 13]] | [[Media:11 17 2015 QIBA MRE BC Call Summary-FINAL.pdf|November 17]] | [[Media:12 14 2015 QIBA MRE BC Call Summary-FINAL.pdf|December 14]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DTI_MRI_Biomarker_Ctte&diff=19451DTI MRI Biomarker Ctte2023-12-21T15:50:03Z<p>SStanfa: /* DTI+ MR Meetings */</p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Walter Schneider, PhD; Christopher Whitlow, MD, PhD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vS-ZSC6I0AVhBrNH47YHV6HdZh2Xpgl90wa5N-9Gf-xVFdt0SkJhkQ3TEyM4jE_nzNNCMsRS6z2YA4Q/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Diffusion Tensor Imaging MRI. <br />
<br />
<br />
<br />
==DTI+ MR Meetings==<br />
'''Recent Approved call summaries:'''<br />
<br />Note: notes are posted after they are approved by the DTI+ BC during the following t-con<br />
<br />
*[[Media:2020_11-02_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|November 2, 2020]]<br />
*[[Media:2020_10-05_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|October 5, 2020]]<br />
*[[Media:2020_05-14_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf|May 14, 2020]]<br />
<br /><br />
Earlier materials can be found on the [[http://qibawiki.rsna.org/index.php/Perfusion,_Diffusion_and_Flow-MRI_Biomarker_Ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
==Reference Materials==<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 5 (placeholder)====<br />
<br />
====Round 6 (placeholder)====</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2020_11-02_QIBA_DTI-MR_BC_Call_Summary-FINAL.pdf&diff=19450File:2020 11-02 QIBA DTI-MR BC Call Summary-FINAL.pdf2023-12-21T15:49:35Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=DCE_MRI_Biomarker_Ctte&diff=19449DCE MRI Biomarker Ctte2023-12-21T14:59:43Z<p>SStanfa: /* Profile Development */</p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Hendrik Laue, PhD; James O'Connor, MD, PhD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRzQYPdYm51Ak3VYii84CtIDFiYRIylH2IkHQZxdAAjJTAVX4iRqlGl2tety1pnDFKN9kLxoKI-RcoM/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Dynamic Contrast Enhanced MRI.<br />
<br />
*[[MR Acquisition Protocols]]<br />
*[[Synthetic DCE-MRI Data]]<br />
<br />
<br />
==DCE MRI Meetings==<br />
Biweekly Zoom meetings, 2nd and 4th Mondays of each month @ 11am-12pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
<br />
'''Recently Approved Call Summaries'''<br />
<br />
*[[Media:2023_12-11_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|December 11, 2023]]<br />
*[[Media:2023_11-13_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|November 13, 2023]]<br />
*[[Media:2023_10-23_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|October 23, 2023]]<br />
<br />
'''''[[DCE-MRI BC Call Summaries Archive]]'''''<br />
<br /><br />
<br /><br />
* [[QIBA DCE-MRI Technical Committee Call Summaries|DCE-MRI TC Call Summaries Archive 2008-2012]]<br />
* Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|'''MR DCE-MRI Quantification (DCEMRI-Q) (V.2) - Stage 2: Consensus 2023-12-06''']]<br />
*[[Media: QIBA DCE v2.0-Stage1 Public Comment Profile.pdf| '''MR DCE-MRI Quantification (DCEMRI-Q) (V.2) - Stage 1: Public Comment 2020-12-09''']]<br />
*[[Media:Compliance v 1 7.doc|DCE-MRI Profile, Section IV Compliance-AG v1.7]] ''05-21-2014''<br />
*[[Media:Compliance (2).doc|DCE-MRI Profile, Section IV Compliance-AG]] ''01-22-2014''<br />
*[[Media:DCEMRIProfile v1 6-20111213.pdf|'''DCE-MRI Quantification Profile v1.6 2011-12-13''']]<br />
*[[Media:Profile Literature Review 20110427 Rev1.xls|DCE-MRI Profile Supporting Literature Review]] ''Revised 05.02.2011''<br />
<br />
*[[Tools and recommendation for structured literature review]]<br />
*[[Archived DCE-MRI Profiles]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Barboriak T1 DRO report 20130903a.pdf|T1 DRO Report -- 20130903 -- Dr Barboriak]]<br />
*[[Media:DWI proposal of DCE-MRI TC 16Nov2011 (2).doc|DWI Proposal for the DCE-MRI Tech Ctte]] ''12.14.2011''<br />
*[[Media:Synthetic data presentation 20110929 redact.pdf|QIBA DCE-MRI Synthetic Data Presentation -- 20110929--Dr. Barboriak]]<br />
*[[Media:RSNA QIBA May2010 MR Phantom.pdf|MR Phantom Development / Data Efforts - May 2010 QIBA Meeting Breakout Session]]<br />
*[[Media:Prototype Phantom 20100203.pdf|Prototype Phantom - 20100203]]<br />
*[[Media:Q-MRI-Poster1-Jackson-20091118.ppt|QIBA Quantitative MRI Poster for RSNA 2009 Annual Meeting]]<br />
*[[Media:Phantom Study Protocol rev20091028.pdf|DCE-MRI Phantom Study Protocol -- rev20091028]]<br />
*[[Proposed Changes to Acquisition Protocol -- 20090315 - E Jackson]]<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 1====<br />
*[[VirtualScopics, Inc.]]<br />
**[[Media:DrJackson QIBA Phantom 09203 AMR3.pdf|Example RSNA DCE-MRI Phantom Data Analysis Report]]<br />
<br />
*[[Duke University Medical Center]]<br />
*[[The University of Texas M.D. Anderson Cancer Center]]<br />
<br />
====Round 2====<br />
<br />
*[[Media:4-UPenn-Test-Retest.-Yr2.pdf|Test-Retest Evaluation of Repeatability of DCE-MRI and DWI in Human Subjects]]<br />
<br />
====Round 3====<br />
<br />
*[[QIBA Artificial Data Evaluation Software]]<br />
<br />
*[[Media:Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis.pdf|Project (J) Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis (Fraunhofer MEVIS, Germany)]]<br />
<br />
*[[Media:DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T.pdf | Project (H) DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T (University Hospital Cologne, Germany)]]<br />
<br />
====Round 4====<br />
<br />
*[[Media:Digital Reference Object for DCE-MRI Analysis Software Verification.pdf|Project (AA) Digital Reference Object for DCE-MRI Analysis Software Verification (Cleveland Clinic Foundation)]]<br />
<br />
*[[Media:DRO for DCE-MRI Analysis Software Verification.pdf|Project (T) Digital Reference Object for DCE-MRI Analysis Software Verification 2 (Duke University)]]<br />
<br />
*[[Media:RSNA DCE-MRI Phantom Automated Analysis Software Package Development.pdf|Project (U) RSNA DCE-MRI Phantom Automated Analysis Software Package Development (University of Wisconsin)]]<br />
<br />
====Round 5====<br />
*[[Media:Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit.pdf | Project (K) Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit (Duke University)]]<br />
<br />
====Round 6====<br />
*[[Media:Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI.pdf | Project (Z) Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI (University of Southern California)]]<br />
<br />
==Historical Background - Formation of the Group==</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Comment_Resolutions&diff=19448Comment Resolutions2023-12-21T14:53:01Z<p>SStanfa: </p>
<hr />
<div>Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee. <br />
<br />
Per the [[Process#Profile_Creation_Process|QIBA Process]], committees record how each '''[[Public Comment Process|collected comment was resolved]]''' and those resolutions are posted here. <br />
<br />
<br />
{| style="width:100%" border="1" cellpadding="3"<br />
! Profile Document<br />
! Feedback Type<br />
! Feedback Closed<br />
! Resolutions<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''CT Profiles'''<br />
|-<br />
| [[Media:QIBA CT Vol LungNoduleAssessmentInCTScreening v5-2-16b.docx| CT Small Lung Nodule Screening 2016-06-01]]<br />
| Public Comment<br />
| 2016.09<br />
| [[Media:2018-06-15 v9 QIBA SLN CommentsAndResolutions.xlsx|Public Comment Resolutions 2018-06-15]]<br />
|-<br />
| [[Media:QIBA CTVol TumorVolumeChangeProfile Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]<br />
| Technical Confirmation<br />
| 2017.02<br />
| [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25]<br />
|-<br />
| [[Media:QIBA CTA Profile as of 2020-March-10.pdf| CT Atherosclerosis 2020-03-10]]<br />
| Public Comment<br />
| 2019.06.03<br />
| [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]]<br />
|-<br />
| [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]]<br />
| Clinically Feasible<br />
| 2023.03.07<br />
| [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]]<br />
|-<br />
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]]<br />
| Public Comment<br />
| 2019.10.16<br />
|[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]]<br />
|-<br />
|[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]]<br />
| Technical Confirmation<br />
| 2020.04<br />
|[[Media:CT Small Lung Nodule Profile Clinically Feasible Comment Resolutions.2023Aug18.pdf|Clinically Feasible Comment Resolutions 2023-08-18]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles'''<br />
|-<br />
| [[Media:Draft-MRE-QIBAProfile-2017-07-28 clean.pdf| MR Elastography 2017-08-15]]<br />
| Public Comment<br />
| 2017.09.15<br />
| [[Media:MRE Profile Public Comments 2018 02 08.pdf| Public comment Resolutions]]<br />
|-<br />
| [[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI Sensorimotor 2017-06-19]]<br />
| Public Comment<br />
| 2017.12.31<br />
| '''Resolving Feedback'''<br />
|-<br />
| [[Media:QIBADWIProfile as of 2019-Feb-05.pdf| MR DWI 2019-02-05]]<br />
| Public Comment #2<br />
| 2019.04.05<br />
| [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DSC-MRI Stage1 Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]]<br />
| Public Comment<br />
| 2020.05.15<br />
| [[Media:QIBA DSC-MRI Public Comment Resolutions v2020Oct.9.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage compositional biomarkers (T1ρ,T2) 2020-05-18]]<br />
| Public Comment<br />
| 2020.10.29<br />
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]]<br />
| Consensus<br />
| 2023.12-06<br />
| [[Media:QIBA DCE-MRI Public Comment Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]<br />
| Technical Confirmation<br />
| 2021.12.16<br />
| [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]]<br />
|-<br />
| [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
| Clinically Feasible<br />
| 2022.12.15<br />
| [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]]<br />
|-<br />
| [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
|Consensus<br />
|2023.09.08<br />
| [[Media:QIBA PDFF Public Comment Resolutions.pdf| Public Comment Resolutions 2023-11-14]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles'''<br />
|-<br />
| SPECT Ioflupane in Neurodegenerative Disease v1.1<br />
| Public Comment<br />
| 2016.12.31<br />
| [[Media:SPECT Profile Response to Public Comments.v2017 06 06.xlsx| Public Comment Resolutions 2017-06-06]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2019-06-15]]<br />
| Technical Confirmation<br />
| 2021<br />
| [[Media:QIBA PET Amyloid Profile changes.pdf| Technical Confirmation Resolutions, 2022-04-15]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2017-06-15]]<br />
|Public Comment<br />
|2017.09.15<br />
|[[Media:QIBA PET Amyloid Comments all resolved.xlsx| Public Comment Resolutions 2018-05-02]]<br />
|-<br />
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]<br />
| Public Comment<br />
| n/a<br />
| v2.0 is an update of v1.0 without additional public comment<br />
|-<br />
|[[Media:QIBA 99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]]<br />
| Public Comment<br />
| 2020.02.03<br />
|[[Media:QIBA 99mTC SPECT Comments 2020-08-11-final.xlsx| Public Comment Resolutions 2020-08-11]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''Ultrasound Profiles'''<br />
|-<br />
| [[Media:QIBA US SWS Profile 10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]]<br />
| Public Comment<br />
| 2019.12.18<br />
| [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]]<br />
| Clinically Feasible<br />
| 2023.02.07<br />
| [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]]<br />
| Consensus<br />
| 2023.12.13<br />
| [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]]<br />
|-<br />
|}</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Profiles&diff=19447Profiles2023-12-21T14:52:55Z<p>SStanfa: /* Stage 2: Consensus Profiles */</p>
<hr />
<div>__NOTOC__<br />
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. <br />
<br />
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.<br />
<br />
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===<br />
<br />
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]<br />
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]<br />
<br />
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists<br />
<br />
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]<br />
<br />
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]<br />
<br />
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]]<br />
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]<br />
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===<br />
<br />
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23<br />
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]<br />
<br />
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]]<br />
<br />
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]<br />
<br />
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]<br />
<br />
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]<br />
<br />
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]<br />
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]<br />
<br />
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]<br />
<br />
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Checklists - US SWS Appendix E 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]<br />
<br />
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===<br />
<br />
'''[https://forms.gle/vfv77Q9pGBxfuoi27 <big>Public Comment Submission Form</big>]'''<br />
<br />
*[[Media:QIBA_Profile_USVBF_Public_Comment_Version.pdf|Ultrasound Volume Blood Flow (USVBF) 2023-10-05]] (comments '''closed''' on November 17, 2023)<br />
<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)<br />
<br />
<br />
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<br />
<br />
'''Tools to aid Biomarker Committees in collating these comments:'''<br />
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''<br />
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' <br />
'''<br />
<br />
<br />
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''<br />
<br />
<br />
====Format for Citing Profiles====<br />
Cite QIBA Profile documents as:<br />
<br />
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''<br />
<br />
Example:<br />
<br />
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles<br />
<br />
<br />
====Statements of Endorsement====<br />
*[[Industry]]<br />
*[[Clinical Sites]]<br />
*[[Additional letters of support can be found here]]<br />
<br />
<br />
====See Also====<br />
*[[How to use QIBA Profiles]]<br />
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.<br />
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.<br />
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')<br />
<br />
*[[Work Product for Review]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Profiles&diff=19446Profiles2023-12-21T14:52:10Z<p>SStanfa: /* Stage 1: Public Comment Profiles */</p>
<hr />
<div>__NOTOC__<br />
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. <br />
<br />
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.<br />
<br />
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===<br />
<br />
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]<br />
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]<br />
<br />
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists<br />
<br />
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]<br />
<br />
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]<br />
<br />
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]]<br />
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]<br />
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===<br />
<br />
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23<br />
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]<br />
<br />
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]]<br />
<br />
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]<br />
<br />
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]<br />
<br />
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]<br />
<br />
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]<br />
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]<br />
<br />
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]<br />
<br />
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Checklists - US SWS Appendix E 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]<br />
<br />
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===<br />
<br />
'''[https://forms.gle/vfv77Q9pGBxfuoi27 <big>Public Comment Submission Form</big>]'''<br />
<br />
*[[Media:QIBA_Profile_USVBF_Public_Comment_Version.pdf|Ultrasound Volume Blood Flow (USVBF) 2023-10-05]] (comments '''closed''' on November 17, 2023)<br />
<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)<br />
<br />
<br />
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<br />
<br />
'''Tools to aid Biomarker Committees in collating these comments:'''<br />
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''<br />
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' <br />
'''<br />
<br />
<br />
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''<br />
<br />
<br />
====Format for Citing Profiles====<br />
Cite QIBA Profile documents as:<br />
<br />
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''<br />
<br />
Example:<br />
<br />
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles<br />
<br />
<br />
====Statements of Endorsement====<br />
*[[Industry]]<br />
*[[Clinical Sites]]<br />
*[[Additional letters of support can be found here]]<br />
<br />
<br />
====See Also====<br />
*[[How to use QIBA Profiles]]<br />
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.<br />
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.<br />
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')<br />
<br />
*[[Work Product for Review]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=Profiles&diff=19445Profiles2023-12-21T14:51:46Z<p>SStanfa: /* Stage 2: Consensus Profiles */</p>
<hr />
<div>__NOTOC__<br />
Profiles published here have completed one of the '''[[QIBA Profile Stages]]''' of development and been approved by their [[Committees|Biomarker Committee]]. <br />
<br />
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.<br />
<br />
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===<br />
<br />
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]<br />
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]<br />
<br />
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists<br />
<br />
*[[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
<br />
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|MR Elastography of the Liver 2022-02-14]]<br />
<br />
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]]<br />
<br />
*[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]]<br />
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]<br />
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===<br />
<br />
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] (Contains Conformance Checklists, Appendix B) 2020-10-23<br />
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]<br />
<br />
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]]<br />
<br />
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]<br />
<br />
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK Cartilage for Joint Disease 2021-09-25]]<br />
<br />
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease 2017-06-26]]<br />
<br />
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease 2019-10-15]]<br />
::*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklists - SPECT Ioflupane]]<br />
<br />
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]<br />
<br />
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Checklists - US SWS Appendix E 2022-04-25]]<br />
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]<br />
<br />
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
<br />
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]]<br />
<br />
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===<br />
<br />
'''[https://forms.gle/vfv77Q9pGBxfuoi27 <big>Public Comment Submission Form</big>]'''<br />
<br />
*[[Media:QIBA_Profile_USVBF_Public_Comment_Version.pdf|Ultrasound Volume Blood Flow (USVBF) 2023-10-05]] (comments '''closed''' on November 17, 2023)<br />
<br />
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE Quantification 2020-10-12]] (comments '''closed''' on March 10, 2021)<br />
<br />
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)<br />
<br />
<br />
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<br />
<br />
'''Tools to aid Biomarker Committees in collating these comments:'''<br />
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]'''<br />
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' <br />
'''<br />
<br />
<br />
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''<br />
<br />
<br />
====Format for Citing Profiles====<br />
Cite QIBA Profile documents as:<br />
<br />
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Profile Stage''. ''Date''. Available from: ''URL''<br />
<br />
Example:<br />
<br />
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles<br />
<br />
<br />
====Statements of Endorsement====<br />
*[[Industry]]<br />
*[[Clinical Sites]]<br />
*[[Additional letters of support can be found here]]<br />
<br />
<br />
====See Also====<br />
*[[How to use QIBA Profiles]]<br />
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.<br />
*[[Profile Conformance]] describes how sites and products claim conformance to a Profile.<br />
*[[QIBA Profile Template]] shows the structure, rationale and content of a Profile (''show "All Markup" to see guidance in the Word comments'')<br />
<br />
*[[Work Product for Review]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:QIBA_DCE-Profile_-_v2.0_-_Consensus_Document.pdf&diff=19444File:QIBA DCE-Profile - v2.0 - Consensus Document.pdf2023-12-21T14:49:44Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:QIBA_DCE-MRI_Public_Comment_Resolutions.pdf&diff=19443File:QIBA DCE-MRI Public Comment Resolutions.pdf2023-12-21T14:45:20Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=Comment_Resolutions&diff=19442Comment Resolutions2023-12-21T14:42:27Z<p>SStanfa: </p>
<hr />
<div>Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee. <br />
<br />
Per the [[Process#Profile_Creation_Process|QIBA Process]], committees record how each '''[[Public Comment Process|collected comment was resolved]]''' and those resolutions are posted here. <br />
<br />
<br />
{| style="width:100%" border="1" cellpadding="3"<br />
! Profile Document<br />
! Feedback Type<br />
! Feedback Closed<br />
! Resolutions<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''CT Profiles'''<br />
|-<br />
| [[Media:QIBA CT Vol LungNoduleAssessmentInCTScreening v5-2-16b.docx| CT Small Lung Nodule Screening 2016-06-01]]<br />
| Public Comment<br />
| 2016.09<br />
| [[Media:2018-06-15 v9 QIBA SLN CommentsAndResolutions.xlsx|Public Comment Resolutions 2018-06-15]]<br />
|-<br />
| [[Media:QIBA CTVol TumorVolumeChangeProfile Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]<br />
| Technical Confirmation<br />
| 2017.02<br />
| [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25]<br />
|-<br />
| [[Media:QIBA CTA Profile as of 2020-March-10.pdf| CT Atherosclerosis 2020-03-10]]<br />
| Public Comment<br />
| 2019.06.03<br />
| [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]]<br />
|-<br />
| [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]]<br />
| Clinically Feasible<br />
| 2023.03.07<br />
| [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]]<br />
|-<br />
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]]<br />
| Public Comment<br />
| 2019.10.16<br />
|[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]]<br />
|-<br />
|[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]]<br />
| Technical Confirmation<br />
| 2020.04<br />
|[[Media:CT Small Lung Nodule Profile Clinically Feasible Comment Resolutions.2023Aug18.pdf|Clinically Feasible Comment Resolutions 2023-08-18]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles'''<br />
|-<br />
| [[Media:Draft-MRE-QIBAProfile-2017-07-28 clean.pdf| MR Elastography 2017-08-15]]<br />
| Public Comment<br />
| 2017.09.15<br />
| [[Media:MRE Profile Public Comments 2018 02 08.pdf| Public comment Resolutions]]<br />
|-<br />
| [[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI Sensorimotor 2017-06-19]]<br />
| Public Comment<br />
| 2017.12.31<br />
| '''Resolving Feedback'''<br />
|-<br />
| [[Media:QIBADWIProfile as of 2019-Feb-05.pdf| MR DWI 2019-02-05]]<br />
| Public Comment #2<br />
| 2019.04.05<br />
| [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DSC-MRI Stage1 Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]]<br />
| Public Comment<br />
| 2020.05.15<br />
| [[Media:QIBA DSC-MRI Public Comment Resolutions v2020Oct.9.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage compositional biomarkers (T1ρ,T2) 2020-05-18]]<br />
| Public Comment<br />
| 2020.10.29<br />
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]]<br />
| Public Comment<br />
| 2021.03.10<br />
| '''Resolving Feedback'''<br />
|-<br />
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]<br />
| Technical Confirmation<br />
| 2021.12.16<br />
| [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]]<br />
|-<br />
| [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
| Clinically Feasible<br />
| 2022.12.15<br />
| [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]]<br />
|-<br />
| [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
|Consensus<br />
|2023.09.08<br />
| [[Media:QIBA PDFF Public Comment Resolutions.pdf| Public Comment Resolutions 2023-11-14]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles'''<br />
|-<br />
| SPECT Ioflupane in Neurodegenerative Disease v1.1<br />
| Public Comment<br />
| 2016.12.31<br />
| [[Media:SPECT Profile Response to Public Comments.v2017 06 06.xlsx| Public Comment Resolutions 2017-06-06]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2019-06-15]]<br />
| Technical Confirmation<br />
| 2021<br />
| [[Media:QIBA PET Amyloid Profile changes.pdf| Technical Confirmation Resolutions, 2022-04-15]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2017-06-15]]<br />
|Public Comment<br />
|2017.09.15<br />
|[[Media:QIBA PET Amyloid Comments all resolved.xlsx| Public Comment Resolutions 2018-05-02]]<br />
|-<br />
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]<br />
| Public Comment<br />
| n/a<br />
| v2.0 is an update of v1.0 without additional public comment<br />
|-<br />
|[[Media:QIBA 99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]]<br />
| Public Comment<br />
| 2020.02.03<br />
|[[Media:QIBA 99mTC SPECT Comments 2020-08-11-final.xlsx| Public Comment Resolutions 2020-08-11]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''Ultrasound Profiles'''<br />
|-<br />
| [[Media:QIBA US SWS Profile 10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]]<br />
| Public Comment<br />
| 2019.12.18<br />
| [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]]<br />
| Clinically Feasible<br />
| 2023.02.07<br />
| [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]]<br />
| Consensus<br />
| 2023.12.13<br />
| [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]]<br />
|-<br />
|}</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:QIBA_PDFF_Public_Comment_Resolutions.pdf&diff=19441File:QIBA PDFF Public Comment Resolutions.pdf2023-12-21T14:42:16Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=Comment_Resolutions&diff=19440Comment Resolutions2023-12-21T14:40:01Z<p>SStanfa: </p>
<hr />
<div>Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee. <br />
<br />
Per the [[Process#Profile_Creation_Process|QIBA Process]], committees record how each '''[[Public Comment Process|collected comment was resolved]]''' and those resolutions are posted here. <br />
<br />
<br />
{| style="width:100%" border="1" cellpadding="3"<br />
! Profile Document<br />
! Feedback Type<br />
! Feedback Closed<br />
! Resolutions<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''CT Profiles'''<br />
|-<br />
| [[Media:QIBA CT Vol LungNoduleAssessmentInCTScreening v5-2-16b.docx| CT Small Lung Nodule Screening 2016-06-01]]<br />
| Public Comment<br />
| 2016.09<br />
| [[Media:2018-06-15 v9 QIBA SLN CommentsAndResolutions.xlsx|Public Comment Resolutions 2018-06-15]]<br />
|-<br />
| [[Media:QIBA CTVol TumorVolumeChangeProfile Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]<br />
| Technical Confirmation<br />
| 2017.02<br />
| [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25]<br />
|-<br />
| [[Media:QIBA CTA Profile as of 2020-March-10.pdf| CT Atherosclerosis 2020-03-10]]<br />
| Public Comment<br />
| 2019.06.03<br />
| [[Media:QIBA CTA Comments all resolved.xlsx| Public Comment Resolutions 2020-03-12]]<br />
|-<br />
| [[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf| CT Atherosclerosis 2023-03-28]]<br />
| Clinically Feasible<br />
| 2023.03.07<br />
| [[Media:CTA Profile Clinically Feasible Comment Resolutions.2023Mar28.pdf|Clinically Feasible Comment Resolutions 2023-03-28]]<br />
|-<br />
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]]<br />
| Public Comment<br />
| 2019.10.16<br />
|[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]]<br />
|-<br />
|[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]]<br />
| Technical Confirmation<br />
| 2020.04<br />
|[[Media:CT Small Lung Nodule Profile Clinically Feasible Comment Resolutions.2023Aug18.pdf|Clinically Feasible Comment Resolutions 2023-08-18]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles'''<br />
|-<br />
| [[Media:Draft-MRE-QIBAProfile-2017-07-28 clean.pdf| MR Elastography 2017-08-15]]<br />
| Public Comment<br />
| 2017.09.15<br />
| [[Media:MRE Profile Public Comments 2018 02 08.pdf| Public comment Resolutions]]<br />
|-<br />
| [[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI Sensorimotor 2017-06-19]]<br />
| Public Comment<br />
| 2017.12.31<br />
| '''Resolving Feedback'''<br />
|-<br />
| [[Media:QIBADWIProfile as of 2019-Feb-05.pdf| MR DWI 2019-02-05]]<br />
| Public Comment #2<br />
| 2019.04.05<br />
| [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DSC-MRI Stage1 Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]]<br />
| Public Comment<br />
| 2020.05.15<br />
| [[Media:QIBA DSC-MRI Public Comment Resolutions v2020Oct.9.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage compositional biomarkers (T1ρ,T2) 2020-05-18]]<br />
| Public Comment<br />
| 2020.10.29<br />
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]]<br />
|-<br />
| [[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]]<br />
| Public Comment<br />
| 2021.03.10<br />
| '''Resolving Feedback'''<br />
|-<br />
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]<br />
| Technical Confirmation<br />
| 2021.12.16<br />
| [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]]<br />
|-<br />
| [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]]<br />
| Clinically Feasible<br />
| 2022.12.15<br />
| [[Media:QIBA DWI-MR Clinical Feasibility Resolutions.pdf| Clinically Feasible Resolutions 2022-12-15]]<br />
|-<br />
| [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]<br />
|Consensus<br />
|2023.09.08<br />
|Public Comment Resolutions 2023-11-14<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles'''<br />
|-<br />
| SPECT Ioflupane in Neurodegenerative Disease v1.1<br />
| Public Comment<br />
| 2016.12.31<br />
| [[Media:SPECT Profile Response to Public Comments.v2017 06 06.xlsx| Public Comment Resolutions 2017-06-06]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2019-06-15]]<br />
| Technical Confirmation<br />
| 2021<br />
| [[Media:QIBA PET Amyloid Profile changes.pdf| Technical Confirmation Resolutions, 2022-04-15]]<br />
|-<br />
| [[Media:QIBA AmyloidPET 15June2017.pdf| PET Amyloid 2017-06-15]]<br />
|Public Comment<br />
|2017.09.15<br />
|[[Media:QIBA PET Amyloid Comments all resolved.xlsx| Public Comment Resolutions 2018-05-02]]<br />
|-<br />
| [[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15]]<br />
| Public Comment<br />
| n/a<br />
| v2.0 is an update of v1.0 without additional public comment<br />
|-<br />
|[[Media:QIBA 99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]]<br />
| Public Comment<br />
| 2020.02.03<br />
|[[Media:QIBA 99mTC SPECT Comments 2020-08-11-final.xlsx| Public Comment Resolutions 2020-08-11]]<br />
|-<br />
| colspan="4" align="center" style="background:#dddddd" | '''Ultrasound Profiles'''<br />
|-<br />
| [[Media:QIBA US SWS Profile 10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]]<br />
| Public Comment<br />
| 2019.12.18<br />
| [[Media:QIBA US SWS Comments 2021-02-06-final.xlsx| Public Comment Resolutions 2021-02-06]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]]<br />
| Clinically Feasible<br />
| 2023.02.07<br />
| [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]]<br />
|-<br />
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]]<br />
| Clinically Feasible<br />
| 2023.12.13<br />
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]]<br />
|-<br />
| [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]]<br />
| Consensus<br />
| 2023.12.13<br />
| [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]]<br />
|-<br />
|}</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DSC_MRI_Biomarker_Ctte&diff=19439DSC MRI Biomarker Ctte2023-12-20T21:55:16Z<p>SStanfa: /* DSC MRI Meetings */</p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Leland S. Hu, MD; Mark S. Shiroishi, MD; Ona Wu, PhD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vSj4UaTtwxjce5uTwiOxw6bjbWwH1q82nhNMsyOsOJJy_mGEsaxky---jmU5B42nShc--icFt4T1Kok/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Dynamic Susceptibility Contrast MRI.<br />
<br />
<br />
This QIBA Profile, Dynamic-Susceptibility-Contrast Magnetic Resonance Imaging (DSC-MRI), released 2020-10-22, addresses the measurement of an imaging biomarker for relative Cerebral Blood Volume (rCBV) for the evaluation of brain tumor progression or response to therapy. We note here, that this profile does not claim to be measuring quantitative rCBV due to lack of existing supporting literature; it does provide claims for a biomarker that is proportional to rCBV, which is the tissue-normalized area under the contrast-agent concentration curve (AUC-TN). The AUC-TN therefore has merit as a potential biomarker for diseases or treatments that impact rCBV. <br />
<br />
This profile places requirements on Sites, Acquisition Devices, Contrast Injectors, Contrast Media, Radiologists, Physicists, Technologists, Reconstruction Software, Image Analysis Tools and Image Analysts involved in Site Conformance, Staff Qualification, Product Validation, Pre-delivery, Periodic QA, Protocol Design, Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, Image Distribution, Image Analysis and Image Interpretation. The requirements are focused on achieving known (ideally negligible) bias and avoiding unnecessary variability of the of the AUC-TN measurements.<br />
<br />
The clinical performance is characterized by a 95% confidence interval for a true change in AUC-TN in enhancing tumor tissue and in normal tissue with respect to baseline values. These estimates are based on current literature values but may be updated based on future studies. <br />
<br />
This profile is intended to help clinicians basing decisions on this biomarker, imaging staff generating this biomarker, vendor staff developing related products, purchasers of such products and investigators designing trials with imaging endpoints.<br />
<br />
Note that this profile only states requirements to achieve the claim, '''not''' “requirements on standard of care.” Conformance to this Profile is secondary to properly caring for the patient.<br />
<br />
==DSC MRI Meetings==<br />
'''Recent Approved call summaries:'''<br />
<br />Note: Call summaries are posted after they are approved by the DSC-MRI BC during the following t-con<br />
<br />
*[[Media:2023-12-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|December 13, 2023]]<br />
*[[Media:2023-11-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|November 8, 2023]]<br />
*[[Media:2023-10-11_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|October 11, 2023]]<br />
<br />
'''''[[DSC-MRI Call Summaries Archive]]'''''<br />
<br />
* Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
<br/><br />
<br />
==Profile Development==<br />
<br />
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile-2023_08-09.pdf | DSC-MRI Stage 2 Consensus Profile August 09, 2023 Maintenance Version (published on September 5, 2023)]]<br />
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf | DSC-MRI Stage 2 Consensus Profile (published on October 22, 2020)]]<br />
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf | DSC-MRI Stage 1 Public Comment Profile]] (comments closed on May 15, 2020)]]<br />
<br />
==Historical Background - Formation of the Group==<br />
<br />
<br/><br />
<br />
==Reference Materials==<br />
<br />
*[[Media:QIBA DSC Phantom Manual.pdf|QIBA/NIST DSC Phantom User & Software Manual]]<br />
*[http://qibadscdro.rsna.org/home DSC MRI Digital Reference Object]<br />
<br />
<br/><br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 5====<br />
*[[Media:DSC-MRI Phantom.pdf|Project (H) Dynamic Susceptibility Contrast MRI Phantom (Massachusetts General Hospital)]]<br />
<br />
:Original Proposal to the QIBA Steering Committee<br />
<br />
====Round 6====<br />
*[[Media:A Web-based Tool for Creating DSC DROs.pdf | Project (Y) A Web-based Tool for Creating DSC Digital Reference Objects (DROs) (Mayo Clinic)]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=DSC-MRI_Call_Summaries_Archive&diff=19438DSC-MRI Call Summaries Archive2023-12-20T21:54:44Z<p>SStanfa: /* 2023 */</p>
<hr />
<div>==2023==<br />
[[Media:2023-01-11_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|January 11]] | [[Media:2023-02-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|February 8]] | [[Media:2023-03-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|March 8]] | [[Media:2023-04-12_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|April 12]] | [[Media:2023-05-31_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|May 31]] | [[Media:2023-07-12_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|July 12]] | [[Media:2023-08-09_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|August 9]] | [[Media:2023-09-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|September 13]]<br />
<br />
==2022==<br />
[[Media:2022_01-12_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|January 12]] | [[Media:2022_02-09_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|February 9]] | [[Media:2022_03-09_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|March 9]] | [[Media:2022_04-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|April 13]] | [[Media:2022_06-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|June 8]] | [[Media:2022_07-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|July 13]] | [[Media:2022_08-10_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|August 10]] | [[Media:2022_09-14_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|September 14]] | [[Media:2022_10-12_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|October 12]] | [[Media:2022_11-09_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|November 9]] | [[Media:2022_12-14_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|December 14]]<br />
<br />
==2021==<br />
[[Media:2021_01-13_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|January 13]] | [[Media:2021_02-10_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|February 10]] | [[Media:2021_03-10_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|March 10]] | [[Media:2021_04-14_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|April 14]] | [[Media:2021_06-09_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|June 9]] | [[Media:2021_07-14_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|July 14]] | [[Media:2021_08-11_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|August 11]] | [[Media:2021_09-08_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|September 8]] | [[Media:2021_10-13_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|October 13]] | [[Media:2021_12-08_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf|December 8]]<br />
<br />
==2020==<br />
[[Media:2020_01-08_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 8]] | [[Media:2020_03-11_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 11]] | [[Media:2020_04-08_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 8]] | [[Media:2020_05-13_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|May 13]] | [[Media:2020_06-10_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|June 10]] | [[Media:2020_07-08_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|July 8]] | [[Media:2020_09-09_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|September 9]] | [[Media:2020_10-14_QIBA_DSC-MRI_BC_Call_Summary-FINAL.pdf|October 14]]<br />
<br />
==2019==<br />
[[Media:2019_01-09_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 9]] | [[Media:2019_02-13_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 13]] | [[Media:2019_03-13_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|March 13]] | [[Media:2019_04-10_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 10]] | [[Media:2019_05-08_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 8]] | [[Media:2019_08-14_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|August 14]] | [[Media:2019_09-11_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|September 11]] | [[Media:2019_10-09_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 9]] | [[Media:2019_11-13_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 13]]<br />
<br />
==2018==<br />
[[Media:2018_10-10_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|October 10]] | [[Media:2018_11-21_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 21]] | [[Media:2018_12-12_QIBA_DSC_Biomarker_Cmte_Call_Summary-FINAL.pdf|December 12]]</div>SStanfahttps://qibawiki.rsna.org/index.php?title=File:2023-12-13_QIBA_DSC-MRI_BC_Meeting_Summary-FINAL.pdf&diff=19437File:2023-12-13 QIBA DSC-MRI BC Meeting Summary-FINAL.pdf2023-12-20T21:54:08Z<p>SStanfa: </p>
<hr />
<div></div>SStanfahttps://qibawiki.rsna.org/index.php?title=DCE_MRI_Biomarker_Ctte&diff=19436DCE MRI Biomarker Ctte2023-12-20T21:52:14Z<p>SStanfa: /* DCE MRI Meetings */</p>
<hr />
<div>{{TOCright}}<br />
:Co-chairs: Hendrik Laue, PhD; James O'Connor, MD, PhD<br />
:RSNA Staff Support: Susan Stanfa<br />
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRzQYPdYm51Ak3VYii84CtIDFiYRIylH2IkHQZxdAAjJTAVX4iRqlGl2tety1pnDFKN9kLxoKI-RcoM/pubhtml?gid=1048658726&single=true Roster]<br />
<br />
<br />
==Project Snapshot==<br />
Develop a quantitative imaging profile for Dynamic Contrast Enhanced MRI.<br />
<br />
*[[MR Acquisition Protocols]]<br />
*[[Synthetic DCE-MRI Data]]<br />
<br />
<br />
==DCE MRI Meetings==<br />
Biweekly Zoom meetings, 2nd and 4th Mondays of each month @ 11am-12pm Central Time (Contact [mailto:qiba@rsna.org qiba@rsna.org] for details)<br />
<br />
'''Recently Approved Call Summaries'''<br />
<br />
*[[Media:2023_12-11_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|December 11, 2023]]<br />
*[[Media:2023_11-13_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|November 13, 2023]]<br />
*[[Media:2023_10-23_QIBA-DCE-MRI_BC_Meeting_Summary-FINAL.pdf|October 23, 2023]]<br />
<br />
'''''[[DCE-MRI BC Call Summaries Archive]]'''''<br />
<br /><br />
<br /><br />
* [[QIBA DCE-MRI Technical Committee Call Summaries|DCE-MRI TC Call Summaries Archive 2008-2012]]<br />
* Earlier materials can be found on the [[Perfusion, Diffusion and Flow-MRI tech ctte|PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee]] page<br />
<br />
==Profile Development==<br />
<br />
*[[Media:Compliance v 1 7.doc|DCE-MRI Profile, Section IV Compliance-AG v1.7]] ''05-21-2014''<br />
*[[Media:Compliance (2).doc|DCE-MRI Profile, Section IV Compliance-AG]] ''01-22-2014''<br />
*[[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification Profile v1.6 2011-12-13]] (''Public comment closed Feb 2012'')<br />
*[[Media:Profile Literature Review 20110427 Rev1.xls|DCE-MRI Profile Supporting Literature Review]] ''Revised 05.02.2011''<br />
<br />
*[[Tools and recommendation for structured literature review]]<br />
*[[Archived DCE-MRI Profiles]]<br />
<br />
==Reference Materials==<br />
<br />
*[[Media:Barboriak T1 DRO report 20130903a.pdf|T1 DRO Report -- 20130903 -- Dr Barboriak]]<br />
*[[Media:DWI proposal of DCE-MRI TC 16Nov2011 (2).doc|DWI Proposal for the DCE-MRI Tech Ctte]] ''12.14.2011''<br />
*[[Media:Synthetic data presentation 20110929 redact.pdf|QIBA DCE-MRI Synthetic Data Presentation -- 20110929--Dr. Barboriak]]<br />
*[[Media:RSNA QIBA May2010 MR Phantom.pdf|MR Phantom Development / Data Efforts - May 2010 QIBA Meeting Breakout Session]]<br />
*[[Media:Prototype Phantom 20100203.pdf|Prototype Phantom - 20100203]]<br />
*[[Media:Q-MRI-Poster1-Jackson-20091118.ppt|QIBA Quantitative MRI Poster for RSNA 2009 Annual Meeting]]<br />
*[[Media:Phantom Study Protocol rev20091028.pdf|DCE-MRI Phantom Study Protocol -- rev20091028]]<br />
*[[Proposed Changes to Acquisition Protocol -- 20090315 - E Jackson]]<br />
<br />
<br />
==QIBA Funded Projects==<br />
<br />
====Round 1====<br />
*[[VirtualScopics, Inc.]]<br />
**[[Media:DrJackson QIBA Phantom 09203 AMR3.pdf|Example RSNA DCE-MRI Phantom Data Analysis Report]]<br />
<br />
*[[Duke University Medical Center]]<br />
*[[The University of Texas M.D. Anderson Cancer Center]]<br />
<br />
====Round 2====<br />
<br />
*[[Media:4-UPenn-Test-Retest.-Yr2.pdf|Test-Retest Evaluation of Repeatability of DCE-MRI and DWI in Human Subjects]]<br />
<br />
====Round 3====<br />
<br />
*[[QIBA Artificial Data Evaluation Software]]<br />
<br />
*[[Media:Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis.pdf|Project (J) Development of a Tool to Evaluate Software using Artificial DCE-MRI Data and Statistical Analysis (Fraunhofer MEVIS, Germany)]]<br />
<br />
*[[Media:DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T.pdf | Project (H) DCE-MRI Phantom Study to Evaluate the Impact of Parallel Imaging and B1 In-homogeneities at Different MR Field Strengths of 1.0T, 1.5T, and 3.0T (University Hospital Cologne, Germany)]]<br />
<br />
====Round 4====<br />
<br />
*[[Media:Digital Reference Object for DCE-MRI Analysis Software Verification.pdf|Project (AA) Digital Reference Object for DCE-MRI Analysis Software Verification (Cleveland Clinic Foundation)]]<br />
<br />
*[[Media:DRO for DCE-MRI Analysis Software Verification.pdf|Project (T) Digital Reference Object for DCE-MRI Analysis Software Verification 2 (Duke University)]]<br />
<br />
*[[Media:RSNA DCE-MRI Phantom Automated Analysis Software Package Development.pdf|Project (U) RSNA DCE-MRI Phantom Automated Analysis Software Package Development (University of Wisconsin)]]<br />
<br />
====Round 5====<br />
*[[Media:Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit.pdf | Project (K) Aggregated Measures of Agreement for QIB Validation-An Open Source Toolkit (Duke University)]]<br />
<br />
====Round 6====<br />
*[[Media:Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI.pdf | Project (Z) Evaluation of RF Transmit Calibration Options for Quantitative DCE-MRI (University of Southern California)]]<br />
<br />
==Historical Background - Formation of the Group==</div>SStanfa